ATC,ATC_info,ATC_hierarchy,used_in_diabetes,is_terminal_category,number_of_children,Mechanism of Action,Targets,Indication,ATC Code,Drug Name,RxCUI,Ingredients,Clinical Dose Groups,Dose Form Groups,Branded Dose Groups,mechanism_keywords,num_targets,mechanism_complexity,indication_category,num_dfg,num_ingridients,missing_mechanism,missing_targets,missing_indication,avg_mechanism_similarity,avg_target_overlap
A07AA10,Colistin,"['A07AA10', 'A07AA', 'A07A', 'A07', 'A']",True,1,1,"Colistin is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistin is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes.","ADihydropteroate synthase (binder, Escherichia coli (strain K12)); ABacterial outer membrane (incorporation into and destabilization, Bacteria)","For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.",A07AA,Colistin,2709,colistin,"colistin / hydrocortisone / neomycin / thonzonium Otic Product, colistin Injectable Product, colistin Oral Product, colistin Pill","Injectable Product, Oral Product, Pill, Otic Product","Coly Mycin M Injectable Product, Cortisporin-TC Otic Product","['interacts', 'that', 'its', 'Colistin', 'effect', 'disrupts', 'This', 'both', 'evidence', 'surface', 'the', 'moieties', 'precipitate', 'polycationic', 'cell', 'permeability', 'membrane', 'has', 'changing', 'primarily', 'active', 'components', 'bacterial', 'It', 'polymyxins', 'enter', 'agent', 'also', 'with', 'a', 'into', 'which', 'and', 'lipophilic', 'hydrophobic', 'There', 'ribosomes', 'bactericidal', 'is', 'penetrates', 'cytoplasmic']",3,54,chronic,4,1,False,False,False,0.03311422923370538,0.0
A08AA10,Sibutramine,"['A08AA10', 'A08AA', 'A08A', 'A08', 'A']",True,1,1,"Sibutramine produces its therapeutic effects by inhibition of norepinephrine (NE), serotonin (5-hydroxytryptamine, 5-HT), and to a lesser extent, dopamine reuptake at the neuronal synapse. By inhibiting the reuptake of these neurotransmitters, sibutramine promotes a sense of satiety and decrease in appetite, thereby reducing food intake. Data from animal studies also suggest that sibutramine may also increase energy expenditure through thermogenic effects in both the basal and fed states, but this has not been confirmed in humans. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines.","ASodium-dependent dopamine transporter (inhibitor, Humans); ASodium-dependent serotonin transporter (inhibitor, Humans); ASodium-dependent noradrenaline transporter (inhibitor, Humans)",For the treatment of obesity.,A08AA,Sibutramine,1294535,sibutramine,"sibutramine Oral Product, sibutramine Pill","Oral Product, Pill",,"['through', 'been', 'energy', 'that', 'promotes', 'its', 'sense', 'monoamines', 'animal', 'both', 'norepinephrine', 'confirmed', 'by', 'the', 'neuronal', 'extent', 'at', 'inhibiting', 'thermogenic', 'major', 'release', 'thereby', 'fed', 'hydroxytryptamine', 'increase', 'this', 'not', 'has', 'By', 'active', 'food', 'appetite', 'reducing', 'M1', 'these', 'also', 'NE', 'lesser', 'in', 'reuptake', 'synapse', 'may', 'a', 'satiety', 'studies', 'from', 'effects', 'metabolites', 'M2', 'produces', 'humans', 'pharmacologically', 'decrease', 'and', 'HT', 'Data', 'expenditure', 'do', 'suggest', 'states', 'intake', 'basal', 'sibutramine', '5', 'inhibition', 'therapeutic', 'to', 'serotonin', 'dopamine', 'neurotransmitters', 'but', 'via', 'Sibutramine', 'of', 'act']",4,93,obesity,2,1,False,False,False,0.044316853698499435,0.001128668171557562
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,2,3,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,3,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,2,3,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,2,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,1,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,3,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,2,3,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,1,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,3,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,2,3,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin glulisine,400008,"insulin glulisine, human","insulin glulisine, human Injectable Product",Injectable Product,Apidra Injectable Product,"['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,2,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,2,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,1,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,3,False,False,False,0.10425168780696994,0.25
A10AB01,Insulin (human),"['A10AB01', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,2,3,False,False,False,0.10425168780696994,0.25
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['Not', 'Available']",3,2,other,2,3,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['Not', 'Available']",3,2,other,1,3,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['Not', 'Available']",3,2,other,2,3,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['Not', 'Available']",3,2,other,1,2,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['Not', 'Available']",3,2,other,1,1,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['Not', 'Available']",3,2,other,1,3,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['Not', 'Available']",3,2,other,2,3,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['Not', 'Available']",3,2,other,1,1,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['Not', 'Available']",3,2,other,1,3,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['Not', 'Available']",3,2,other,2,3,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin glulisine,400008,"insulin glulisine, human","insulin glulisine, human Injectable Product",Injectable Product,Apidra Injectable Product,"['Not', 'Available']",3,2,other,1,2,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['Not', 'Available']",3,2,other,1,2,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['Not', 'Available']",3,2,other,1,1,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['Not', 'Available']",3,2,other,1,3,True,False,True,,0.21788990825688073
A10AB02,Insulin (beef),"['A10AB02', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['Not', 'Available']",3,2,other,2,3,True,False,True,,0.21788990825688073
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,2,3,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,3,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,2,3,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,2,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,3,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,2,3,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,3,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,2,3,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin glulisine,400008,"insulin glulisine, human","insulin glulisine, human Injectable Product",Injectable Product,Apidra Injectable Product,"['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,2,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,2,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,3,False,True,False,0.11092225645622798,0.016055045871559634
A10AB03,Insulin (pork),"['A10AB03', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,2,3,False,True,False,0.11092225645622798,0.016055045871559634
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,2,3,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,1,3,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,2,3,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,1,2,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,1,1,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,1,3,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,2,3,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,1,1,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,1,3,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,2,3,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin glulisine,400008,"insulin glulisine, human","insulin glulisine, human Injectable Product",Injectable Product,Apidra Injectable Product,"['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,1,2,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,1,2,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,1,1,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,1,3,False,False,False,0.08887885938443765,0.21788990825688073
A10AB04,Insulin lispro,"['A10AB04', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.9,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'absorbed', 'C', 'upon', 'dissociate', 'at', 'quickly', 'zinc', '1', 'binds', 'leads', 'two', 'phosphorylates', 'presence', 'roles', 'PI3', 'GLUT4', 'downstream', 'stored', 'monomers', 'interactions', 'cells', 'play', 'hydrophobic', 'Akt', 'however', 'protein', 'subcutaneous', 'associated', 'Insulin', 'including', 'lysine', 'proline', 'that', 'glucose', 'lispro', 'eliminates', 'activation', 'metabolism', 'produced', 'stability', 'B28', 'properties', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'hydrogen', 'endothelial', 'which', 'and', 'molecules', 'intracellular', 'activity', 'residues', 'tyrosine', 'Reversal', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'through', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'm', 'these', 'cresol', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'give', 'insulin', '4', 'dimers', 'consisting', 'contribute', 'units', 'native', 'bonds', 'injection', 'is', 'weakens', 'positions', 'of', 'Cbl', 'Shc', 'comprise', 'its', 'These', 'acting', 'the', 'The', 'heterotetrameric', 'weakly', 'some', 'fast', 'interact', 'a', 'regulates', 'Hexamers', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'vascular', 'IRS', 'B29']",3,205,other,2,3,False,False,False,0.08887885938443765,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,2,3,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,1,3,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,2,3,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,1,2,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,1,1,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,1,3,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,2,3,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,1,1,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,1,3,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,2,3,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin glulisine,400008,"insulin glulisine, human","insulin glulisine, human Injectable Product",Injectable Product,Apidra Injectable Product,"['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,1,2,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,1,2,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,1,1,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,1,3,False,False,False,0.10483390400915049,0.21788990825688073
A10AB05,Insulin aspart,"['A10AB05', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin aspart binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the proline residue at B28 with aspartic acid reduces the tendency to form hexamers and results in a faster rate of absorption and onset of action and shorter duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.5,6",A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'C', 'at', '1', 'shorter', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'GLUT4', 'downstream', 'stored', 'monomers', 'reduces', 'play', 'Akt', 'however', 'protein', 'absorption', 'Insulin', 'including', 'proline', 'glucose', 'activation', 'metabolism', 'onset', 'B28', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'residue', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'able', 'autophosphorylates', 'both', 'PKC', 'only', 'Activation', 'binding', 'extracellular', 'faster', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'is', 'of', 'Cbl', 'Shc', 'tendency', 'the', 'aspart', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'aspartic', 'IRS', 'acid', 'results']",3,161,other,2,3,False,False,False,0.10483390400915049,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,2,3,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,1,3,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,2,3,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,1,2,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,1,1,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,1,3,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,2,3,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,1,1,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,1,3,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,2,3,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin glulisine,400008,"insulin glulisine, human","insulin glulisine, human Injectable Product",Injectable Product,Apidra Injectable Product,"['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,1,2,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,1,2,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,1,1,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,1,3,False,False,False,0.10172776309703262,0.21788990825688073
A10AB06,Insulin glulisine,"['A10AB06', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,"Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['bound', 'C', 'at', '1', 'binds', 'leads', 'Substitution', 'two', 'phosphorylates', 'roles', 'PI3', 'duration', 'monomeric', 'GLUT4', 'downstream', 'propensity', 'monomers', 'stored', 'play', 'Akt', 'however', 'protein', 'rapid', 'absorption', 'Insulin', 'including', 'lysine', 'glucose', 'activation', 'metabolism', 'numerous', 'IR', 'APS', 'are', 'Gab', 'arginine', 'receptor', 'proteins', 'with', 'signaling', 'kinase', 'which', 'and', 'position', 'molecules', 'intracellular', 'activity', 'for', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'decreases', 'B3', 'able', 'autophosphorylates', 'glutamic', 'both', 'PKC', 'hormone', 'only', 'Activation', 'binding', 'extracellular', 'replacement', 'these', 'critical', 'in', 'beta', 'form', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'rate', 'stabilizes', 'is', 'of', 'Cbl', 'Shc', 'the', 'short', 'The', 'heterotetrameric', 'action', 'interact', 'a', 'regulates', 'hexamers', 'humans', 'glulisine', 'subunit', 'In', 'transmembrane', 'substrates', 'such', 'transporter', 'IRS', 'acid', 'results', 'B29']",3,171,other,2,3,False,False,False,0.10172776309703262,0.21788990825688073
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['mechanism', 'No', 'found']",1,3,other,2,3,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['mechanism', 'No', 'found']",1,3,other,1,3,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['mechanism', 'No', 'found']",1,3,other,2,3,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['mechanism', 'No', 'found']",1,3,other,1,2,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['mechanism', 'No', 'found']",1,3,other,1,1,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['mechanism', 'No', 'found']",1,3,other,1,3,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['mechanism', 'No', 'found']",1,3,other,2,3,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['mechanism', 'No', 'found']",1,3,other,1,1,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['mechanism', 'No', 'found']",1,3,other,1,3,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['mechanism', 'No', 'found']",1,3,other,2,3,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin glulisine,400008,"insulin glulisine, human","insulin glulisine, human Injectable Product",Injectable Product,Apidra Injectable Product,"['mechanism', 'No', 'found']",1,3,other,1,2,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin aspart,51428,"insulin aspart, human","insulin aspart protamine, human / insulin aspart, human Injectable Product, insulin aspart, human Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"NovoLog Injectable Product, NovoLog Mix Injectable Product, Fiasp Injectable Product","['mechanism', 'No', 'found']",1,3,other,1,2,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin lispro,86009,insulin lispro,"insulin lispro / insulin lispro protamine, human Injectable Product, insulin lispro Injectable Product",Injectable Product,"Humalog Injectable Product, Humalog Mix Injectable Product, Admelog Injectable Product, Lyumjev Injectable Product","['mechanism', 'No', 'found']",1,3,other,1,1,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin (pork),221109,"insulin, regular, pork","insulin, regular, pork Injectable Product, insulin isophane / insulin, regular, pork Injectable Product",Injectable Product,,"['mechanism', 'No', 'found']",1,3,other,1,3,True,True,True,,
A10AB30,Combinations,"['A10AB30', 'A10AB', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AB,Insulin (human),253182,"insulin, regular, human","insulin, regular, human Injectable Product, insulin, regular, human Inhalant Product, insulin isophane / insulin, regular, human Injectable Product","Inhalant Product, Injectable Product","Humulin Injectable Product, Humulin R Injectable Product, Novolin Injectable Product, Novolin R Injectable Product, Afrezza Inhalant Product, Myxredlin Injectable Product","['mechanism', 'No', 'found']",1,3,other,2,3,True,True,True,,
A10AE01,Insulin (human),"['A10AE01', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AE,Lixisenatide,1440051,lixisenatide,"lixisenatide Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Adlyxin Injectable Product, Soliqua Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,1,False,False,False,0.11239485428145203,0.30227272727272725
A10AE01,Insulin (human),"['A10AE01', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AE,Liraglutide,475968,liraglutide,"liraglutide Injectable Product, insulin degludec / liraglutide Injectable Product",Injectable Product,"Victoza Injectable Product, Saxenda Injectable Product, Xultophy Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,1,False,False,False,0.11239485428145203,0.30227272727272725
A10AE01,Insulin (human),"['A10AE01', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AE,Insulin glargine and lixisenatide,1858994,"lixisenatide, insulin glargine",insulin glargine / lixisenatide Injectable Product,Injectable Product,Soliqua Injectable Product,"['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,2,False,False,False,0.11239485428145203,0.30227272727272725
A10AE01,Insulin (human),"['A10AE01', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AE,Insulin degludec and liraglutide,1727493,"insulin degludec, liraglutide",insulin degludec / liraglutide Injectable Product,Injectable Product,Xultophy Injectable Product,"['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,2,False,False,False,0.11239485428145203,0.30227272727272725
A10AE01,Insulin (human),"['A10AE01', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AE,Insulin degludec,1670007,insulin degludec,"insulin degludec Injectable Product, insulin degludec / liraglutide Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"Tresiba Injectable Product, Xultophy Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,1,False,False,False,0.11239485428145203,0.30227272727272725
A10AE01,Insulin (human),"['A10AE01', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AE,Insulin detemir,139825,insulin detemir,insulin detemir Injectable Product,Injectable Product,Levemir Injectable Product,"['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,1,False,False,False,0.11239485428145203,0.30227272727272725
A10AE01,Insulin (human),"['A10AE01', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans); UCarboxypeptidase E (modulatorproduct of, Humans); UCCN family member 3 (downregulator, Humans); ULow-density lipoprotein receptor-related protein 2 (substrate, Humans); UInsulin-like growth factor-binding protein 7 (inhibitorbinder, Humans)",Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.,A10AE,Insulin glargine,274783,insulin glargine,"insulin glargine Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Lantus Injectable Product, Toujeo Injectable Product, Basaglar Injectable Product, Soliqua Injectable Product, Semglee Injectable Product, Rezvoglar Injectable Product","['bound', 'inhibits', 'regulation', 'C', '1', 'binds', 'muscle', 'two', 'PI3', 'also', 'gluconeogenesis', 'GLUT4', 'downstream', 'an', 'stimulating', 'play', 'Akt', 'protein', 'uptake', 'anabolic', 'Insulin', 'including', 'autophosphorylate', 'glucose', 'metabolism', 'activation', 'except', 'numerous', 'primary', 'IR', 'APS', 'activated', 'Gab', 'receptor', 'fatty', 'proteins', 'signaling', 'kinase', 'other', 'which', 'and', 'molecules', 'intracellular', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'catabolism', 'lead', 'able', 'amino', 'promotes', 'PKC', 'role', 'binding', 'extracellular', 'It', 'critical', 'in', 'beta', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'is', 'phosphorylate', 'glycogen', 'of', 'Cbl', 'Shc', 'brain', 'These', 'the', 'The', 'tissues', 'heterotetrameric', 'has', 'synthesis', 'liver', 'a', 'regulates', 'into', 'subunit', 'transmembrane', 'substrates', 'such', 'turn', 'transporter', 'IRS', 'acid', 'adipose']",7,160,other,1,1,False,False,False,0.11239485428145203,0.30227272727272725
A10AE02,Insulin (beef),"['A10AE02', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AE,Lixisenatide,1440051,lixisenatide,"lixisenatide Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Adlyxin Injectable Product, Soliqua Injectable Product","['Not', 'Available']",3,2,other,1,1,True,False,True,,0.2340909090909091
A10AE02,Insulin (beef),"['A10AE02', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AE,Liraglutide,475968,liraglutide,"liraglutide Injectable Product, insulin degludec / liraglutide Injectable Product",Injectable Product,"Victoza Injectable Product, Saxenda Injectable Product, Xultophy Injectable Product","['Not', 'Available']",3,2,other,1,1,True,False,True,,0.2340909090909091
A10AE02,Insulin (beef),"['A10AE02', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AE,Insulin glargine and lixisenatide,1858994,"lixisenatide, insulin glargine",insulin glargine / lixisenatide Injectable Product,Injectable Product,Soliqua Injectable Product,"['Not', 'Available']",3,2,other,1,2,True,False,True,,0.2340909090909091
A10AE02,Insulin (beef),"['A10AE02', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AE,Insulin degludec and liraglutide,1727493,"insulin degludec, liraglutide",insulin degludec / liraglutide Injectable Product,Injectable Product,Xultophy Injectable Product,"['Not', 'Available']",3,2,other,1,2,True,False,True,,0.2340909090909091
A10AE02,Insulin (beef),"['A10AE02', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AE,Insulin degludec,1670007,insulin degludec,"insulin degludec Injectable Product, insulin degludec / liraglutide Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"Tresiba Injectable Product, Xultophy Injectable Product","['Not', 'Available']",3,2,other,1,1,True,False,True,,0.2340909090909091
A10AE02,Insulin (beef),"['A10AE02', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AE,Insulin detemir,139825,insulin detemir,insulin detemir Injectable Product,Injectable Product,Levemir Injectable Product,"['Not', 'Available']",3,2,other,1,1,True,False,True,,0.2340909090909091
A10AE02,Insulin (beef),"['A10AE02', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,Not Available,"AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Not Available,A10AE,Insulin glargine,274783,insulin glargine,"insulin glargine Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Lantus Injectable Product, Toujeo Injectable Product, Basaglar Injectable Product, Soliqua Injectable Product, Semglee Injectable Product, Rezvoglar Injectable Product","['Not', 'Available']",3,2,other,1,1,True,False,True,,0.2340909090909091
A10AE03,Insulin (pork),"['A10AE03', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AE,Lixisenatide,1440051,lixisenatide,"lixisenatide Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Adlyxin Injectable Product, Soliqua Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,True,False,0.11900478139753498,0.03409090909090909
A10AE03,Insulin (pork),"['A10AE03', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AE,Liraglutide,475968,liraglutide,"liraglutide Injectable Product, insulin degludec / liraglutide Injectable Product",Injectable Product,"Victoza Injectable Product, Saxenda Injectable Product, Xultophy Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,True,False,0.11900478139753498,0.03409090909090909
A10AE03,Insulin (pork),"['A10AE03', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AE,Insulin glargine and lixisenatide,1858994,"lixisenatide, insulin glargine",insulin glargine / lixisenatide Injectable Product,Injectable Product,Soliqua Injectable Product,"['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,2,False,True,False,0.11900478139753498,0.03409090909090909
A10AE03,Insulin (pork),"['A10AE03', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AE,Insulin degludec and liraglutide,1727493,"insulin degludec, liraglutide",insulin degludec / liraglutide Injectable Product,Injectable Product,Xultophy Injectable Product,"['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,2,False,True,False,0.11900478139753498,0.03409090909090909
A10AE03,Insulin (pork),"['A10AE03', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AE,Insulin degludec,1670007,insulin degludec,"insulin degludec Injectable Product, insulin degludec / liraglutide Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"Tresiba Injectable Product, Xultophy Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,True,False,0.11900478139753498,0.03409090909090909
A10AE03,Insulin (pork),"['A10AE03', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AE,Insulin detemir,139825,insulin detemir,insulin detemir Injectable Product,Injectable Product,Levemir Injectable Product,"['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,True,False,0.11900478139753498,0.03409090909090909
A10AE03,Insulin (pork),"['A10AE03', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.","AInsulin receptor (binder, Humans); UInsulin-like growth factor 1 receptor (Not Available, Humans)",For the treatment of type I and II diabetes mellitus.,A10AE,Insulin glargine,274783,insulin glargine,"insulin glargine Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Lantus Injectable Product, Toujeo Injectable Product, Basaglar Injectable Product, Soliqua Injectable Product, Semglee Injectable Product, Rezvoglar Injectable Product","['Shc', 'able', 'autophosphorylate', 'glucose', 'These', 'bound', 'activation', 'metabolism', 'PKC', 'role', 'the', 'C', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'activated', 'receptor', 'two', 'PI3', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'turn', 'activity', 'is', 'transporter', 'protein', 'tyrosine', 'phosphorylate', 'as', 'to', 'stimulates', 'IRS', 'lead', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,True,False,0.11900478139753498,0.03409090909090909
A10AE04,Insulin glargine,"['A10AE04', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.11,14,15",A10AE,Lixisenatide,1440051,lixisenatide,"lixisenatide Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Adlyxin Injectable Product, Soliqua Injectable Product","['pH', 'signalling', 'bound', 'mimic', 'C', 'administered', 'at', 'release', 'completely', '1', 'microprecipitates', 'binds', 'leads', 'two', 'phosphorylates', 'roles', 'PI3', 'GLUT4', 'downstream', 'body', '24', 'play', 'Akt', 'protein', 'basal', 'Insulin', 'including', 'solubility', 'glucose', 'neutralized', 'peak', 'activation', 'metabolism', 'constant', 'amounts', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'time', 'proteins', 'with', 'allows', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'profile', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'solution', 'levels', 'autophosphorylates', 'low', 'both', 'PKC', 'mechanism', 'no', 'Small', 'Activation', 'binding', 'extracellular', 'pronounced', 'over', 'Upon', 'these', 'critical', 'in', 'beta', 'from', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'injection', 'is', 'of', 'glargine', 'Cbl', 'Shc', 'hours', 'This', 'the', 'physiological', 'The', 'relatively', 'heterotetrameric', 'has', 'released', 'subcuteous', 'giving', 'a', 'formation', 'regulates', 'subunit', 'transmembrane', 'resulting', 'substrates', 'drug', 'soluble', 'concentration', 'such', 'transporter', 'IRS', '7', 'within']",3,180,other,1,1,False,False,False,0.09616855090596323,0.2340909090909091
A10AE04,Insulin glargine,"['A10AE04', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.11,14,15",A10AE,Liraglutide,475968,liraglutide,"liraglutide Injectable Product, insulin degludec / liraglutide Injectable Product",Injectable Product,"Victoza Injectable Product, Saxenda Injectable Product, Xultophy Injectable Product","['pH', 'signalling', 'bound', 'mimic', 'C', 'administered', 'at', 'release', 'completely', '1', 'microprecipitates', 'binds', 'leads', 'two', 'phosphorylates', 'roles', 'PI3', 'GLUT4', 'downstream', 'body', '24', 'play', 'Akt', 'protein', 'basal', 'Insulin', 'including', 'solubility', 'glucose', 'neutralized', 'peak', 'activation', 'metabolism', 'constant', 'amounts', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'time', 'proteins', 'with', 'allows', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'profile', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'solution', 'levels', 'autophosphorylates', 'low', 'both', 'PKC', 'mechanism', 'no', 'Small', 'Activation', 'binding', 'extracellular', 'pronounced', 'over', 'Upon', 'these', 'critical', 'in', 'beta', 'from', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'injection', 'is', 'of', 'glargine', 'Cbl', 'Shc', 'hours', 'This', 'the', 'physiological', 'The', 'relatively', 'heterotetrameric', 'has', 'released', 'subcuteous', 'giving', 'a', 'formation', 'regulates', 'subunit', 'transmembrane', 'resulting', 'substrates', 'drug', 'soluble', 'concentration', 'such', 'transporter', 'IRS', '7', 'within']",3,180,other,1,1,False,False,False,0.09616855090596323,0.2340909090909091
A10AE04,Insulin glargine,"['A10AE04', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.11,14,15",A10AE,Insulin glargine and lixisenatide,1858994,"lixisenatide, insulin glargine",insulin glargine / lixisenatide Injectable Product,Injectable Product,Soliqua Injectable Product,"['pH', 'signalling', 'bound', 'mimic', 'C', 'administered', 'at', 'release', 'completely', '1', 'microprecipitates', 'binds', 'leads', 'two', 'phosphorylates', 'roles', 'PI3', 'GLUT4', 'downstream', 'body', '24', 'play', 'Akt', 'protein', 'basal', 'Insulin', 'including', 'solubility', 'glucose', 'neutralized', 'peak', 'activation', 'metabolism', 'constant', 'amounts', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'time', 'proteins', 'with', 'allows', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'profile', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'solution', 'levels', 'autophosphorylates', 'low', 'both', 'PKC', 'mechanism', 'no', 'Small', 'Activation', 'binding', 'extracellular', 'pronounced', 'over', 'Upon', 'these', 'critical', 'in', 'beta', 'from', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'injection', 'is', 'of', 'glargine', 'Cbl', 'Shc', 'hours', 'This', 'the', 'physiological', 'The', 'relatively', 'heterotetrameric', 'has', 'released', 'subcuteous', 'giving', 'a', 'formation', 'regulates', 'subunit', 'transmembrane', 'resulting', 'substrates', 'drug', 'soluble', 'concentration', 'such', 'transporter', 'IRS', '7', 'within']",3,180,other,1,2,False,False,False,0.09616855090596323,0.2340909090909091
A10AE04,Insulin glargine,"['A10AE04', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.11,14,15",A10AE,Insulin degludec and liraglutide,1727493,"insulin degludec, liraglutide",insulin degludec / liraglutide Injectable Product,Injectable Product,Xultophy Injectable Product,"['pH', 'signalling', 'bound', 'mimic', 'C', 'administered', 'at', 'release', 'completely', '1', 'microprecipitates', 'binds', 'leads', 'two', 'phosphorylates', 'roles', 'PI3', 'GLUT4', 'downstream', 'body', '24', 'play', 'Akt', 'protein', 'basal', 'Insulin', 'including', 'solubility', 'glucose', 'neutralized', 'peak', 'activation', 'metabolism', 'constant', 'amounts', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'time', 'proteins', 'with', 'allows', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'profile', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'solution', 'levels', 'autophosphorylates', 'low', 'both', 'PKC', 'mechanism', 'no', 'Small', 'Activation', 'binding', 'extracellular', 'pronounced', 'over', 'Upon', 'these', 'critical', 'in', 'beta', 'from', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'injection', 'is', 'of', 'glargine', 'Cbl', 'Shc', 'hours', 'This', 'the', 'physiological', 'The', 'relatively', 'heterotetrameric', 'has', 'released', 'subcuteous', 'giving', 'a', 'formation', 'regulates', 'subunit', 'transmembrane', 'resulting', 'substrates', 'drug', 'soluble', 'concentration', 'such', 'transporter', 'IRS', '7', 'within']",3,180,other,1,2,False,False,False,0.09616855090596323,0.2340909090909091
A10AE04,Insulin glargine,"['A10AE04', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.11,14,15",A10AE,Insulin degludec,1670007,insulin degludec,"insulin degludec Injectable Product, insulin degludec / liraglutide Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"Tresiba Injectable Product, Xultophy Injectable Product","['pH', 'signalling', 'bound', 'mimic', 'C', 'administered', 'at', 'release', 'completely', '1', 'microprecipitates', 'binds', 'leads', 'two', 'phosphorylates', 'roles', 'PI3', 'GLUT4', 'downstream', 'body', '24', 'play', 'Akt', 'protein', 'basal', 'Insulin', 'including', 'solubility', 'glucose', 'neutralized', 'peak', 'activation', 'metabolism', 'constant', 'amounts', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'time', 'proteins', 'with', 'allows', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'profile', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'solution', 'levels', 'autophosphorylates', 'low', 'both', 'PKC', 'mechanism', 'no', 'Small', 'Activation', 'binding', 'extracellular', 'pronounced', 'over', 'Upon', 'these', 'critical', 'in', 'beta', 'from', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'injection', 'is', 'of', 'glargine', 'Cbl', 'Shc', 'hours', 'This', 'the', 'physiological', 'The', 'relatively', 'heterotetrameric', 'has', 'released', 'subcuteous', 'giving', 'a', 'formation', 'regulates', 'subunit', 'transmembrane', 'resulting', 'substrates', 'drug', 'soluble', 'concentration', 'such', 'transporter', 'IRS', '7', 'within']",3,180,other,1,1,False,False,False,0.09616855090596323,0.2340909090909091
A10AE04,Insulin glargine,"['A10AE04', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.11,14,15",A10AE,Insulin detemir,139825,insulin detemir,insulin detemir Injectable Product,Injectable Product,Levemir Injectable Product,"['pH', 'signalling', 'bound', 'mimic', 'C', 'administered', 'at', 'release', 'completely', '1', 'microprecipitates', 'binds', 'leads', 'two', 'phosphorylates', 'roles', 'PI3', 'GLUT4', 'downstream', 'body', '24', 'play', 'Akt', 'protein', 'basal', 'Insulin', 'including', 'solubility', 'glucose', 'neutralized', 'peak', 'activation', 'metabolism', 'constant', 'amounts', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'time', 'proteins', 'with', 'allows', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'profile', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'solution', 'levels', 'autophosphorylates', 'low', 'both', 'PKC', 'mechanism', 'no', 'Small', 'Activation', 'binding', 'extracellular', 'pronounced', 'over', 'Upon', 'these', 'critical', 'in', 'beta', 'from', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'injection', 'is', 'of', 'glargine', 'Cbl', 'Shc', 'hours', 'This', 'the', 'physiological', 'The', 'relatively', 'heterotetrameric', 'has', 'released', 'subcuteous', 'giving', 'a', 'formation', 'regulates', 'subunit', 'transmembrane', 'resulting', 'substrates', 'drug', 'soluble', 'concentration', 'such', 'transporter', 'IRS', '7', 'within']",3,180,other,1,1,False,False,False,0.09616855090596323,0.2340909090909091
A10AE04,Insulin glargine,"['A10AE04', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)","Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.11,14,15",A10AE,Insulin glargine,274783,insulin glargine,"insulin glargine Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Lantus Injectable Product, Toujeo Injectable Product, Basaglar Injectable Product, Soliqua Injectable Product, Semglee Injectable Product, Rezvoglar Injectable Product","['pH', 'signalling', 'bound', 'mimic', 'C', 'administered', 'at', 'release', 'completely', '1', 'microprecipitates', 'binds', 'leads', 'two', 'phosphorylates', 'roles', 'PI3', 'GLUT4', 'downstream', 'body', '24', 'play', 'Akt', 'protein', 'basal', 'Insulin', 'including', 'solubility', 'glucose', 'neutralized', 'peak', 'activation', 'metabolism', 'constant', 'amounts', 'numerous', 'IR', 'APS', 'are', 'Gab', 'receptor', 'time', 'proteins', 'with', 'allows', 'kinase', 'which', 'and', 'molecules', 'intracellular', 'profile', 'activity', 'tyrosine', 'as', 'to', 'stimulates', 'solution', 'levels', 'autophosphorylates', 'low', 'both', 'PKC', 'mechanism', 'no', 'Small', 'Activation', 'binding', 'extracellular', 'pronounced', 'over', 'Upon', 'these', 'critical', 'in', 'beta', 'from', 'alpha', 'intrinsic', 'insulin', '4', 'consisting', 'units', 'injection', 'is', 'of', 'glargine', 'Cbl', 'Shc', 'hours', 'This', 'the', 'physiological', 'The', 'relatively', 'heterotetrameric', 'has', 'released', 'subcuteous', 'giving', 'a', 'formation', 'regulates', 'subunit', 'transmembrane', 'resulting', 'substrates', 'drug', 'soluble', 'concentration', 'such', 'transporter', 'IRS', '7', 'within']",3,180,other,1,1,False,False,False,0.09616855090596323,0.2340909090909091
A10AE05,Insulin detemir,"['A10AE05', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8,9 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1.9 Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt.9 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.9,10","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.12,A10AE,Lixisenatide,1440051,lixisenatide,"lixisenatide Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Adlyxin Injectable Product, Soliqua Injectable Product","['Shc', 'autophosphorylates', 'signalling', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', '10', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', '9', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,False,False,0.11468949992569934,0.2340909090909091
A10AE05,Insulin detemir,"['A10AE05', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8,9 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1.9 Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt.9 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.9,10","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.12,A10AE,Liraglutide,475968,liraglutide,"liraglutide Injectable Product, insulin degludec / liraglutide Injectable Product",Injectable Product,"Victoza Injectable Product, Saxenda Injectable Product, Xultophy Injectable Product","['Shc', 'autophosphorylates', 'signalling', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', '10', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', '9', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,False,False,0.11468949992569934,0.2340909090909091
A10AE05,Insulin detemir,"['A10AE05', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8,9 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1.9 Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt.9 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.9,10","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.12,A10AE,Insulin glargine and lixisenatide,1858994,"lixisenatide, insulin glargine",insulin glargine / lixisenatide Injectable Product,Injectable Product,Soliqua Injectable Product,"['Shc', 'autophosphorylates', 'signalling', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', '10', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', '9', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,2,False,False,False,0.11468949992569934,0.2340909090909091
A10AE05,Insulin detemir,"['A10AE05', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8,9 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1.9 Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt.9 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.9,10","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.12,A10AE,Insulin degludec and liraglutide,1727493,"insulin degludec, liraglutide",insulin degludec / liraglutide Injectable Product,Injectable Product,Xultophy Injectable Product,"['Shc', 'autophosphorylates', 'signalling', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', '10', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', '9', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,2,False,False,False,0.11468949992569934,0.2340909090909091
A10AE05,Insulin detemir,"['A10AE05', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8,9 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1.9 Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt.9 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.9,10","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.12,A10AE,Insulin degludec,1670007,insulin degludec,"insulin degludec Injectable Product, insulin degludec / liraglutide Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"Tresiba Injectable Product, Xultophy Injectable Product","['Shc', 'autophosphorylates', 'signalling', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', '10', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', '9', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,False,False,0.11468949992569934,0.2340909090909091
A10AE05,Insulin detemir,"['A10AE05', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8,9 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1.9 Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt.9 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.9,10","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.12,A10AE,Insulin detemir,139825,insulin detemir,insulin detemir Injectable Product,Injectable Product,Levemir Injectable Product,"['Shc', 'autophosphorylates', 'signalling', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', '10', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', '9', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,False,False,0.11468949992569934,0.2340909090909091
A10AE05,Insulin detemir,"['A10AE05', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8,9 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1.9 Activation of these proteins leads to the activation of downstream signalling molecules including PI3 kinase and Akt.9 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.9,10","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.12,A10AE,Insulin glargine,274783,insulin glargine,"insulin glargine Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Lantus Injectable Product, Toujeo Injectable Product, Basaglar Injectable Product, Soliqua Injectable Product, Semglee Injectable Product, Rezvoglar Injectable Product","['Shc', 'autophosphorylates', 'signalling', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', '10', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', '9', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",3,108,other,1,1,False,False,False,0.11468949992569934,0.2340909090909091
A10AE06,Insulin degludec,"['A10AE06', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc, and Gab 1.8 Activation of these proteins leads to activation of downstream signaling molecules including PI3 kinase and Akt.8 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.8","AInsulin (modulator, Humans); AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.10,A10AE,Lixisenatide,1440051,lixisenatide,"lixisenatide Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Adlyxin Injectable Product, Soliqua Injectable Product","['Shc', 'autophosphorylates', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",4,107,other,1,1,False,False,False,0.11564174521984098,0.11704545454545455
A10AE06,Insulin degludec,"['A10AE06', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc, and Gab 1.8 Activation of these proteins leads to activation of downstream signaling molecules including PI3 kinase and Akt.8 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.8","AInsulin (modulator, Humans); AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.10,A10AE,Liraglutide,475968,liraglutide,"liraglutide Injectable Product, insulin degludec / liraglutide Injectable Product",Injectable Product,"Victoza Injectable Product, Saxenda Injectable Product, Xultophy Injectable Product","['Shc', 'autophosphorylates', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",4,107,other,1,1,False,False,False,0.11564174521984098,0.11704545454545455
A10AE06,Insulin degludec,"['A10AE06', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc, and Gab 1.8 Activation of these proteins leads to activation of downstream signaling molecules including PI3 kinase and Akt.8 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.8","AInsulin (modulator, Humans); AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.10,A10AE,Insulin glargine and lixisenatide,1858994,"lixisenatide, insulin glargine",insulin glargine / lixisenatide Injectable Product,Injectable Product,Soliqua Injectable Product,"['Shc', 'autophosphorylates', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",4,107,other,1,2,False,False,False,0.11564174521984098,0.11704545454545455
A10AE06,Insulin degludec,"['A10AE06', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc, and Gab 1.8 Activation of these proteins leads to activation of downstream signaling molecules including PI3 kinase and Akt.8 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.8","AInsulin (modulator, Humans); AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.10,A10AE,Insulin degludec and liraglutide,1727493,"insulin degludec, liraglutide",insulin degludec / liraglutide Injectable Product,Injectable Product,Xultophy Injectable Product,"['Shc', 'autophosphorylates', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",4,107,other,1,2,False,False,False,0.11564174521984098,0.11704545454545455
A10AE06,Insulin degludec,"['A10AE06', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc, and Gab 1.8 Activation of these proteins leads to activation of downstream signaling molecules including PI3 kinase and Akt.8 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.8","AInsulin (modulator, Humans); AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.10,A10AE,Insulin degludec,1670007,insulin degludec,"insulin degludec Injectable Product, insulin degludec / liraglutide Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"Tresiba Injectable Product, Xultophy Injectable Product","['Shc', 'autophosphorylates', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",4,107,other,1,1,False,False,False,0.11564174521984098,0.11704545454545455
A10AE06,Insulin degludec,"['A10AE06', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc, and Gab 1.8 Activation of these proteins leads to activation of downstream signaling molecules including PI3 kinase and Akt.8 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.8","AInsulin (modulator, Humans); AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.10,A10AE,Insulin detemir,139825,insulin detemir,insulin detemir Injectable Product,Injectable Product,Levemir Injectable Product,"['Shc', 'autophosphorylates', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",4,107,other,1,1,False,False,False,0.11564174521984098,0.11704545454545455
A10AE06,Insulin degludec,"['A10AE06', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin detemir binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units.8 The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor.8 The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc, and Gab 1.8 Activation of these proteins leads to activation of downstream signaling molecules including PI3 kinase and Akt.8 Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism.8","AInsulin (modulator, Humans); AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (activator, Humans)",Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.10,A10AE,Insulin glargine,274783,insulin glargine,"insulin glargine Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Lantus Injectable Product, Toujeo Injectable Product, Basaglar Injectable Product, Soliqua Injectable Product, Semglee Injectable Product, Rezvoglar Injectable Product","['Shc', 'autophosphorylates', 'glucose', 'bound', 'activation', 'metabolism', 'both', 'PKC', 'the', '8', 'C', 'detemir', 'Activation', 'binding', 'extracellular', 'The', 'numerous', '1', 'binds', 'IR', 'APS', 'Gab', 'heterotetrameric', 'leads', 'receptor', 'two', 'phosphorylates', 'roles', 'PI3', 'these', 'proteins', 'critical', 'in', 'beta', 'GLUT4', 'downstream', 'a', 'signaling', 'regulates', 'alpha', 'intrinsic', 'kinase', 'subunit', 'insulin', 'transmembrane', '4', 'which', 'and', 'consisting', 'units', 'substrates', 'molecules', 'play', 'intracellular', 'such', 'Akt', 'activity', 'transporter', 'protein', 'tyrosine', 'as', 'to', 'stimulates', 'IRS', 'catabolism', 'of', 'Insulin', 'including', 'Cbl']",4,107,other,1,1,False,False,False,0.11564174521984098,0.11704545454545455
A10AE07,Insulin icodec,"['A10AE07', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin and its analogues, including insulin icodec, lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.3 Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.3","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (agonist, Humans)","Insulin icodec is indicated for the once-weekly treatment of adults with diabetes mellitus in order to improve glycemic control.3,4",A10AE,Lixisenatide,1440051,lixisenatide,"lixisenatide Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Adlyxin Injectable Product, Soliqua Injectable Product","['its', 'glucose', 'inhibits', '3', 'by', 'lipolysis', 'inhibiting', 'production', 'icodec', 'hepatic', 'peripheral', 'especially', 'muscle', 'synthesis', 'also', 'skeletal', 'stimulating', 'insulin', 'enhances', 'fat', 'and', 'proteolysis', 'blood', 'analogues', 'protein', 'uptake', 'lower', 'Insulin', 'including']",3,37,other,1,1,False,False,False,0.03148770851677048,0.11704545454545455
A10AE07,Insulin icodec,"['A10AE07', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin and its analogues, including insulin icodec, lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.3 Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.3","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (agonist, Humans)","Insulin icodec is indicated for the once-weekly treatment of adults with diabetes mellitus in order to improve glycemic control.3,4",A10AE,Liraglutide,475968,liraglutide,"liraglutide Injectable Product, insulin degludec / liraglutide Injectable Product",Injectable Product,"Victoza Injectable Product, Saxenda Injectable Product, Xultophy Injectable Product","['its', 'glucose', 'inhibits', '3', 'by', 'lipolysis', 'inhibiting', 'production', 'icodec', 'hepatic', 'peripheral', 'especially', 'muscle', 'synthesis', 'also', 'skeletal', 'stimulating', 'insulin', 'enhances', 'fat', 'and', 'proteolysis', 'blood', 'analogues', 'protein', 'uptake', 'lower', 'Insulin', 'including']",3,37,other,1,1,False,False,False,0.03148770851677048,0.11704545454545455
A10AE07,Insulin icodec,"['A10AE07', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin and its analogues, including insulin icodec, lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.3 Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.3","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (agonist, Humans)","Insulin icodec is indicated for the once-weekly treatment of adults with diabetes mellitus in order to improve glycemic control.3,4",A10AE,Insulin glargine and lixisenatide,1858994,"lixisenatide, insulin glargine",insulin glargine / lixisenatide Injectable Product,Injectable Product,Soliqua Injectable Product,"['its', 'glucose', 'inhibits', '3', 'by', 'lipolysis', 'inhibiting', 'production', 'icodec', 'hepatic', 'peripheral', 'especially', 'muscle', 'synthesis', 'also', 'skeletal', 'stimulating', 'insulin', 'enhances', 'fat', 'and', 'proteolysis', 'blood', 'analogues', 'protein', 'uptake', 'lower', 'Insulin', 'including']",3,37,other,1,2,False,False,False,0.03148770851677048,0.11704545454545455
A10AE07,Insulin icodec,"['A10AE07', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin and its analogues, including insulin icodec, lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.3 Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.3","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (agonist, Humans)","Insulin icodec is indicated for the once-weekly treatment of adults with diabetes mellitus in order to improve glycemic control.3,4",A10AE,Insulin degludec and liraglutide,1727493,"insulin degludec, liraglutide",insulin degludec / liraglutide Injectable Product,Injectable Product,Xultophy Injectable Product,"['its', 'glucose', 'inhibits', '3', 'by', 'lipolysis', 'inhibiting', 'production', 'icodec', 'hepatic', 'peripheral', 'especially', 'muscle', 'synthesis', 'also', 'skeletal', 'stimulating', 'insulin', 'enhances', 'fat', 'and', 'proteolysis', 'blood', 'analogues', 'protein', 'uptake', 'lower', 'Insulin', 'including']",3,37,other,1,2,False,False,False,0.03148770851677048,0.11704545454545455
A10AE07,Insulin icodec,"['A10AE07', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin and its analogues, including insulin icodec, lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.3 Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.3","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (agonist, Humans)","Insulin icodec is indicated for the once-weekly treatment of adults with diabetes mellitus in order to improve glycemic control.3,4",A10AE,Insulin degludec,1670007,insulin degludec,"insulin degludec Injectable Product, insulin degludec / liraglutide Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"Tresiba Injectable Product, Xultophy Injectable Product","['its', 'glucose', 'inhibits', '3', 'by', 'lipolysis', 'inhibiting', 'production', 'icodec', 'hepatic', 'peripheral', 'especially', 'muscle', 'synthesis', 'also', 'skeletal', 'stimulating', 'insulin', 'enhances', 'fat', 'and', 'proteolysis', 'blood', 'analogues', 'protein', 'uptake', 'lower', 'Insulin', 'including']",3,37,other,1,1,False,False,False,0.03148770851677048,0.11704545454545455
A10AE07,Insulin icodec,"['A10AE07', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin and its analogues, including insulin icodec, lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.3 Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.3","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (agonist, Humans)","Insulin icodec is indicated for the once-weekly treatment of adults with diabetes mellitus in order to improve glycemic control.3,4",A10AE,Insulin detemir,139825,insulin detemir,insulin detemir Injectable Product,Injectable Product,Levemir Injectable Product,"['its', 'glucose', 'inhibits', '3', 'by', 'lipolysis', 'inhibiting', 'production', 'icodec', 'hepatic', 'peripheral', 'especially', 'muscle', 'synthesis', 'also', 'skeletal', 'stimulating', 'insulin', 'enhances', 'fat', 'and', 'proteolysis', 'blood', 'analogues', 'protein', 'uptake', 'lower', 'Insulin', 'including']",3,37,other,1,1,False,False,False,0.03148770851677048,0.11704545454545455
A10AE07,Insulin icodec,"['A10AE07', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,"Insulin and its analogues, including insulin icodec, lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.3 Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.3","AInsulin receptor (agonist, Humans); UInsulin-like growth factor 1 receptor (agonist, Humans)","Insulin icodec is indicated for the once-weekly treatment of adults with diabetes mellitus in order to improve glycemic control.3,4",A10AE,Insulin glargine,274783,insulin glargine,"insulin glargine Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Lantus Injectable Product, Toujeo Injectable Product, Basaglar Injectable Product, Soliqua Injectable Product, Semglee Injectable Product, Rezvoglar Injectable Product","['its', 'glucose', 'inhibits', '3', 'by', 'lipolysis', 'inhibiting', 'production', 'icodec', 'hepatic', 'peripheral', 'especially', 'muscle', 'synthesis', 'also', 'skeletal', 'stimulating', 'insulin', 'enhances', 'fat', 'and', 'proteolysis', 'blood', 'analogues', 'protein', 'uptake', 'lower', 'Insulin', 'including']",3,37,other,1,1,False,False,False,0.03148770851677048,0.11704545454545455
A10AE30,Combinations,"['A10AE30', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AE,Lixisenatide,1440051,lixisenatide,"lixisenatide Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Adlyxin Injectable Product, Soliqua Injectable Product","['mechanism', 'No', 'found']",1,3,other,1,1,True,True,True,,
A10AE30,Combinations,"['A10AE30', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AE,Liraglutide,475968,liraglutide,"liraglutide Injectable Product, insulin degludec / liraglutide Injectable Product",Injectable Product,"Victoza Injectable Product, Saxenda Injectable Product, Xultophy Injectable Product","['mechanism', 'No', 'found']",1,3,other,1,1,True,True,True,,
A10AE30,Combinations,"['A10AE30', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AE,Insulin glargine and lixisenatide,1858994,"lixisenatide, insulin glargine",insulin glargine / lixisenatide Injectable Product,Injectable Product,Soliqua Injectable Product,"['mechanism', 'No', 'found']",1,3,other,1,2,True,True,True,,
A10AE30,Combinations,"['A10AE30', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AE,Insulin degludec and liraglutide,1727493,"insulin degludec, liraglutide",insulin degludec / liraglutide Injectable Product,Injectable Product,Xultophy Injectable Product,"['mechanism', 'No', 'found']",1,3,other,1,2,True,True,True,,
A10AE30,Combinations,"['A10AE30', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AE,Insulin degludec,1670007,insulin degludec,"insulin degludec Injectable Product, insulin degludec / liraglutide Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"Tresiba Injectable Product, Xultophy Injectable Product","['mechanism', 'No', 'found']",1,3,other,1,1,True,True,True,,
A10AE30,Combinations,"['A10AE30', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AE,Insulin detemir,139825,insulin detemir,insulin detemir Injectable Product,Injectable Product,Levemir Injectable Product,"['mechanism', 'No', 'found']",1,3,other,1,1,True,True,True,,
A10AE30,Combinations,"['A10AE30', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10AE,Insulin glargine,274783,insulin glargine,"insulin glargine Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Lantus Injectable Product, Toujeo Injectable Product, Basaglar Injectable Product, Soliqua Injectable Product, Semglee Injectable Product, Rezvoglar Injectable Product","['mechanism', 'No', 'found']",1,3,other,1,1,True,True,True,,
A10AE54,Insulin glargine and lixisenatide,"['A10AE54', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Lixisenatide,1440051,lixisenatide,"lixisenatide Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Adlyxin Injectable Product, Soliqua Injectable Product",[],0,0,unknown,1,1,False,False,False,,0.3806818181818182
A10AE54,Insulin glargine and lixisenatide,"['A10AE54', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Liraglutide,475968,liraglutide,"liraglutide Injectable Product, insulin degludec / liraglutide Injectable Product",Injectable Product,"Victoza Injectable Product, Saxenda Injectable Product, Xultophy Injectable Product",[],0,0,unknown,1,1,False,False,False,,0.3806818181818182
A10AE54,Insulin glargine and lixisenatide,"['A10AE54', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Insulin glargine and lixisenatide,1858994,"lixisenatide, insulin glargine",insulin glargine / lixisenatide Injectable Product,Injectable Product,Soliqua Injectable Product,[],0,0,unknown,1,2,False,False,False,,0.3806818181818182
A10AE54,Insulin glargine and lixisenatide,"['A10AE54', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Insulin degludec and liraglutide,1727493,"insulin degludec, liraglutide",insulin degludec / liraglutide Injectable Product,Injectable Product,Xultophy Injectable Product,[],0,0,unknown,1,2,False,False,False,,0.3806818181818182
A10AE54,Insulin glargine and lixisenatide,"['A10AE54', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Insulin degludec,1670007,insulin degludec,"insulin degludec Injectable Product, insulin degludec / liraglutide Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"Tresiba Injectable Product, Xultophy Injectable Product",[],0,0,unknown,1,1,False,False,False,,0.3806818181818182
A10AE54,Insulin glargine and lixisenatide,"['A10AE54', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Insulin detemir,139825,insulin detemir,insulin detemir Injectable Product,Injectable Product,Levemir Injectable Product,[],0,0,unknown,1,1,False,False,False,,0.3806818181818182
A10AE54,Insulin glargine and lixisenatide,"['A10AE54', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Insulin glargine,274783,insulin glargine,"insulin glargine Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Lantus Injectable Product, Toujeo Injectable Product, Basaglar Injectable Product, Soliqua Injectable Product, Semglee Injectable Product, Rezvoglar Injectable Product",[],0,0,unknown,1,1,False,False,False,,0.3806818181818182
A10AE56,Insulin degludec and liraglutide,"['A10AE56', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Lixisenatide,1440051,lixisenatide,"lixisenatide Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Adlyxin Injectable Product, Soliqua Injectable Product",[],0,0,unknown,1,1,False,False,False,,0.3806818181818182
A10AE56,Insulin degludec and liraglutide,"['A10AE56', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Liraglutide,475968,liraglutide,"liraglutide Injectable Product, insulin degludec / liraglutide Injectable Product",Injectable Product,"Victoza Injectable Product, Saxenda Injectable Product, Xultophy Injectable Product",[],0,0,unknown,1,1,False,False,False,,0.3806818181818182
A10AE56,Insulin degludec and liraglutide,"['A10AE56', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Insulin glargine and lixisenatide,1858994,"lixisenatide, insulin glargine",insulin glargine / lixisenatide Injectable Product,Injectable Product,Soliqua Injectable Product,[],0,0,unknown,1,2,False,False,False,,0.3806818181818182
A10AE56,Insulin degludec and liraglutide,"['A10AE56', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Insulin degludec and liraglutide,1727493,"insulin degludec, liraglutide",insulin degludec / liraglutide Injectable Product,Injectable Product,Xultophy Injectable Product,[],0,0,unknown,1,2,False,False,False,,0.3806818181818182
A10AE56,Insulin degludec and liraglutide,"['A10AE56', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Insulin degludec,1670007,insulin degludec,"insulin degludec Injectable Product, insulin degludec / liraglutide Injectable Product, insulin aspart, human / insulin degludec Injectable Product",Injectable Product,"Tresiba Injectable Product, Xultophy Injectable Product",[],0,0,unknown,1,1,False,False,False,,0.3806818181818182
A10AE56,Insulin degludec and liraglutide,"['A10AE56', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Insulin detemir,139825,insulin detemir,insulin detemir Injectable Product,Injectable Product,Levemir Injectable Product,[],0,0,unknown,1,1,False,False,False,,0.3806818181818182
A10AE56,Insulin degludec and liraglutide,"['A10AE56', 'A10AE', 'A10A', 'A10', 'A']",True,1,1,,,,A10AE,Insulin glargine,274783,insulin glargine,"insulin glargine Injectable Product, insulin glargine / lixisenatide Injectable Product",Injectable Product,"Lantus Injectable Product, Toujeo Injectable Product, Basaglar Injectable Product, Soliqua Injectable Product, Semglee Injectable Product, Rezvoglar Injectable Product",[],0,0,unknown,1,1,False,False,False,,0.3806818181818182
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,"Metformin, linagliptin and empagliflozin",2281864,"linagliptin, empagliflozin, metformin","empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Trijardy Oral Product, Trijardy Pill","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,3,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,"Metformin, saxagliptin and dapagliflozin",2117292,"dapagliflozin, metformin, saxagliptin",,,,"['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,0,3,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and ertugliflozin,1992684,"ertugliflozin, metformin","ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and empagliflozin,1664314,"empagliflozin, metformin","empagliflozin / metformin Oral Product, empagliflozin / metformin Pill","Oral Product, Pill","Synjardy Oral Product, Synjardy Pill","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and canagliflozin,1545149,"canagliflozin, metformin","canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokamet Oral Product, Invokamet Pill","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and dapagliflozin,1486436,"dapagliflozin, metformin","dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill","Oral Product, Pill","Xigduo Oral Product, Xigduo Pill","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and repaglinide,802646,"metformin, repaglinide","metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill",,"['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and alogliptin,1368384,"alogliptin, metformin","alogliptin / metformin Oral Product, alogliptin / metformin Pill","Oral Product, Pill","Kazano Oral Product, Kazano Pill","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and linagliptin,1243019,"linagliptin, metformin","linagliptin / metformin Oral Product, linagliptin / metformin Pill","Oral Product, Pill","Jentadueto Oral Product, Jentadueto Pill","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and saxagliptin,1043562,"metformin, saxagliptin","metformin / saxagliptin Oral Product, metformin / saxagliptin Pill","Oral Product, Pill","Kombiglyze Pill, Kombiglyze Oral Product","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and sitagliptin,729717,"sitagliptin, metformin","metformin / sitagliptin Oral Product, metformin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Zituvimet Oral Product, Zituvimet Pill","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and pioglitazone,607999,"pioglitazone, metformin","metformin / pioglitazone Oral Product, metformin / pioglitazone Pill","Oral Product, Pill","Actoplus Met Oral Product, Actoplus Met Pill","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin and rosiglitazone,614348,"metformin, rosiglitazone","metformin / rosiglitazone Oral Product, metformin / rosiglitazone Pill","Oral Product, Pill",,"['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,2,2,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Metformin,235743,metformin,"glyburide / metformin Pill, metformin / pioglitazone Oral Product, metformin / pioglitazone Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill, metformin / rosiglitazone Oral Product, metformin / rosiglitazone Pill, metformin / saxagliptin Oral Product, metformin / saxagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, metformin Oral Liquid Product, metformin Oral Product, metformin Pill, glipizide / metformin Oral Product, glipizide / metformin Pill, glyburide / metformin Oral Product, linagliptin / metformin Oral Product, linagliptin / metformin Pill, alogliptin / metformin Oral Product, alogliptin / metformin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill, Oral Liquid Product","Janumet Oral Product, Janumet Pill, Actoplus Met Oral Product, Actoplus Met Pill, Glucophage Oral Product, Glucophage Pill, Glumetza Oral Product, Glumetza Pill, Kombiglyze Pill, Kombiglyze Oral Product, Riomet Oral Liquid Product, Riomet Oral Product, Jentadueto Oral Product, Jentadueto Pill, Kazano Oral Product, Kazano Pill, Invokamet Oral Product, Invokamet Pill, Xigduo Oral Product, Xigduo Pill, Synjardy Oral Product, Synjardy Pill, Segluromet Oral Product, Segluromet Pill, Trijardy Oral Product, Trijardy Pill, Zituvimet Oral Product, Zituvimet Pill","['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,3,1,False,False,False,0.05813789741207869,0.0
A10BA01,Phenformin,"['A10BA01', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).","A5'-AMP-activated protein kinase catalytic subunit alpha-1 (activator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (activator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (activator, Humans); UATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",For the reatment of type II diabetes mellitus.,A10BA,Phenformin,235288,phenformin,,,,"['when', '1', 'binds', 'monitors', 'also', 'inhibit', 'body', 'an', 'cells', 'decrease', 'activate', 'influence', 'protein', 'ATP', 'causing', 'energy', 'that', 'glucose', 'metabolism', 'AMPK', 'processes', 'are', 'activated', 'sensitive', 'receptor', 'seems', 'state', 'kinase', 'varients', 'activating', 'and', 'activity', 'fooling', 'independently', 'as', 'to', 'levels', 'Phenformin', 'ion', 'low', 'down', 'effect', 'biguanide', 'subtype', 'consuming', 'consumption', 'several', 'it', 'in', 'ultra', 'potassium', 'insulin', 'transport', 'is', 'been', 'if', 'caloric', 'of', 'sensor', 'This', 'the', 'use', 'hypoglycemic', 'phenformin', 's', 'The', 'AMP', 'has', 'Kir6', 'channels', 'thinking', 'namely', 'shown', 'a', 'regulates', 'into', 'drug', 'related', 'cellular']",5,100,other,0,1,False,False,False,0.05813789741207869,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,"Metformin, linagliptin and empagliflozin",2281864,"linagliptin, empagliflozin, metformin","empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Trijardy Oral Product, Trijardy Pill","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,3,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,"Metformin, saxagliptin and dapagliflozin",2117292,"dapagliflozin, metformin, saxagliptin",,,,"['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,0,3,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and ertugliflozin,1992684,"ertugliflozin, metformin","ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and empagliflozin,1664314,"empagliflozin, metformin","empagliflozin / metformin Oral Product, empagliflozin / metformin Pill","Oral Product, Pill","Synjardy Oral Product, Synjardy Pill","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and canagliflozin,1545149,"canagliflozin, metformin","canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokamet Oral Product, Invokamet Pill","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and dapagliflozin,1486436,"dapagliflozin, metformin","dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill","Oral Product, Pill","Xigduo Oral Product, Xigduo Pill","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and repaglinide,802646,"metformin, repaglinide","metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill",,"['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and alogliptin,1368384,"alogliptin, metformin","alogliptin / metformin Oral Product, alogliptin / metformin Pill","Oral Product, Pill","Kazano Oral Product, Kazano Pill","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and linagliptin,1243019,"linagliptin, metformin","linagliptin / metformin Oral Product, linagliptin / metformin Pill","Oral Product, Pill","Jentadueto Oral Product, Jentadueto Pill","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and saxagliptin,1043562,"metformin, saxagliptin","metformin / saxagliptin Oral Product, metformin / saxagliptin Pill","Oral Product, Pill","Kombiglyze Pill, Kombiglyze Oral Product","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and sitagliptin,729717,"sitagliptin, metformin","metformin / sitagliptin Oral Product, metformin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Zituvimet Oral Product, Zituvimet Pill","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and pioglitazone,607999,"pioglitazone, metformin","metformin / pioglitazone Oral Product, metformin / pioglitazone Pill","Oral Product, Pill","Actoplus Met Oral Product, Actoplus Met Pill","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin and rosiglitazone,614348,"metformin, rosiglitazone","metformin / rosiglitazone Oral Product, metformin / rosiglitazone Pill","Oral Product, Pill",,"['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,2,2,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Metformin,235743,metformin,"glyburide / metformin Pill, metformin / pioglitazone Oral Product, metformin / pioglitazone Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill, metformin / rosiglitazone Oral Product, metformin / rosiglitazone Pill, metformin / saxagliptin Oral Product, metformin / saxagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, metformin Oral Liquid Product, metformin Oral Product, metformin Pill, glipizide / metformin Oral Product, glipizide / metformin Pill, glyburide / metformin Oral Product, linagliptin / metformin Oral Product, linagliptin / metformin Pill, alogliptin / metformin Oral Product, alogliptin / metformin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill, Oral Liquid Product","Janumet Oral Product, Janumet Pill, Actoplus Met Oral Product, Actoplus Met Pill, Glucophage Oral Product, Glucophage Pill, Glumetza Oral Product, Glumetza Pill, Kombiglyze Pill, Kombiglyze Oral Product, Riomet Oral Liquid Product, Riomet Oral Product, Jentadueto Oral Product, Jentadueto Pill, Kazano Oral Product, Kazano Pill, Invokamet Oral Product, Invokamet Pill, Xigduo Oral Product, Xigduo Pill, Synjardy Oral Product, Synjardy Pill, Segluromet Oral Product, Segluromet Pill, Trijardy Oral Product, Trijardy Pill, Zituvimet Oral Product, Zituvimet Pill","['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,3,1,False,False,False,0.04744699931645266,0.0
A10BA02,Metformin,"['A10BA02', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,"Metformin's mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.23 It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.6,11   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.","AMultidrug and toxin extrusion protein 1 (modulator, Humans); AAcetyl-CoA carboxylase 2 (activator, Humans); AElectron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (inhibitor, Humans); A5'-AMP-activated protein kinase subunit beta-1 (induceractivator, Humans); UGlycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (inhibitor, Humans)",Metformin immediate-release formulations,A10BA,Phenformin,235288,phenformin,,,,"['inhibits', 'II', 'production', 'since', 'peripheral', 'also', 'decreasing', 'gluconeogenesis', 'control', 'mechanisms', 'exerting', '11', 'positive', 'decrease', 'blood', 'absorption', 'uptake', 'sensitivity', 'that', 'glucose', 'by', 'intestinal', 'processes', 'are', 'hepatic', 'called', 'oral', 'potent', 'managing', 'utilization', 'other', 'drugs', 'and', 'activity', 'to', 'decreases', 'lead', 'levels', 'through', 'mitochondrial', 'classes', 'mechanism', 'complex', 'increasing', 'type', 'antihyperglycemic', 'It', 'it', 'in', 'from', 'insulin', 'is', 'been', 'on', 'antidiabetic', 'well', 'of', 'generally', 'above', 'its', 'the', 'glycemic', 's', 'Metformin', 'established', 'diabetes', 'The', 'this', '23', 'has', 'metformin', 'postulated', 'action', 'a', '6', 'effects', 'unique', 'I', 'occur']",8,91,other,0,1,False,False,False,0.04744699931645266,0.0
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,"Metformin, linagliptin and empagliflozin",2281864,"linagliptin, empagliflozin, metformin","empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Trijardy Oral Product, Trijardy Pill","['Not', 'Available']",1,2,other,2,3,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,"Metformin, saxagliptin and dapagliflozin",2117292,"dapagliflozin, metformin, saxagliptin",,,,"['Not', 'Available']",1,2,other,0,3,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and ertugliflozin,1992684,"ertugliflozin, metformin","ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and empagliflozin,1664314,"empagliflozin, metformin","empagliflozin / metformin Oral Product, empagliflozin / metformin Pill","Oral Product, Pill","Synjardy Oral Product, Synjardy Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and canagliflozin,1545149,"canagliflozin, metformin","canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokamet Oral Product, Invokamet Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and dapagliflozin,1486436,"dapagliflozin, metformin","dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill","Oral Product, Pill","Xigduo Oral Product, Xigduo Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and repaglinide,802646,"metformin, repaglinide","metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and alogliptin,1368384,"alogliptin, metformin","alogliptin / metformin Oral Product, alogliptin / metformin Pill","Oral Product, Pill","Kazano Oral Product, Kazano Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and linagliptin,1243019,"linagliptin, metformin","linagliptin / metformin Oral Product, linagliptin / metformin Pill","Oral Product, Pill","Jentadueto Oral Product, Jentadueto Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and saxagliptin,1043562,"metformin, saxagliptin","metformin / saxagliptin Oral Product, metformin / saxagliptin Pill","Oral Product, Pill","Kombiglyze Pill, Kombiglyze Oral Product","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and sitagliptin,729717,"sitagliptin, metformin","metformin / sitagliptin Oral Product, metformin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Zituvimet Oral Product, Zituvimet Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and pioglitazone,607999,"pioglitazone, metformin","metformin / pioglitazone Oral Product, metformin / pioglitazone Pill","Oral Product, Pill","Actoplus Met Oral Product, Actoplus Met Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin and rosiglitazone,614348,"metformin, rosiglitazone","metformin / rosiglitazone Oral Product, metformin / rosiglitazone Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Metformin,235743,metformin,"glyburide / metformin Pill, metformin / pioglitazone Oral Product, metformin / pioglitazone Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill, metformin / rosiglitazone Oral Product, metformin / rosiglitazone Pill, metformin / saxagliptin Oral Product, metformin / saxagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, metformin Oral Liquid Product, metformin Oral Product, metformin Pill, glipizide / metformin Oral Product, glipizide / metformin Pill, glyburide / metformin Oral Product, linagliptin / metformin Oral Product, linagliptin / metformin Pill, alogliptin / metformin Oral Product, alogliptin / metformin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill, Oral Liquid Product","Janumet Oral Product, Janumet Pill, Actoplus Met Oral Product, Actoplus Met Pill, Glucophage Oral Product, Glucophage Pill, Glumetza Oral Product, Glumetza Pill, Kombiglyze Pill, Kombiglyze Oral Product, Riomet Oral Liquid Product, Riomet Oral Product, Jentadueto Oral Product, Jentadueto Pill, Kazano Oral Product, Kazano Pill, Invokamet Oral Product, Invokamet Pill, Xigduo Oral Product, Xigduo Pill, Synjardy Oral Product, Synjardy Pill, Segluromet Oral Product, Segluromet Pill, Trijardy Oral Product, Trijardy Pill, Zituvimet Oral Product, Zituvimet Pill","['Not', 'Available']",1,2,other,3,1,True,True,True,,
A10BA03,Buformin,"['A10BA03', 'A10BA', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BA,Phenformin,235288,phenformin,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,2,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,2,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,1,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,1,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,1,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,1,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,1,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Carbutamide,2068,carbutamide,,,,"['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,0,1,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,1,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Glibornuride,102846,glibornuride,,,,"['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,0,1,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,1,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,1,False,False,False,0.03778426453062452,0.0
A10BB01,Glibenclamide,"['A10BB01', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Glyburide belongs to a class of drugs known as sulfonylureas.7  These drugs act by closing ATP-sensitive potassium channels on pancreatic beta cells.7 The ATP-sensitive potassium channels on beta cells are known as sulfonylurea receptor 1 (SUR1).7,"AATP-binding cassette sub-family C member 8 (modulator, Humans); ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); UATP-binding cassette sub-family C member 9 (modulator, Humans); UBile salt export pump (inhibitor, Humans); UPhospholipid-transporting ATPase ABCA1 (inhibitor, Humans); UMitochondrial ATP-sensitive potassium channel (inhibitor, Humans); UCarnitine O-palmitoyltransferase 1, liver isoform (inhibitor, Humans); UCystic fibrosis transmembrane conductance regulator (antagonist, Humans); UTransient receptor potential cation channel subfamily M member 4 (inhibitor, Humans)","Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.11,12",A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['class', 'sulfonylurea', 'These', 'by', 'The', '1', 'are', 'sensitive', 'receptor', 'channels', 'Glyburide', 'known', 'closing', 'beta', 'a', 'pancreatic', 'sulfonylureas', 'potassium', 'drugs', 'cells', 'belongs', 'on', 'ATP', 'as', 'to', '7', 'of', 'SUR1', 'act']",12,36,other,2,1,False,False,False,0.03778426453062452,0.0
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,2,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,2,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Carbutamide,2068,carbutamide,,,,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,0,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glibornuride,102846,glibornuride,,,,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,0,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB02,Chlorpropamide,"['A10BB02', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'chlorpropamide', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'such', 'intracellular', 'conductance', 'on', 'ATP', 'as', 'to', 'causing', 'stimulates', 'calcium', 'secretion', 'bind', 'of']",3,46,other,2,1,False,False,False,0.06581408600820451,0.07665903890160183
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,2,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,2,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Carbutamide,2068,carbutamide,,,,"['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,0,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Glibornuride,102846,glibornuride,,,,"['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,0,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB03,Tolbutamide,"['A10BB03', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas lower blood glucose in patients with NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor (receptor 1) on the beta cell. Sulfonylureas inhibit the ATP-potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin-containing granules by exocytosis, an effect similar to that of glucose.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans)",For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise.,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['that', 'exocytosis', 'glucose', 'NIDDM', 'functioning', 'sulfonylurea', 'patients', 'effect', 'activation', 'by', 'the', 'release', 'cell', 'depolarization', 'binding', '1', 'similar', 'membrane', 'granules', 'receptor', 'Sulfonylureas', 'channels', 'involves', 'directly', 'influx', 'process', 'unknown', 'with', 'inhibit', 'in', 'beta', 'calmodulin', 'a', 'from', 'containing', 'pancreatic', 'an', 'stimulating', 'potassium', 'efflux', 'kinase', 'insulin', 'acute', 'cells', 'which', 'islet', 'and', 'tissue', 'blood', 'on', 'ATP', 'calcium', 'to', 'results', 'lower', 'of']",4,77,other,2,1,False,False,False,0.0724238513374395,0.02631578947368421
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Carbutamide,2068,carbutamide,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glibornuride,102846,glibornuride,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB04,Glibornuride,"['A10BB04', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,2,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,2,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Carbutamide,2068,carbutamide,,,,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,0,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Glibornuride,102846,glibornuride,,,,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,0,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB05,Tolazamide,"['A10BB05', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.","ASulfonylurea receptor 1, Kir6.2 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans)",For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['through', 'exocytosis', 'ion', 'raising', 'or', 'surface', 'the', 'concentrations', 'voltage', 'depolarization', 'cell', 'likely', 'induces', 'sensitive', 'membrane', 'Sulfonylureas', 'channels', 'influx', 'reducing', 'Depolarization', 'channel', 'pancreatic', 'potassium', 'ions', 'which', 'insulin', 'and', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'bind', 'of']",4,44,other,2,1,False,False,False,0.06358545754358015,0.03546910755148741
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Carbutamide,2068,carbutamide,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glibornuride,102846,glibornuride,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB06,Carbutamide,"['A10BB06', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,2,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,2,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Carbutamide,2068,carbutamide,,,,"['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,0,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Glibornuride,102846,glibornuride,,,,"['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,0,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB07,Glipizide,"['A10BB07', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.5 Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Label,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['lifestyle', 'response', 'Early', 'Characterized', 'production', 'diet', 'islets', 'behavioral', 'muscle', 'interaction', 'chronic', 'resistance', '2', 'there', 'cells', 'environmental', 'blood', 'worldwide', 'T2DM', 'uptake', 'complications', 'normal', 'Insulin', 'that', 'normally', 'events', 'glucose', 'controlled', 'by', 'are', 'mainly', 'arises', 'involves', 'reducing', 'produce', 'with', 'occurring', 'genetic', 'factors', 'storage', 'risk', 'secondary', 'and', 'for', 'as', 'to', 'mortality', 'lead', 'levels', 'management', 'promotes', 'exercise', 'than', 'role', 'complex', 'hormone', 'increasing', 'Type', 'regulating', 'critical', 'in', 'beta', 'from', 'pancreatic', 'pathophysiology', 'insulin', 'long', 'disorder', 'is', 'of', 'insensitivity', 'peptide', 'the', 'between', 'declining', 'prevalence', 'high', 'diabetes', 'failure', 'eventual', 'intervention', 'result', 'term', 'liver', 'plays', 'Although', 'a', 'cardiovascular', 'into', 'In', 'fat', 'multiple', 'such', 'mellitus', 'metabolic', '5', 'higher']",4,142,other,2,1,False,False,False,0.057383359586739624,0.09382151029748284
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,2,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,2,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Carbutamide,2068,carbutamide,,,,"['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,0,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Glibornuride,102846,glibornuride,,,,"['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,0,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB08,Gliquidone,"['A10BB08', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans)",Used in the treatment of diabetes mellitus type 2.,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['through', 'appears', 'ion', 'glucose', 'functioning', 'This', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'likely', 'The', 'increase', 'induces', 'binds', 'peripheral', 'tissues', 'sensitive', 'membrane', 'channels', 'influx', 'reducing', 'action', 'in', 'dependent', 'beta', 'channel', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'concentration', 'gliquidone', 'blood', 'intracellular', 'conductance', 'on', 'Gliquidone', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,77,other,2,1,False,False,False,0.07977180942961117,0.057208237986270026
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,2,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,2,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,1,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,1,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,1,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,1,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,1,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Carbutamide,2068,carbutamide,,,,"['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,0,1,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,1,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glibornuride,102846,glibornuride,,,,"['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,0,1,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,1,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,1,False,False,False,0.06485465519766392,0.0
A10BB09,Gliclazide,"['A10BB09', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.","AATP-binding cassette sub-family C member 8 (binder, Humans); UVascular endothelial growth factor A, long form (other/unknown, Humans)",For the treatment of NIDDM in conjunction with diet and exercise.,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['exocytosis', 'This', 'activation', 'the', 'voltage', 'depolarization', 'cell', 'binding', 'The', 'binds', 'leads', 'sensitive', 'granules', 'receptor', 'channels', 'Gliclazide', 'secretorty', 'in', 'dependent', 'calmodulin', 'a', 'containing', 'potassium', 'efflux', 'subsequently', 'opens', 'β', 'resulting', 'cells', 'decrease', 'and', 'which', 'insulin', 'closure', 'sulfonyl', 'turn', 'ATP', 'to', 'calcium', 'results', 'blocks', 'urea', 'of', 'SUR1']",4,67,other,2,1,False,False,False,0.06485465519766392,0.0
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,2,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Carbutamide,2068,carbutamide,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glibornuride,102846,glibornuride,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB10,Metahexamide,"['A10BB10', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,2,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,2,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Carbutamide,2068,carbutamide,,,,"['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,0,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Glibornuride,102846,glibornuride,,,,"['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,0,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB11,Glisoxepide,"['A10BB11', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Glisoxepide is a hypoglycemic sulphonylurea agent. The sulphonylureas are a family of drugs based on a common sulphonylurea core. These drugs act via augmentation of secretion of insulin from pancreatic beta-cells. Sulphonylureas may also cause a reduction in serum glucagon and potentiate the action of insulin at the extrapancreatic tissues.  Glisoxepide functions as a non-selective K(ATP) channel blocker.  It is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. This inhibits a tonic, hyperpolarizing efflux of potassium, thus causing the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 8 (inhibitor, Humans); UInsulin (regulator, Humans)",For the treatment of diabetes mellitus type 2.,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['inhibits', 'non', 'at', 'leads', 'cause', 'sulphonylurea', 'hyperpolarizing', 'also', 'reduction', '2', 'common', 'positive', 'opens', 'cells', 'thought', 'more', 'ATP', 'causing', 'calcium', 'secretion', 'thus', 'glucagon', 'rise', 'by', 'potentiate', 'depolarization', 'stimulate', 'serum', 'augmentation', 'are', 'sensitive', 'selective', 'become', 'agent', 'with', 'channel', 'Glisoxepide', 'efflux', 'K', 'drugs', 'and', 'potential', 'intracellular', 'via', 'as', 'to', 'family', 'fusion', 'granulae', 'complex', 'functions', 'Sulphonylureas', 'membrane', 'over', 'increased', 'It', 'in', 'beta', 'may', 'from', 'pancreatic', 'KATP', 'potassium', 'insulin', 'is', 'on', 'gated', 'of', 'core', 'based', 'These', 'Ca2', 'This', 'the', 'hypoglycemic', 'voltage', 'cell', 'pro', 'The', 'tissues', 'Kir6', 'tonic', 'blocker', 'channels', 'action', 'closing', 'electric', 'a', 'therefore', 'extrapancreatic', 'sulphonylureas', 'SUR1', 'act']",4,127,other,2,1,False,False,False,0.07147151578062143,0.014874141876430207
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,2,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,2,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Carbutamide,2068,carbutamide,,,,"['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,0,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Glibornuride,102846,glibornuride,,,,"['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,0,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB12,Glimepiride,"['A10BB12', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.7 In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).6 When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.6 In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.6 Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.3 Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.3","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-sensitive inward rectifier potassium channel 11 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (inducer, Humans)",Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['ADP', 'non', 'at', 'subunits', 'forming', 'elevated', 'ratio', '1', 'leads', 'granules', 'contrast', 'A', 'regulatory', 'sites', '2', 'Glimepiride', 'causes', 'an', 'stored', 'there', 'regulators', 'When', 'cells', 'decrease', 'play', 'opening', 'closure', 'ATP', 'calcium', 'secretion', 'uptake', 'SUR', 'that', 'exocytosis', 'glucose', 'activation', 'by', 'depolarization', 'are', 'activated', 'sensitive', 'isoforms', 'composed', 'receptor', 'essential', 'open', 'vesicles', 'with', 'channel', 'allows', 'sensors', 'efflux', 'splicing', 'K', 'specifically', 'and', 'consequently', 'intracellular', 'for', 'excitability', 'as', 'to', 'couple', 'levels', 'Elevated', 'hyperpolarization', 'sulfonylurea', '3', 'both', 'contraction', 'role', 'complex', 'concentrations', 'binding', 'membrane', 'increased', 'SUR1', 'influx', 'in', 'dependent', 'beta', 'suppression', 'actomyosin', 'leading', 'from', 'pancreatic', 'potassium', 'hetero', 'octomeric', 'pore', 'insulin', 'promote', 'expressed', 'is', 'on', 'filaments', 'well', 'gated', 'blocks', 'of', 'SUR2A', 'different', 'Ca2', 'the', 'Alternative', 'voltage', 'cell', 'The', 'tissues', 'four', 'Kir6', 'channels', 'Depolarization', 'responsible', 'a', 'stimulated', 'formation', '6', '2A', 'into', 'subunit', 'In', 'ions', 'B', 'GSIS', 'metabolic', '7', 'site', 'varying']",5,218,other,2,1,False,False,False,0.06674136416221985,0.020594965675057208
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Glimepiride and pioglitazone,647235,"glimepiride, pioglitazone","glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill","['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,2,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Glimepiride and rosiglitazone,606253,"glimepiride, rosiglitazone","glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill","Oral Product, Pill",,"['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,2,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Acetohexamide,173,acetohexamide,"acetohexamide Oral Product, acetohexamide Pill","Oral Product, Pill",,"['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,1,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Glimepiride,25789,glimepiride,"glimepiride / pioglitazone Oral Product, glimepiride / pioglitazone Pill, glimepiride / rosiglitazone Oral Product, glimepiride / rosiglitazone Pill, glimepiride Oral Product, glimepiride Pill","Oral Product, Pill","Duetact Oral Product, Duetact Pill, Amaryl Oral Product, Amaryl Pill","['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,1,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Gliclazide,4816,gliclazide,"gliclazide Oral Product, gliclazide Pill","Oral Product, Pill",,"['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,1,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Gliquidone,25793,gliquidone,"gliquidone Oral Product, gliquidone Pill","Oral Product, Pill",,"['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,1,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Glipizide,4821,glipizide,"glipizide / metformin Oral Product, glipizide / metformin Pill, glipizide Oral Product, glipizide Pill","Oral Product, Pill","Glucotrol Oral Product, Glucotrol Pill","['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,1,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Carbutamide,2068,carbutamide,,,,"['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,0,1,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Tolazamide,10633,tolazamide,"tolazamide Oral Product, tolazamide Pill","Oral Product, Pill",,"['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,1,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Glibornuride,102846,glibornuride,,,,"['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,0,1,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Tolbutamide,10635,tolbutamide,"tolbutamide Oral Product, tolbutamide Pill","Oral Product, Pill",,"['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,1,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Chlorpropamide,2404,chlorpropamide,"chlorpropamide Oral Product, chlorpropamide Pill","Oral Product, Pill",,"['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,1,False,False,False,0.06950740821312708,0.0
A10BB31,Acetohexamide,"['A10BB31', 'A10BB', 'A10B', 'A10', 'A']",True,1,1,"Sulfonylureas such as acetohexamide bind to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing outflux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (inhibitor, Humans); AATP-binding cassette sub-family C member 8 (modulator, Humans)",Used in the management of diabetes mellitus type 2 (adult-onset).,A10BB,Glibenclamide,4815,glyburide,"glyburide / metformin Pill, glyburide Oral Product, glyburide Pill, glyburide / metformin Oral Product","Oral Product, Pill","Glynase Oral Product, Glynase Pill","['acetohexamide', 'rise', 'fusion', 'granulae', 'inhibits', 'This', 'Ca2', 'the', 'voltage', 'depolarization', 'cell', 'pro', 'The', 'leads', 'outflux', 'membrane', 'over', 'increased', 'tonic', 'become', 'Sulfonylureas', 'channels', 'hyperpolarizing', 'electric', 'with', 'in', 'dependent', 'channel', 'beta', 'a', 'therefore', 'pancreatic', 'an', 'causes', 'potassium', 'positive', 'K', 'opens', 'cells', 'which', 'insulin', 'and', 'potential', 'such', 'intracellular', 'more', 'on', 'ATP', 'as', 'to', 'calcium', 'secretion', 'bind', 'gated', 'of']",3,66,other,2,1,False,False,False,0.06950740821312708,0.0
A10BC01,Glymidine,"['A10BC01', 'A10BC', 'A10B', 'A10', 'A']",True,1,1,"The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. The rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of (pro)insulin.","AATP-sensitive inward rectifier potassium channel 1 (other/unknown, Humans); AATP-sensitive inward rectifier potassium channel 10 (binder, Humans); UATP-binding cassette sub-family C member 8 (inducer, Humans)",Glycodiazine is used concomitantly with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.,A10BC,Glymidine,102848,glymidine,,,,"['through', 'appears', 'ion', 'rise', 'glucose', 'functioning', 'fusion', 'granulae', 'mechanism', 'lowering', 'be', 'the', 'surface', 'voltage', 'increasing', 'release', 'cell', 'depolarization', 'pro', 'likely', 'glycodiazine', 'The', 'binds', 'leads', 'peripheral', 'tissues', 'sensitive', 'membrane', 'increased', 'channels', 'influx', 'reducing', 'action', 'with', 'in', 'Glycodiazine', 'dependent', 'beta', 'channel', 'therefore', 'from', 'pancreatic', 'stimulating', 'potassium', 'Membrane', 'insulin', 'cells', 'and', 'blood', 'intracellular', 'conductance', 'on', 'ATP', 'causing', 'to', 'stimulates', 'calcium', 'secretion', 'receptors', 'sensitivity', 'of']",4,87,other,0,1,False,False,False,0.0924835290550387,0.014672686230248307
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD01,Phenformin and sulfonylureas,"['A10BD01', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD02,Metformin and sulfonylureas,"['A10BD02', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD03,Metformin and rosiglitazone,"['A10BD03', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD04,Glimepiride and rosiglitazone,"['A10BD04', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD05,Metformin and pioglitazone,"['A10BD05', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD06,Glimepiride and pioglitazone,"['A10BD06', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD07,Metformin and sitagliptin,"['A10BD07', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD08,Metformin and vildagliptin,"['A10BD08', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD09,Pioglitazone and alogliptin,"['A10BD09', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD10,Metformin and saxagliptin,"['A10BD10', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD11,Metformin and linagliptin,"['A10BD11', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD12,Pioglitazone and sitagliptin,"['A10BD12', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD13,Metformin and alogliptin,"['A10BD13', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD14,Metformin and repaglinide,"['A10BD14', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD15,Metformin and dapagliflozin,"['A10BD15', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD16,Metformin and canagliflozin,"['A10BD16', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD17,Metformin and acarbose,"['A10BD17', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD18,Metformin and gemigliptin,"['A10BD18', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD19,Linagliptin and empagliflozin,"['A10BD19', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD20,Metformin and empagliflozin,"['A10BD20', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD21,Saxagliptin and dapagliflozin,"['A10BD21', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD22,Metformin and evogliptin,"['A10BD22', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD23,Metformin and ertugliflozin,"['A10BD23', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD24,Sitagliptin and ertugliflozin,"['A10BD24', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD25,"Metformin, saxagliptin and dapagliflozin","['A10BD25', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD26,Metformin and lobeglitazone,"['A10BD26', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD27,"Metformin, linagliptin and empagliflozin","['A10BD27', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD28,Metformin and teneligliptin,"['A10BD28', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Ertugliflozin,1992672,ertugliflozin,"ertugliflozin / metformin Oral Product, ertugliflozin / metformin Pill, ertugliflozin Oral Product, ertugliflozin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Segluromet Oral Product, Segluromet Pill, Steglatro Oral Product, Steglatro Pill, Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Empagliflozin,1545653,empagliflozin,"empagliflozin Oral Product, empagliflozin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / metformin Oral Product, empagliflozin / metformin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Jardiance Oral Product, Jardiance Pill, Glyxambi Oral Product, Glyxambi Pill, Synjardy Oral Product, Synjardy Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Canagliflozin,1373458,canagliflozin,"canagliflozin Oral Product, canagliflozin Pill, canagliflozin / metformin Oral Product, canagliflozin / metformin Pill","Oral Product, Pill","Invokana Oral Product, Invokana Pill, Invokamet Oral Product, Invokamet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Dapagliflozin,1488564,dapagliflozin,"dapagliflozin Oral Product, dapagliflozin Pill, dapagliflozin / metformin Oral Product, dapagliflozin / metformin Pill, dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill, dapagliflozin / metformin / saxagliptin Oral Product","Oral Product, Pill","Farxiga Oral Product, Farxiga Pill, Xigduo Oral Product, Xigduo Pill, Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Repaglinide,73044,repaglinide,"repaglinide Oral Product, repaglinide Pill, metformin / repaglinide Oral Product, metformin / repaglinide Pill","Oral Product, Pill","Prandin Oral Product, Prandin Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin,1100699,linagliptin,"linagliptin Oral Product, linagliptin Pill, linagliptin / metformin Oral Product, linagliptin / metformin Pill, empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill, empagliflozin / linagliptin / metformin Oral Product, empagliflozin / linagliptin / metformin Pill","Oral Product, Pill","Tradjenta Oral Product, Tradjenta Pill, Jentadueto Oral Product, Jentadueto Pill, Glyxambi Oral Product, Glyxambi Pill, Trijardy Oral Product, Trijardy Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin,593411,sitagliptin,"sitagliptin Oral Product, sitagliptin Pill, metformin / sitagliptin Oral Product, metformin / sitagliptin Pill, ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Janumet Oral Product, Janumet Pill, Januvia Oral Product, Januvia Pill, Steglujan Oral Product, Steglujan Pill, Zituvio Oral Product, Zituvio Pill, Zituvimet Oral Product, Zituvimet Pill",[],0,0,unknown,2,1,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Sitagliptin and ertugliflozin,1992825,"ertugliflozin, sitagliptin","ertugliflozin / sitagliptin Oral Product, ertugliflozin / sitagliptin Pill","Oral Product, Pill","Steglujan Oral Product, Steglujan Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Saxagliptin and dapagliflozin,1727500,"dapagliflozin, saxagliptin","dapagliflozin / saxagliptin Oral Product, dapagliflozin / saxagliptin Pill","Oral Product, Pill","Qtern Oral Product, Qtern Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Linagliptin and empagliflozin,1598392,"linagliptin, empagliflozin","empagliflozin / linagliptin Oral Product, empagliflozin / linagliptin Pill","Oral Product, Pill","Glyxambi Oral Product, Glyxambi Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BD29,Sitagliptin and dapagliflozin,"['A10BD29', 'A10BD', 'A10B', 'A10', 'A']",True,1,1,,,,A10BD,Pioglitazone and alogliptin,1368402,"alogliptin, pioglitazone","alogliptin / pioglitazone Oral Product, alogliptin / pioglitazone Pill","Oral Product, Pill","Oseni Oral Product, Oseni Pill",[],0,0,unknown,2,2,False,False,False,,0.3778538812785388
A10BF01,Acarbose,"['A10BF01', 'A10BF', 'A10B', 'A10', 'A']",True,1,1,"Alpha-glucosidase enzymes are located in the brush-border of the intestinal mucosa and serve to metabolize oligo-, tri-, and disaccharides (e.g. sucrose) into smaller monosaccharides (e.g. glucose, fructose) which are more readily absorbed.4 These work in conjunction with pancreatic alpha-amylase, an enzyme found in the intestinal lumen that hydrolyzes complex starches to oligosaccharides.7","AMaltase-glucoamylase (inhibitor, Humans); ASucrase-isomaltase, intestinal (inhibitor, Humans); APancreatic alpha-amylase (inhibitor, Humans); ULysosomal alpha-glucosidase (inhibitor, Humans)",Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.6,A10BF,Miglitol,30009,miglitol,"miglitol Oral Product, miglitol Pill","Oral Product, Pill",,"['that', 'glucose', 'These', 'smaller', 'disaccharides', 'tri', 'absorbed', 'located', 'metabolize', 'the', 'amylase', 'conjunction', 'intestinal', 'complex', 'oligosaccharides', 'work', 'are', 'e', 'found', 'mucosa', 'starches', 'border', 'brush', 'Alpha', 'serve', 'with', 'in', 'g', 'enzyme', 'alpha', 'pancreatic', 'readily', 'an', 'into', 'fructose', 'which', '4', 'lumen', 'and', 'hydrolyzes', 'enzymes', 'monosaccharides', 'more', 'oligo', 'to', '7', 'sucrose', 'glucosidase', 'of']",6,52,other,2,1,False,False,False,0.043764700772721536,0.0022598870056497176
A10BF01,Acarbose,"['A10BF01', 'A10BF', 'A10B', 'A10', 'A']",True,1,1,"Alpha-glucosidase enzymes are located in the brush-border of the intestinal mucosa and serve to metabolize oligo-, tri-, and disaccharides (e.g. sucrose) into smaller monosaccharides (e.g. glucose, fructose) which are more readily absorbed.4 These work in conjunction with pancreatic alpha-amylase, an enzyme found in the intestinal lumen that hydrolyzes complex starches to oligosaccharides.7","AMaltase-glucoamylase (inhibitor, Humans); ASucrase-isomaltase, intestinal (inhibitor, Humans); APancreatic alpha-amylase (inhibitor, Humans); ULysosomal alpha-glucosidase (inhibitor, Humans)",Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.6,A10BF,Acarbose,16681,acarbose,"acarbose Oral Product, acarbose Pill","Oral Product, Pill","Precose Oral Product, Precose Pill","['that', 'glucose', 'These', 'smaller', 'disaccharides', 'tri', 'absorbed', 'located', 'metabolize', 'the', 'amylase', 'conjunction', 'intestinal', 'complex', 'oligosaccharides', 'work', 'are', 'e', 'found', 'mucosa', 'starches', 'border', 'brush', 'Alpha', 'serve', 'with', 'in', 'g', 'enzyme', 'alpha', 'pancreatic', 'readily', 'an', 'into', 'fructose', 'which', '4', 'lumen', 'and', 'hydrolyzes', 'enzymes', 'monosaccharides', 'more', 'oligo', 'to', '7', 'sucrose', 'glucosidase', 'of']",6,52,other,2,1,False,False,False,0.043764700772721536,0.0022598870056497176
A10BF02,Miglitol,"['A10BF02', 'A10BF', 'A10B', 'A10', 'A']",True,1,1,"In contrast to sulfonylureas, miglitol does not enhance insulin secretion. The antihyperglycemic action of miglitol results from a reversible inhibition of membrane-bound intestinal a-glucoside hydrolase enzymes. Membrane-bound intestinal a-glucosidases hydrolyze oligosaccharides and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In diabetic patients, this enzyme inhibition results in delayed glucose absorption and lowering of postprandial hyperglycemia.","ALysosomal alpha-glucosidase (antagonist, Humans); ANeutral alpha-glucosidase AB (antagonist, Humans); ANeutral alpha-glucosidase C (antagonist, Humans); AMaltase-glucoamylase (antagonistinhibitor, Humans)",For use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone.,A10BF,Miglitol,30009,miglitol,"miglitol Oral Product, miglitol Pill","Oral Product, Pill",,"['postprandial', 'reversible', 'glucose', 'bound', 'patients', 'disaccharides', 'lowering', 'the', 'intestinal', 'oligosaccharides', 'does', 'The', 'glucoside', 'this', 'membrane', 'not', 'contrast', 'miglitol', 'antihyperglycemic', 'hyperglycemia', 'small', 'action', 'border', 'enhance', 'brush', 'diabetic', 'hydrolase', 'in', 'enzyme', 'a', 'from', 'sulfonylureas', 'other', 'Membrane', 'insulin', 'In', 'hydrolyze', 'delayed', 'and', 'enzymes', 'intestine', 'monosaccharides', 'inhibition', 'to', 'glucosidases', 'absorption', 'secretion', 'results', 'of']",5,62,other,2,1,False,False,False,0.05360857106117582,0.0
A10BF02,Miglitol,"['A10BF02', 'A10BF', 'A10B', 'A10', 'A']",True,1,1,"In contrast to sulfonylureas, miglitol does not enhance insulin secretion. The antihyperglycemic action of miglitol results from a reversible inhibition of membrane-bound intestinal a-glucoside hydrolase enzymes. Membrane-bound intestinal a-glucosidases hydrolyze oligosaccharides and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In diabetic patients, this enzyme inhibition results in delayed glucose absorption and lowering of postprandial hyperglycemia.","ALysosomal alpha-glucosidase (antagonist, Humans); ANeutral alpha-glucosidase AB (antagonist, Humans); ANeutral alpha-glucosidase C (antagonist, Humans); AMaltase-glucoamylase (antagonistinhibitor, Humans)",For use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone.,A10BF,Acarbose,16681,acarbose,"acarbose Oral Product, acarbose Pill","Oral Product, Pill","Precose Oral Product, Precose Pill","['postprandial', 'reversible', 'glucose', 'bound', 'patients', 'disaccharides', 'lowering', 'the', 'intestinal', 'oligosaccharides', 'does', 'The', 'glucoside', 'this', 'membrane', 'not', 'contrast', 'miglitol', 'antihyperglycemic', 'hyperglycemia', 'small', 'action', 'border', 'enhance', 'brush', 'diabetic', 'hydrolase', 'in', 'enzyme', 'a', 'from', 'sulfonylureas', 'other', 'Membrane', 'insulin', 'In', 'hydrolyze', 'delayed', 'and', 'enzymes', 'intestine', 'monosaccharides', 'inhibition', 'to', 'glucosidases', 'absorption', 'secretion', 'results', 'of']",5,62,other,2,1,False,False,False,0.05360857106117582,0.0
A10BF03,Voglibose,"['A10BF03', 'A10BF', 'A10B', 'A10', 'A']",True,1,1,"Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines. The membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Acarbose also blocks pancreatic alpha-amylase in addition to inhibiting membrane-bound alpha-glucosidases. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin-A1c level. (From Drug Therapy in Nursing, 2nd ed)","AMaltase-glucoamylase (inhibitor, Humans)",For the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.,A10BF,Miglitol,30009,miglitol,"miglitol Oral Product, miglitol Pill","Oral Product, Pill",,"['bound', 'absorbed', 'carbohydrates', 'oligosaccharides', 'not', 'border', 'also', 'reduction', 'enzyme', 'ed', 'addition', 'lumen', 'reduces', 'decrease', 'enzymes', 'blood', 'monosaccharides', 'intestines', 'glucosidase', 'hydrolyzes', 'hemoglobin', 'that', 'glucose', 'patients', 'Acarbose', 'intestinal', 'inhibiting', 'are', 'Nursing', 'Pancreatic', 'Therapy', 'diabetic', 'Alpha', 'therapies', 'systems', 'Less', 'other', 'specifically', 'drugs', 'and', 'molecules', 'Inhibition', 'level', 'as', 'to', 'levels', 'digestion', 'down', 'effect', 'amylase', 'complex', 'membrane', 'competitive', 'small', 'starches', 'these', 'brush', 'in', 'alpha', 'pancreatic', 'long', 'digest', 'rate', 'saccharides', 'intestine', 'is', 'blocks', 'current', 'of', '2nd', 'A1c', 'needed', 'broken', 'disaccharides', 'the', 'short', 'The', 'Drug', 'term', 'From', 'trisaccharides', 'a', 'into', 'hydrolyze', 'inhibitors', 'In', 'because', 'glucosidases', 'act']",2,131,other,2,1,False,False,False,0.05417800874993112,0.0022598870056497176
A10BF03,Voglibose,"['A10BF03', 'A10BF', 'A10B', 'A10', 'A']",True,1,1,"Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines. The membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Acarbose also blocks pancreatic alpha-amylase in addition to inhibiting membrane-bound alpha-glucosidases. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin-A1c level. (From Drug Therapy in Nursing, 2nd ed)","AMaltase-glucoamylase (inhibitor, Humans)",For the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.,A10BF,Acarbose,16681,acarbose,"acarbose Oral Product, acarbose Pill","Oral Product, Pill","Precose Oral Product, Precose Pill","['bound', 'absorbed', 'carbohydrates', 'oligosaccharides', 'not', 'border', 'also', 'reduction', 'enzyme', 'ed', 'addition', 'lumen', 'reduces', 'decrease', 'enzymes', 'blood', 'monosaccharides', 'intestines', 'glucosidase', 'hydrolyzes', 'hemoglobin', 'that', 'glucose', 'patients', 'Acarbose', 'intestinal', 'inhibiting', 'are', 'Nursing', 'Pancreatic', 'Therapy', 'diabetic', 'Alpha', 'therapies', 'systems', 'Less', 'other', 'specifically', 'drugs', 'and', 'molecules', 'Inhibition', 'level', 'as', 'to', 'levels', 'digestion', 'down', 'effect', 'amylase', 'complex', 'membrane', 'competitive', 'small', 'starches', 'these', 'brush', 'in', 'alpha', 'pancreatic', 'long', 'digest', 'rate', 'saccharides', 'intestine', 'is', 'blocks', 'current', 'of', '2nd', 'A1c', 'needed', 'broken', 'disaccharides', 'the', 'short', 'The', 'Drug', 'term', 'From', 'trisaccharides', 'a', 'into', 'hydrolyze', 'inhibitors', 'In', 'because', 'glucosidases', 'act']",2,131,other,2,1,False,False,False,0.05417800874993112,0.0022598870056497176
A10BG01,Troglitazone,"['A10BG01', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Troglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin. It has a unique mechanism of action that is dependent on the presence of insulin for activity. Troglitazone decreases hepatic glucose output and increases insulin dependent glucose disposal in skeletal muscle. Its mechanism of action is thought to involve binding to nuclear receptors (PPAR) that regulate the transcription of a number of insulin responsive genes critical for the control of glucose and lipid metabolism. Troglitazone is a ligand to both PPARα and PPARγ, with a highter affinity for PPARγ. The drug also contains an α-tocopheroyl moiety, potentially giving it vitamin E-like activity. Troglitazone has been shown to reduce inflammation, and is associated with a decrase in nuclear factor kappa-B (NF-κB) and a concomitant increase in its inhibitor (IκB). Unlike sulfonylureas, troglitazone is not an insulin secretagogue.","APeroxisome proliferator-activated receptor gamma (agonistregulator, Humans); NEstrogen-related receptor gamma (inverse agonist, Humans); NSteroid hormone receptor ERR1 (inverse agonist, Humans); UPeroxisome proliferator-activated receptor delta (Not Available, Humans); UPeroxisome proliferator-activated receptor alpha (Not Available, Humans); UGlutathione S-transferase P (Not Available, Humans); NLong-chain-fatty-acid--CoA ligase 4 (inhibitor, Humans); UPlasminogen activator inhibitor 1 (antagonist, Humans); NEquilibrative nucleoside transporter 1 (inhibitor, Humans)","For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.",A10BG,Pioglitazone,259319,pioglitazone,,,,"['response', 'κB', 'IκB', 'troglitazone', 'not', 'muscle', 'presence', 'also', 'control', 'α', 'transcription', 'an', 'thought', 'blood', 'regulate', 'disposal', 'concomitant', 'associated', 'that', 'glucose', 'Unlike', 'metabolism', 'increases', 'by', 'increase', 'hepatic', 'tocopheroyl', 'ligand', 'PPAR', 'contains', 'secretagogue', 'agent', 'nuclear', 'with', 'NF', 'highter', 'and', 'PPARγ', 'affinity', 'for', 'activity', 'to', 'responsive', 'decreases', 'factor', 'mechanism', 'both', 'output', 'involve', 'Troglitazone', 'binding', 'reduce', 'improving', 'Its', 'It', 'PPARα', 'it', 'critical', 'decrase', 'in', 'dependent', 'thiazolidinedione', 'target', 'E', 'kappa', 'sulfonylureas', 'like', 'insulin', 'is', 'lowers', 'on', 'been', 'genes', 'antidiabetic', 'of', 'its', 'lipid', 'the', 'cell', 'The', 'has', 'inhibitor', 'action', 'giving', 'shown', 'a', 'skeletal', 'vitamin', 'number', 'inflammation', 'drug', 'B', 'unique', 'potentially', 'moiety', 'receptors']",10,143,other,0,1,False,True,False,0.061303613536730896,0.006787330316742082
A10BG01,Troglitazone,"['A10BG01', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Troglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin. It has a unique mechanism of action that is dependent on the presence of insulin for activity. Troglitazone decreases hepatic glucose output and increases insulin dependent glucose disposal in skeletal muscle. Its mechanism of action is thought to involve binding to nuclear receptors (PPAR) that regulate the transcription of a number of insulin responsive genes critical for the control of glucose and lipid metabolism. Troglitazone is a ligand to both PPARα and PPARγ, with a highter affinity for PPARγ. The drug also contains an α-tocopheroyl moiety, potentially giving it vitamin E-like activity. Troglitazone has been shown to reduce inflammation, and is associated with a decrase in nuclear factor kappa-B (NF-κB) and a concomitant increase in its inhibitor (IκB). Unlike sulfonylureas, troglitazone is not an insulin secretagogue.","APeroxisome proliferator-activated receptor gamma (agonistregulator, Humans); NEstrogen-related receptor gamma (inverse agonist, Humans); NSteroid hormone receptor ERR1 (inverse agonist, Humans); UPeroxisome proliferator-activated receptor delta (Not Available, Humans); UPeroxisome proliferator-activated receptor alpha (Not Available, Humans); UGlutathione S-transferase P (Not Available, Humans); NLong-chain-fatty-acid--CoA ligase 4 (inhibitor, Humans); UPlasminogen activator inhibitor 1 (antagonist, Humans); NEquilibrative nucleoside transporter 1 (inhibitor, Humans)","For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.",A10BG,Rosiglitazone,253198,rosiglitazone,,,,"['response', 'κB', 'IκB', 'troglitazone', 'not', 'muscle', 'presence', 'also', 'control', 'α', 'transcription', 'an', 'thought', 'blood', 'regulate', 'disposal', 'concomitant', 'associated', 'that', 'glucose', 'Unlike', 'metabolism', 'increases', 'by', 'increase', 'hepatic', 'tocopheroyl', 'ligand', 'PPAR', 'contains', 'secretagogue', 'agent', 'nuclear', 'with', 'NF', 'highter', 'and', 'PPARγ', 'affinity', 'for', 'activity', 'to', 'responsive', 'decreases', 'factor', 'mechanism', 'both', 'output', 'involve', 'Troglitazone', 'binding', 'reduce', 'improving', 'Its', 'It', 'PPARα', 'it', 'critical', 'decrase', 'in', 'dependent', 'thiazolidinedione', 'target', 'E', 'kappa', 'sulfonylureas', 'like', 'insulin', 'is', 'lowers', 'on', 'been', 'genes', 'antidiabetic', 'of', 'its', 'lipid', 'the', 'cell', 'The', 'has', 'inhibitor', 'action', 'giving', 'shown', 'a', 'skeletal', 'vitamin', 'number', 'inflammation', 'drug', 'B', 'unique', 'potentially', 'moiety', 'receptors']",10,143,other,0,1,False,True,False,0.061303613536730896,0.006787330316742082
A10BG01,Troglitazone,"['A10BG01', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Troglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin. It has a unique mechanism of action that is dependent on the presence of insulin for activity. Troglitazone decreases hepatic glucose output and increases insulin dependent glucose disposal in skeletal muscle. Its mechanism of action is thought to involve binding to nuclear receptors (PPAR) that regulate the transcription of a number of insulin responsive genes critical for the control of glucose and lipid metabolism. Troglitazone is a ligand to both PPARα and PPARγ, with a highter affinity for PPARγ. The drug also contains an α-tocopheroyl moiety, potentially giving it vitamin E-like activity. Troglitazone has been shown to reduce inflammation, and is associated with a decrase in nuclear factor kappa-B (NF-κB) and a concomitant increase in its inhibitor (IκB). Unlike sulfonylureas, troglitazone is not an insulin secretagogue.","APeroxisome proliferator-activated receptor gamma (agonistregulator, Humans); NEstrogen-related receptor gamma (inverse agonist, Humans); NSteroid hormone receptor ERR1 (inverse agonist, Humans); UPeroxisome proliferator-activated receptor delta (Not Available, Humans); UPeroxisome proliferator-activated receptor alpha (Not Available, Humans); UGlutathione S-transferase P (Not Available, Humans); NLong-chain-fatty-acid--CoA ligase 4 (inhibitor, Humans); UPlasminogen activator inhibitor 1 (antagonist, Humans); NEquilibrative nucleoside transporter 1 (inhibitor, Humans)","For the treatment of Type II diabetes mellitus. It is used alone or in combination with a sulfonylurea, metformin, or insulin as an adjunct to diet and exercise.",A10BG,Troglitazone,72610,troglitazone,"troglitazone Oral Product, troglitazone Pill","Oral Product, Pill",,"['response', 'κB', 'IκB', 'troglitazone', 'not', 'muscle', 'presence', 'also', 'control', 'α', 'transcription', 'an', 'thought', 'blood', 'regulate', 'disposal', 'concomitant', 'associated', 'that', 'glucose', 'Unlike', 'metabolism', 'increases', 'by', 'increase', 'hepatic', 'tocopheroyl', 'ligand', 'PPAR', 'contains', 'secretagogue', 'agent', 'nuclear', 'with', 'NF', 'highter', 'and', 'PPARγ', 'affinity', 'for', 'activity', 'to', 'responsive', 'decreases', 'factor', 'mechanism', 'both', 'output', 'involve', 'Troglitazone', 'binding', 'reduce', 'improving', 'Its', 'It', 'PPARα', 'it', 'critical', 'decrase', 'in', 'dependent', 'thiazolidinedione', 'target', 'E', 'kappa', 'sulfonylureas', 'like', 'insulin', 'is', 'lowers', 'on', 'been', 'genes', 'antidiabetic', 'of', 'its', 'lipid', 'the', 'cell', 'The', 'has', 'inhibitor', 'action', 'giving', 'shown', 'a', 'skeletal', 'vitamin', 'number', 'inflammation', 'drug', 'B', 'unique', 'potentially', 'moiety', 'receptors']",10,143,other,2,1,False,True,False,0.061303613536730896,0.006787330316742082
A10BG02,Rosiglitazone,"['A10BG02', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.","APeroxisome proliferator-activated receptor gamma (agonist, Humans); ULong-chain-fatty-acid--CoA ligase 4 (inhibitor, Humans); UPeroxisome proliferator-activated receptor alpha (Not Available, Humans); UPeroxisome proliferator-activated receptor delta (Not Available, Humans); URetinoic acid receptor RXR-alpha (Not Available, Humans); URetinoic acid receptor RXR-beta (Not Available, Humans); URetinoic acid receptor RXR-gamma (Not Available, Humans)",Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BG,Pioglitazone,259319,pioglitazone,,,,"['involved', 'glucose', 'gamma', 'the', 'highly', 'at', 'peroxisome', 'production', 'Activation', 'acts', 'this', 'activated', 'tissues', 'selective', 'muscle', 'PPAR', 'action', 'potent', 'liver', 'control', 'in', 'rosiglitazone', 'utilization', 'a', 'target', 'skeletal', 'transcription', 'regulates', 'agonist', 'insulin', 'proliferator', 'In', 'way', 'and', 'enhances', 'tissue', 'such', 'transport', 'of', 'for', 'as', 'genes', 'to', 'receptors', 'sensitivity', 'responsive', 'Rosiglitazone', 'adipose']",8,58,other,0,1,False,True,False,0.05278877293870891,0.010180995475113122
A10BG02,Rosiglitazone,"['A10BG02', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.","APeroxisome proliferator-activated receptor gamma (agonist, Humans); ULong-chain-fatty-acid--CoA ligase 4 (inhibitor, Humans); UPeroxisome proliferator-activated receptor alpha (Not Available, Humans); UPeroxisome proliferator-activated receptor delta (Not Available, Humans); URetinoic acid receptor RXR-alpha (Not Available, Humans); URetinoic acid receptor RXR-beta (Not Available, Humans); URetinoic acid receptor RXR-gamma (Not Available, Humans)",Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BG,Rosiglitazone,253198,rosiglitazone,,,,"['involved', 'glucose', 'gamma', 'the', 'highly', 'at', 'peroxisome', 'production', 'Activation', 'acts', 'this', 'activated', 'tissues', 'selective', 'muscle', 'PPAR', 'action', 'potent', 'liver', 'control', 'in', 'rosiglitazone', 'utilization', 'a', 'target', 'skeletal', 'transcription', 'regulates', 'agonist', 'insulin', 'proliferator', 'In', 'way', 'and', 'enhances', 'tissue', 'such', 'transport', 'of', 'for', 'as', 'genes', 'to', 'receptors', 'sensitivity', 'responsive', 'Rosiglitazone', 'adipose']",8,58,other,0,1,False,True,False,0.05278877293870891,0.010180995475113122
A10BG02,Rosiglitazone,"['A10BG02', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.","APeroxisome proliferator-activated receptor gamma (agonist, Humans); ULong-chain-fatty-acid--CoA ligase 4 (inhibitor, Humans); UPeroxisome proliferator-activated receptor alpha (Not Available, Humans); UPeroxisome proliferator-activated receptor delta (Not Available, Humans); URetinoic acid receptor RXR-alpha (Not Available, Humans); URetinoic acid receptor RXR-beta (Not Available, Humans); URetinoic acid receptor RXR-gamma (Not Available, Humans)",Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BG,Troglitazone,72610,troglitazone,"troglitazone Oral Product, troglitazone Pill","Oral Product, Pill",,"['involved', 'glucose', 'gamma', 'the', 'highly', 'at', 'peroxisome', 'production', 'Activation', 'acts', 'this', 'activated', 'tissues', 'selective', 'muscle', 'PPAR', 'action', 'potent', 'liver', 'control', 'in', 'rosiglitazone', 'utilization', 'a', 'target', 'skeletal', 'transcription', 'regulates', 'agonist', 'insulin', 'proliferator', 'In', 'way', 'and', 'enhances', 'tissue', 'such', 'transport', 'of', 'for', 'as', 'genes', 'to', 'receptors', 'sensitivity', 'responsive', 'Rosiglitazone', 'adipose']",8,58,other,2,1,False,True,False,0.05278877293870891,0.010180995475113122
A10BG03,Pioglitazone,"['A10BG03', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Pioglitazone is a selective agonist at peroxisome proliferator-activated receptor-gamma (PPARγ) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.4,2 Activation of PPARγ increases the transcription of insulin-responsive genes involved in the control of glucose and lipid production, transport, and utilization.2 Through this mechanism, pioglitazone both enhances tissue sensitivity to insulin and reduces the hepatic production of glucose (i.e. gluconeogenesis) - insulin resistance associated with type 2 diabetes mellitus is therefore improved without an increase in insulin secretion by pancreatic beta cells.4,2","APeroxisome proliferator-activated receptor gamma (agonist, Humans); UAmine oxidase [flavin-containing] B (inhibitor, Humans)","Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.4 It is also available in combination with metformin,5 glimepiride,6 or alogliptin7 for the same indication.",A10BG,Pioglitazone,259319,pioglitazone,,,,"['involved', 'glucose', 'beta', 'mechanism', 'increases', 'gamma', 'lipid', 'the', 'both', 'by', 'at', 'type', 'peroxisome', 'production', 'Activation', 'associated', 'diabetes', 'improved', 'increase', 'this', 'activated', 'hepatic', 'tissues', 'selective', 'receptor', 'muscle', 'e', 'resistance', 'action', 'liver', '2', 'control', 'i', 'gluconeogenesis', 'in', 'with', 'without', 'utilization', 'Pioglitazone', 'a', 'target', 'skeletal', 'transcription', 'Through', 'pioglitazone', 'therefore', 'an', 'pancreatic', 'agonist', 'insulin', 'proliferator', '4', 'enhances', 'PPARγ', 'and', 'reduces', 'cells', 'tissue', 'such', 'mellitus', 'transport', 'of', 'for', 'is', 'as', 'genes', 'to', 'secretion', 'sensitivity', 'responsive', 'adipose']",3,86,other,0,1,False,False,False,0.0686958592879363,0.003393665158371041
A10BG03,Pioglitazone,"['A10BG03', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Pioglitazone is a selective agonist at peroxisome proliferator-activated receptor-gamma (PPARγ) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.4,2 Activation of PPARγ increases the transcription of insulin-responsive genes involved in the control of glucose and lipid production, transport, and utilization.2 Through this mechanism, pioglitazone both enhances tissue sensitivity to insulin and reduces the hepatic production of glucose (i.e. gluconeogenesis) - insulin resistance associated with type 2 diabetes mellitus is therefore improved without an increase in insulin secretion by pancreatic beta cells.4,2","APeroxisome proliferator-activated receptor gamma (agonist, Humans); UAmine oxidase [flavin-containing] B (inhibitor, Humans)","Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.4 It is also available in combination with metformin,5 glimepiride,6 or alogliptin7 for the same indication.",A10BG,Rosiglitazone,253198,rosiglitazone,,,,"['involved', 'glucose', 'beta', 'mechanism', 'increases', 'gamma', 'lipid', 'the', 'both', 'by', 'at', 'type', 'peroxisome', 'production', 'Activation', 'associated', 'diabetes', 'improved', 'increase', 'this', 'activated', 'hepatic', 'tissues', 'selective', 'receptor', 'muscle', 'e', 'resistance', 'action', 'liver', '2', 'control', 'i', 'gluconeogenesis', 'in', 'with', 'without', 'utilization', 'Pioglitazone', 'a', 'target', 'skeletal', 'transcription', 'Through', 'pioglitazone', 'therefore', 'an', 'pancreatic', 'agonist', 'insulin', 'proliferator', '4', 'enhances', 'PPARγ', 'and', 'reduces', 'cells', 'tissue', 'such', 'mellitus', 'transport', 'of', 'for', 'is', 'as', 'genes', 'to', 'secretion', 'sensitivity', 'responsive', 'adipose']",3,86,other,0,1,False,False,False,0.0686958592879363,0.003393665158371041
A10BG03,Pioglitazone,"['A10BG03', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Pioglitazone is a selective agonist at peroxisome proliferator-activated receptor-gamma (PPARγ) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.4,2 Activation of PPARγ increases the transcription of insulin-responsive genes involved in the control of glucose and lipid production, transport, and utilization.2 Through this mechanism, pioglitazone both enhances tissue sensitivity to insulin and reduces the hepatic production of glucose (i.e. gluconeogenesis) - insulin resistance associated with type 2 diabetes mellitus is therefore improved without an increase in insulin secretion by pancreatic beta cells.4,2","APeroxisome proliferator-activated receptor gamma (agonist, Humans); UAmine oxidase [flavin-containing] B (inhibitor, Humans)","Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.4 It is also available in combination with metformin,5 glimepiride,6 or alogliptin7 for the same indication.",A10BG,Troglitazone,72610,troglitazone,"troglitazone Oral Product, troglitazone Pill","Oral Product, Pill",,"['involved', 'glucose', 'beta', 'mechanism', 'increases', 'gamma', 'lipid', 'the', 'both', 'by', 'at', 'type', 'peroxisome', 'production', 'Activation', 'associated', 'diabetes', 'improved', 'increase', 'this', 'activated', 'hepatic', 'tissues', 'selective', 'receptor', 'muscle', 'e', 'resistance', 'action', 'liver', '2', 'control', 'i', 'gluconeogenesis', 'in', 'with', 'without', 'utilization', 'Pioglitazone', 'a', 'target', 'skeletal', 'transcription', 'Through', 'pioglitazone', 'therefore', 'an', 'pancreatic', 'agonist', 'insulin', 'proliferator', '4', 'enhances', 'PPARγ', 'and', 'reduces', 'cells', 'tissue', 'such', 'mellitus', 'transport', 'of', 'for', 'is', 'as', 'genes', 'to', 'secretion', 'sensitivity', 'responsive', 'adipose']",3,86,other,2,1,False,False,False,0.0686958592879363,0.003393665158371041
A10BG04,Lobeglitazone,"['A10BG04', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Lobeglitazone acts as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By promoting the binding of insulin at fat cells, lobeglitazone has been shown to reduce blood sugar levels, lower hemoglobain A1C (HbA1C) levels, and improve lipid and liver profiles 1. Unlike Pioglitazone, which is a dual PPAR agonist at PPAR-alpha and PPAR-gamma, Lobeglitazone is a pure PPAR-alpha agonist.","APeroxisome proliferator-activated receptor alpha (agonist, Humans); APeroxisome proliferator-activated receptor gamma (activator, Humans)","Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.",A10BG,Pioglitazone,259319,pioglitazone,,,,"['levels', 'sugar', 'improve', 'Unlike', 'lipid', 'gamma', 'by', 'the', 'at', 'Proliferator', 'Lobeglitazone', 'Activated', 'binding', 'Peroxisome', 'acts', 'promoting', 'reduce', 'HbA1C', '1', 'has', 'profiles', 'By', 'PPAR', 'dual', 'liver', 'Receptors', 'sensitizer', 'shown', 'Pioglitazone', 'a', 'lower', 'alpha', 'an', 'agonist', 'cells', 'insulin', 'which', 'activating', 'fat', 'and', 'pure', 'blood', 'A1C', 'is', 'been', 'as', 'to', 'hemoglobain', 'within', 'lobeglitazone', 'of']",3,66,other,0,1,False,False,False,0.040538585531664395,0.0
A10BG04,Lobeglitazone,"['A10BG04', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Lobeglitazone acts as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By promoting the binding of insulin at fat cells, lobeglitazone has been shown to reduce blood sugar levels, lower hemoglobain A1C (HbA1C) levels, and improve lipid and liver profiles 1. Unlike Pioglitazone, which is a dual PPAR agonist at PPAR-alpha and PPAR-gamma, Lobeglitazone is a pure PPAR-alpha agonist.","APeroxisome proliferator-activated receptor alpha (agonist, Humans); APeroxisome proliferator-activated receptor gamma (activator, Humans)","Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.",A10BG,Rosiglitazone,253198,rosiglitazone,,,,"['levels', 'sugar', 'improve', 'Unlike', 'lipid', 'gamma', 'by', 'the', 'at', 'Proliferator', 'Lobeglitazone', 'Activated', 'binding', 'Peroxisome', 'acts', 'promoting', 'reduce', 'HbA1C', '1', 'has', 'profiles', 'By', 'PPAR', 'dual', 'liver', 'Receptors', 'sensitizer', 'shown', 'Pioglitazone', 'a', 'lower', 'alpha', 'an', 'agonist', 'cells', 'insulin', 'which', 'activating', 'fat', 'and', 'pure', 'blood', 'A1C', 'is', 'been', 'as', 'to', 'hemoglobain', 'within', 'lobeglitazone', 'of']",3,66,other,0,1,False,False,False,0.040538585531664395,0.0
A10BG04,Lobeglitazone,"['A10BG04', 'A10BG', 'A10B', 'A10', 'A']",True,1,1,"Lobeglitazone acts as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By promoting the binding of insulin at fat cells, lobeglitazone has been shown to reduce blood sugar levels, lower hemoglobain A1C (HbA1C) levels, and improve lipid and liver profiles 1. Unlike Pioglitazone, which is a dual PPAR agonist at PPAR-alpha and PPAR-gamma, Lobeglitazone is a pure PPAR-alpha agonist.","APeroxisome proliferator-activated receptor alpha (agonist, Humans); APeroxisome proliferator-activated receptor gamma (activator, Humans)","Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.",A10BG,Troglitazone,72610,troglitazone,"troglitazone Oral Product, troglitazone Pill","Oral Product, Pill",,"['levels', 'sugar', 'improve', 'Unlike', 'lipid', 'gamma', 'by', 'the', 'at', 'Proliferator', 'Lobeglitazone', 'Activated', 'binding', 'Peroxisome', 'acts', 'promoting', 'reduce', 'HbA1C', '1', 'has', 'profiles', 'By', 'PPAR', 'dual', 'liver', 'Receptors', 'sensitizer', 'shown', 'Pioglitazone', 'a', 'lower', 'alpha', 'an', 'agonist', 'cells', 'insulin', 'which', 'activating', 'fat', 'and', 'pure', 'blood', 'A1C', 'is', 'been', 'as', 'to', 'hemoglobain', 'within', 'lobeglitazone', 'of']",3,66,other,2,1,False,False,False,0.040538585531664395,0.0
A10BH01,Sitagliptin,"['A10BH01', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Inhibition of DPP-4 by sitagliptin slows DPP-4 mediated inactivation of incretins like GLP-1 and GIPLabel,2. Incretins are released throughout the day and upregulated in response to meals as part of glucose homeostasisLabel,4. Reduced inhibition of incretins increase insulin synthesis and decrease glucagon release in a manner dependant on glucose concentrationsLabel,1. These effects lead to an overall increase in blood glucose control which is demonstrated by reduced glycosylated hemoglobin (HbA1c)Label,4.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.9,A10BH,Sitagliptin and simvastatin,1189803,"simvastatin, sitagliptin",,,,"['Label', 'incretins', 'upregulated', 'hemoglobin', 'glucose', 'These', 'response', 'by', 'slows', 'the', 'day', 'DPP', 'release', 'part', 'inactivation', 'meals', '1', 'increase', 'are', 'GIPLabel', 'GLP', 'demonstrated', 'synthesis', 'homeostasisLabel', 'released', 'concentrationsLabel', 'Incretins', 'manner', 'sitagliptin', '2', 'throughout', 'control', 'in', 'HbA1c', 'Reduced', 'dependant', 'a', 'effects', 'an', 'like', '4', 'insulin', 'which', 'decrease', 'and', 'mediated', 'blood', 'Inhibition', 'is', 'reduced', 'on', 'as', 'to', 'inhibition', 'overall', 'glycosylated', 'lead', 'of', 'glucagon']",2,69,other,0,2,False,False,False,0.05325765650555831,0.027180067950169876
A10BH01,Sitagliptin,"['A10BH01', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Inhibition of DPP-4 by sitagliptin slows DPP-4 mediated inactivation of incretins like GLP-1 and GIPLabel,2. Incretins are released throughout the day and upregulated in response to meals as part of glucose homeostasisLabel,4. Reduced inhibition of incretins increase insulin synthesis and decrease glucagon release in a manner dependant on glucose concentrationsLabel,1. These effects lead to an overall increase in blood glucose control which is demonstrated by reduced glycosylated hemoglobin (HbA1c)Label,4.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.9,A10BH,Alogliptin,1368000,alogliptin,,,,"['Label', 'incretins', 'upregulated', 'hemoglobin', 'glucose', 'These', 'response', 'by', 'slows', 'the', 'day', 'DPP', 'release', 'part', 'inactivation', 'meals', '1', 'increase', 'are', 'GIPLabel', 'GLP', 'demonstrated', 'synthesis', 'homeostasisLabel', 'released', 'concentrationsLabel', 'Incretins', 'manner', 'sitagliptin', '2', 'throughout', 'control', 'in', 'HbA1c', 'Reduced', 'dependant', 'a', 'effects', 'an', 'like', '4', 'insulin', 'which', 'decrease', 'and', 'mediated', 'blood', 'Inhibition', 'is', 'reduced', 'on', 'as', 'to', 'inhibition', 'overall', 'glycosylated', 'lead', 'of', 'glucagon']",2,69,other,0,1,False,False,False,0.05325765650555831,0.027180067950169876
A10BH01,Sitagliptin,"['A10BH01', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Inhibition of DPP-4 by sitagliptin slows DPP-4 mediated inactivation of incretins like GLP-1 and GIPLabel,2. Incretins are released throughout the day and upregulated in response to meals as part of glucose homeostasisLabel,4. Reduced inhibition of incretins increase insulin synthesis and decrease glucagon release in a manner dependant on glucose concentrationsLabel,1. These effects lead to an overall increase in blood glucose control which is demonstrated by reduced glycosylated hemoglobin (HbA1c)Label,4.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.9,A10BH,Saxagliptin,1043560,saxagliptin,,,,"['Label', 'incretins', 'upregulated', 'hemoglobin', 'glucose', 'These', 'response', 'by', 'slows', 'the', 'day', 'DPP', 'release', 'part', 'inactivation', 'meals', '1', 'increase', 'are', 'GIPLabel', 'GLP', 'demonstrated', 'synthesis', 'homeostasisLabel', 'released', 'concentrationsLabel', 'Incretins', 'manner', 'sitagliptin', '2', 'throughout', 'control', 'in', 'HbA1c', 'Reduced', 'dependant', 'a', 'effects', 'an', 'like', '4', 'insulin', 'which', 'decrease', 'and', 'mediated', 'blood', 'Inhibition', 'is', 'reduced', 'on', 'as', 'to', 'inhibition', 'overall', 'glycosylated', 'lead', 'of', 'glucagon']",2,69,other,0,1,False,False,False,0.05325765650555831,0.027180067950169876
A10BH01,Sitagliptin,"['A10BH01', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Inhibition of DPP-4 by sitagliptin slows DPP-4 mediated inactivation of incretins like GLP-1 and GIPLabel,2. Incretins are released throughout the day and upregulated in response to meals as part of glucose homeostasisLabel,4. Reduced inhibition of incretins increase insulin synthesis and decrease glucagon release in a manner dependant on glucose concentrationsLabel,1. These effects lead to an overall increase in blood glucose control which is demonstrated by reduced glycosylated hemoglobin (HbA1c)Label,4.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.9,A10BH,Vildagliptin,596554,vildagliptin,"vildagliptin Oral Product, vildagliptin Pill","Oral Product, Pill",,"['Label', 'incretins', 'upregulated', 'hemoglobin', 'glucose', 'These', 'response', 'by', 'slows', 'the', 'day', 'DPP', 'release', 'part', 'inactivation', 'meals', '1', 'increase', 'are', 'GIPLabel', 'GLP', 'demonstrated', 'synthesis', 'homeostasisLabel', 'released', 'concentrationsLabel', 'Incretins', 'manner', 'sitagliptin', '2', 'throughout', 'control', 'in', 'HbA1c', 'Reduced', 'dependant', 'a', 'effects', 'an', 'like', '4', 'insulin', 'which', 'decrease', 'and', 'mediated', 'blood', 'Inhibition', 'is', 'reduced', 'on', 'as', 'to', 'inhibition', 'overall', 'glycosylated', 'lead', 'of', 'glucagon']",2,69,other,2,1,False,False,False,0.05325765650555831,0.027180067950169876
A10BH02,Vildagliptin,"['A10BH02', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones that regulate blood glucose levels and maintain glucose homeostasis. It is estimated that the activity of GLP-1 and GIP contribute more than 70% to the insulin response to an oral glucose challenge. They stimulate insulin secretion in a glucose-dependent manner via G-protein-coupled GIP and GLP-1 receptor signalling. In addition to their effects on insulin secretion, GLP-1 is also involved in promoting islet neogenesis and differentiation, as well as attenuating pancreatic beta-cell apoptosis. Incretin hormones also exert extra-pancreatic effects, such as lipogenesis and myocardial function.3 In type II diabetes mellitus, GLP-1 secretion is impaired, and the insulinotropic effect of GIP is significantly diminished.2","ADipeptidyl peptidase 4 (inhibitor, Humans)","Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.6 It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thiazolidinedione in adults patients with insufficient glycemic control despite maximal tolerated dose of monotherapy.6",A10BH,Sitagliptin and simvastatin,1189803,"simvastatin, sitagliptin",,,,"['insulinotropic', 'involved', 'signalling', 'attenuating', 'hormones', 'Glucagon', 'response', 'II', 'homeostasis', 'promoting', '1', 'also', '2', 'Incretin', 'addition', 'an', 'blood', 'regulate', 'more', 'protein', 'secretion', '70', 'that', 'glucose', 'coupled', 'maintain', 'exert', 'stimulate', 'are', 'their', 'receptor', 'function', 'oral', 'significantly', 'differentiation', 'and', 'GIP', 'activity', 'via', 'as', 'to', 'myocardial', 'levels', 'effect', 'than', 'G', '3', 'lipogenesis', 'type', 'It', 'estimated', 'manner', 'in', 'extra', 'dependent', 'beta', 'pancreatic', 'like', 'insulin', 'contribute', 'is', 'on', 'apoptosis', 'well', 'They', 'of', 'peptide', 'the', 'cell', 'diabetes', 'impaired', 'GLP', 'diminished', 'a', 'effects', 'incretin', 'In', 'islet', 'challenge', 'such', 'mellitus', 'neogenesis']",2,113,other,0,2,False,False,False,0.059830624777295414,0.027180067950169876
A10BH02,Vildagliptin,"['A10BH02', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones that regulate blood glucose levels and maintain glucose homeostasis. It is estimated that the activity of GLP-1 and GIP contribute more than 70% to the insulin response to an oral glucose challenge. They stimulate insulin secretion in a glucose-dependent manner via G-protein-coupled GIP and GLP-1 receptor signalling. In addition to their effects on insulin secretion, GLP-1 is also involved in promoting islet neogenesis and differentiation, as well as attenuating pancreatic beta-cell apoptosis. Incretin hormones also exert extra-pancreatic effects, such as lipogenesis and myocardial function.3 In type II diabetes mellitus, GLP-1 secretion is impaired, and the insulinotropic effect of GIP is significantly diminished.2","ADipeptidyl peptidase 4 (inhibitor, Humans)","Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.6 It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thiazolidinedione in adults patients with insufficient glycemic control despite maximal tolerated dose of monotherapy.6",A10BH,Alogliptin,1368000,alogliptin,,,,"['insulinotropic', 'involved', 'signalling', 'attenuating', 'hormones', 'Glucagon', 'response', 'II', 'homeostasis', 'promoting', '1', 'also', '2', 'Incretin', 'addition', 'an', 'blood', 'regulate', 'more', 'protein', 'secretion', '70', 'that', 'glucose', 'coupled', 'maintain', 'exert', 'stimulate', 'are', 'their', 'receptor', 'function', 'oral', 'significantly', 'differentiation', 'and', 'GIP', 'activity', 'via', 'as', 'to', 'myocardial', 'levels', 'effect', 'than', 'G', '3', 'lipogenesis', 'type', 'It', 'estimated', 'manner', 'in', 'extra', 'dependent', 'beta', 'pancreatic', 'like', 'insulin', 'contribute', 'is', 'on', 'apoptosis', 'well', 'They', 'of', 'peptide', 'the', 'cell', 'diabetes', 'impaired', 'GLP', 'diminished', 'a', 'effects', 'incretin', 'In', 'islet', 'challenge', 'such', 'mellitus', 'neogenesis']",2,113,other,0,1,False,False,False,0.059830624777295414,0.027180067950169876
A10BH02,Vildagliptin,"['A10BH02', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones that regulate blood glucose levels and maintain glucose homeostasis. It is estimated that the activity of GLP-1 and GIP contribute more than 70% to the insulin response to an oral glucose challenge. They stimulate insulin secretion in a glucose-dependent manner via G-protein-coupled GIP and GLP-1 receptor signalling. In addition to their effects on insulin secretion, GLP-1 is also involved in promoting islet neogenesis and differentiation, as well as attenuating pancreatic beta-cell apoptosis. Incretin hormones also exert extra-pancreatic effects, such as lipogenesis and myocardial function.3 In type II diabetes mellitus, GLP-1 secretion is impaired, and the insulinotropic effect of GIP is significantly diminished.2","ADipeptidyl peptidase 4 (inhibitor, Humans)","Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.6 It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thiazolidinedione in adults patients with insufficient glycemic control despite maximal tolerated dose of monotherapy.6",A10BH,Saxagliptin,1043560,saxagliptin,,,,"['insulinotropic', 'involved', 'signalling', 'attenuating', 'hormones', 'Glucagon', 'response', 'II', 'homeostasis', 'promoting', '1', 'also', '2', 'Incretin', 'addition', 'an', 'blood', 'regulate', 'more', 'protein', 'secretion', '70', 'that', 'glucose', 'coupled', 'maintain', 'exert', 'stimulate', 'are', 'their', 'receptor', 'function', 'oral', 'significantly', 'differentiation', 'and', 'GIP', 'activity', 'via', 'as', 'to', 'myocardial', 'levels', 'effect', 'than', 'G', '3', 'lipogenesis', 'type', 'It', 'estimated', 'manner', 'in', 'extra', 'dependent', 'beta', 'pancreatic', 'like', 'insulin', 'contribute', 'is', 'on', 'apoptosis', 'well', 'They', 'of', 'peptide', 'the', 'cell', 'diabetes', 'impaired', 'GLP', 'diminished', 'a', 'effects', 'incretin', 'In', 'islet', 'challenge', 'such', 'mellitus', 'neogenesis']",2,113,other,0,1,False,False,False,0.059830624777295414,0.027180067950169876
A10BH02,Vildagliptin,"['A10BH02', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones that regulate blood glucose levels and maintain glucose homeostasis. It is estimated that the activity of GLP-1 and GIP contribute more than 70% to the insulin response to an oral glucose challenge. They stimulate insulin secretion in a glucose-dependent manner via G-protein-coupled GIP and GLP-1 receptor signalling. In addition to their effects on insulin secretion, GLP-1 is also involved in promoting islet neogenesis and differentiation, as well as attenuating pancreatic beta-cell apoptosis. Incretin hormones also exert extra-pancreatic effects, such as lipogenesis and myocardial function.3 In type II diabetes mellitus, GLP-1 secretion is impaired, and the insulinotropic effect of GIP is significantly diminished.2","ADipeptidyl peptidase 4 (inhibitor, Humans)","Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.6 It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thiazolidinedione in adults patients with insufficient glycemic control despite maximal tolerated dose of monotherapy.6",A10BH,Vildagliptin,596554,vildagliptin,"vildagliptin Oral Product, vildagliptin Pill","Oral Product, Pill",,"['insulinotropic', 'involved', 'signalling', 'attenuating', 'hormones', 'Glucagon', 'response', 'II', 'homeostasis', 'promoting', '1', 'also', '2', 'Incretin', 'addition', 'an', 'blood', 'regulate', 'more', 'protein', 'secretion', '70', 'that', 'glucose', 'coupled', 'maintain', 'exert', 'stimulate', 'are', 'their', 'receptor', 'function', 'oral', 'significantly', 'differentiation', 'and', 'GIP', 'activity', 'via', 'as', 'to', 'myocardial', 'levels', 'effect', 'than', 'G', '3', 'lipogenesis', 'type', 'It', 'estimated', 'manner', 'in', 'extra', 'dependent', 'beta', 'pancreatic', 'like', 'insulin', 'contribute', 'is', 'on', 'apoptosis', 'well', 'They', 'of', 'peptide', 'the', 'cell', 'diabetes', 'impaired', 'GLP', 'diminished', 'a', 'effects', 'incretin', 'In', 'islet', 'challenge', 'such', 'mellitus', 'neogenesis']",2,113,other,2,1,False,False,False,0.059830624777295414,0.027180067950169876
A10BH03,Saxagliptin,"['A10BH03', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatment of type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. Incretins decrease blood sugar by increasing consumption of sugar by the body, mainly through increasing insulin production in the pancreas, and by reducing production of sugar by the liver. [Bristol-Myers Squibb Press Release]
DPP-4 is a membrane associated peptidase which is found in many tissues, lymphocytes and plasma. DPP-4 has two main mechanisms of action, an enzymatic function and another mechanism where DPP-4 binds adenosine deaminase, which conveys intracellular signals via dimerization when activated. Saxagliptin forms a reversible, histidine-assisted covalent bond between its nitrile group and the S630 hydroxyl oxygen on DPP-4. The inhibition of DPP-4 increases levels active of glucagon like peptide 1 (GLP-1), which inhibits glucagon production from pancreatic alpha cells and increases production of insulin from pancreatic beta cells.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.,A10BH,Sitagliptin and simvastatin,1189803,"simvastatin, sitagliptin",,,,"['dipeptidyl', 'incretins', 'conveys', 'hormones', 'inhibits', 'affecting', 'when', 'where', 'production', 'work', '1', 'Bristol', 'binds', 'S630', 'peptidase', 'two', '2', 'lymphocytes', 'mechanisms', 'Press', 'body', 'an', 'dimerization', 'cells', 'decrease', 'plasma', 'blood', 'enzymatic', 'associated', 'glucagon', 'treatment', 'that', 'adenosine', 'increases', 'by', 'pancreas', 'are', 'mainly', 'activated', 'called', 'function', 'reducing', 'many', 'histidine', 'another', 'Release', 'deaminase', 'nitrile', 'oxygen', 'which', 'natural', 'and', 'intracellular', 'for', 'via', 'through', 'levels', 'reversible', 'group', 'mechanism', 'main', 'type', 'increasing', 'consumption', 'membrane', 'compounds', 'found', 'in', 'beta', 'from', 'alpha', 'pancreatic', 'like', '4', 'insulin', 'Squibb', 'signals', 'is', 'on', 'inhibition', 'antidiabetic', 'of', 'sugar', 'peptide', 'class', 'its', 'the', 'between', 'DPP', 'bond', 'diabetes', 'The', 'tissues', 'assisted', 'has', 'Saxagliptin', 'covalent', 'active', 'forms', 'GLP', 'inhibitor', 'Incretins', 'action', 'liver', 'a', 'hydroxyl', 'inhibitors', 'Myers']",2,158,other,0,2,False,False,False,0.0566596907959597,0.027180067950169876
A10BH03,Saxagliptin,"['A10BH03', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatment of type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. Incretins decrease blood sugar by increasing consumption of sugar by the body, mainly through increasing insulin production in the pancreas, and by reducing production of sugar by the liver. [Bristol-Myers Squibb Press Release]
DPP-4 is a membrane associated peptidase which is found in many tissues, lymphocytes and plasma. DPP-4 has two main mechanisms of action, an enzymatic function and another mechanism where DPP-4 binds adenosine deaminase, which conveys intracellular signals via dimerization when activated. Saxagliptin forms a reversible, histidine-assisted covalent bond between its nitrile group and the S630 hydroxyl oxygen on DPP-4. The inhibition of DPP-4 increases levels active of glucagon like peptide 1 (GLP-1), which inhibits glucagon production from pancreatic alpha cells and increases production of insulin from pancreatic beta cells.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.,A10BH,Alogliptin,1368000,alogliptin,,,,"['dipeptidyl', 'incretins', 'conveys', 'hormones', 'inhibits', 'affecting', 'when', 'where', 'production', 'work', '1', 'Bristol', 'binds', 'S630', 'peptidase', 'two', '2', 'lymphocytes', 'mechanisms', 'Press', 'body', 'an', 'dimerization', 'cells', 'decrease', 'plasma', 'blood', 'enzymatic', 'associated', 'glucagon', 'treatment', 'that', 'adenosine', 'increases', 'by', 'pancreas', 'are', 'mainly', 'activated', 'called', 'function', 'reducing', 'many', 'histidine', 'another', 'Release', 'deaminase', 'nitrile', 'oxygen', 'which', 'natural', 'and', 'intracellular', 'for', 'via', 'through', 'levels', 'reversible', 'group', 'mechanism', 'main', 'type', 'increasing', 'consumption', 'membrane', 'compounds', 'found', 'in', 'beta', 'from', 'alpha', 'pancreatic', 'like', '4', 'insulin', 'Squibb', 'signals', 'is', 'on', 'inhibition', 'antidiabetic', 'of', 'sugar', 'peptide', 'class', 'its', 'the', 'between', 'DPP', 'bond', 'diabetes', 'The', 'tissues', 'assisted', 'has', 'Saxagliptin', 'covalent', 'active', 'forms', 'GLP', 'inhibitor', 'Incretins', 'action', 'liver', 'a', 'hydroxyl', 'inhibitors', 'Myers']",2,158,other,0,1,False,False,False,0.0566596907959597,0.027180067950169876
A10BH03,Saxagliptin,"['A10BH03', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatment of type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. Incretins decrease blood sugar by increasing consumption of sugar by the body, mainly through increasing insulin production in the pancreas, and by reducing production of sugar by the liver. [Bristol-Myers Squibb Press Release]
DPP-4 is a membrane associated peptidase which is found in many tissues, lymphocytes and plasma. DPP-4 has two main mechanisms of action, an enzymatic function and another mechanism where DPP-4 binds adenosine deaminase, which conveys intracellular signals via dimerization when activated. Saxagliptin forms a reversible, histidine-assisted covalent bond between its nitrile group and the S630 hydroxyl oxygen on DPP-4. The inhibition of DPP-4 increases levels active of glucagon like peptide 1 (GLP-1), which inhibits glucagon production from pancreatic alpha cells and increases production of insulin from pancreatic beta cells.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.,A10BH,Saxagliptin,1043560,saxagliptin,,,,"['dipeptidyl', 'incretins', 'conveys', 'hormones', 'inhibits', 'affecting', 'when', 'where', 'production', 'work', '1', 'Bristol', 'binds', 'S630', 'peptidase', 'two', '2', 'lymphocytes', 'mechanisms', 'Press', 'body', 'an', 'dimerization', 'cells', 'decrease', 'plasma', 'blood', 'enzymatic', 'associated', 'glucagon', 'treatment', 'that', 'adenosine', 'increases', 'by', 'pancreas', 'are', 'mainly', 'activated', 'called', 'function', 'reducing', 'many', 'histidine', 'another', 'Release', 'deaminase', 'nitrile', 'oxygen', 'which', 'natural', 'and', 'intracellular', 'for', 'via', 'through', 'levels', 'reversible', 'group', 'mechanism', 'main', 'type', 'increasing', 'consumption', 'membrane', 'compounds', 'found', 'in', 'beta', 'from', 'alpha', 'pancreatic', 'like', '4', 'insulin', 'Squibb', 'signals', 'is', 'on', 'inhibition', 'antidiabetic', 'of', 'sugar', 'peptide', 'class', 'its', 'the', 'between', 'DPP', 'bond', 'diabetes', 'The', 'tissues', 'assisted', 'has', 'Saxagliptin', 'covalent', 'active', 'forms', 'GLP', 'inhibitor', 'Incretins', 'action', 'liver', 'a', 'hydroxyl', 'inhibitors', 'Myers']",2,158,other,0,1,False,False,False,0.0566596907959597,0.027180067950169876
A10BH03,Saxagliptin,"['A10BH03', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatment of type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. Incretins decrease blood sugar by increasing consumption of sugar by the body, mainly through increasing insulin production in the pancreas, and by reducing production of sugar by the liver. [Bristol-Myers Squibb Press Release]
DPP-4 is a membrane associated peptidase which is found in many tissues, lymphocytes and plasma. DPP-4 has two main mechanisms of action, an enzymatic function and another mechanism where DPP-4 binds adenosine deaminase, which conveys intracellular signals via dimerization when activated. Saxagliptin forms a reversible, histidine-assisted covalent bond between its nitrile group and the S630 hydroxyl oxygen on DPP-4. The inhibition of DPP-4 increases levels active of glucagon like peptide 1 (GLP-1), which inhibits glucagon production from pancreatic alpha cells and increases production of insulin from pancreatic beta cells.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.,A10BH,Vildagliptin,596554,vildagliptin,"vildagliptin Oral Product, vildagliptin Pill","Oral Product, Pill",,"['dipeptidyl', 'incretins', 'conveys', 'hormones', 'inhibits', 'affecting', 'when', 'where', 'production', 'work', '1', 'Bristol', 'binds', 'S630', 'peptidase', 'two', '2', 'lymphocytes', 'mechanisms', 'Press', 'body', 'an', 'dimerization', 'cells', 'decrease', 'plasma', 'blood', 'enzymatic', 'associated', 'glucagon', 'treatment', 'that', 'adenosine', 'increases', 'by', 'pancreas', 'are', 'mainly', 'activated', 'called', 'function', 'reducing', 'many', 'histidine', 'another', 'Release', 'deaminase', 'nitrile', 'oxygen', 'which', 'natural', 'and', 'intracellular', 'for', 'via', 'through', 'levels', 'reversible', 'group', 'mechanism', 'main', 'type', 'increasing', 'consumption', 'membrane', 'compounds', 'found', 'in', 'beta', 'from', 'alpha', 'pancreatic', 'like', '4', 'insulin', 'Squibb', 'signals', 'is', 'on', 'inhibition', 'antidiabetic', 'of', 'sugar', 'peptide', 'class', 'its', 'the', 'between', 'DPP', 'bond', 'diabetes', 'The', 'tissues', 'assisted', 'has', 'Saxagliptin', 'covalent', 'active', 'forms', 'GLP', 'inhibitor', 'Incretins', 'action', 'liver', 'a', 'hydroxyl', 'inhibitors', 'Myers']",2,158,other,2,1,False,False,False,0.0566596907959597,0.027180067950169876
A10BH04,Alogliptin,"['A10BH04', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BH,Sitagliptin and simvastatin,1189803,"simvastatin, sitagliptin",,,,"['dipeptidyl', 'incretins', 'insulinotropic', 'normally', 'peptide', 'glucose', 'inhibits', 'increases', 'the', 'degrades', 'glycemic', 'suppressing', 'DPP', 'stimulate', 'additional', '1', 'The', 'emptying', 'has', 'peptidase', 'active', 'GLP', 'food', 'gastric', 'reducing', 'helps', 'polypeptide', 'Alogliptin', 'control', 'with', 'in', 'dependent', 'beta', 'amount', 'satiety', 'effects', 'pancreatic', 'like', 'which', '4', 'insulin', 'cells', 'and', 'inducing', 'plasma', 'GIP', 'intake', 'inhibition', 'secretion', 'of', 'glucagon']",2,71,other,0,2,False,False,False,0.05105653813348249,0.027180067950169876
A10BH04,Alogliptin,"['A10BH04', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BH,Alogliptin,1368000,alogliptin,,,,"['dipeptidyl', 'incretins', 'insulinotropic', 'normally', 'peptide', 'glucose', 'inhibits', 'increases', 'the', 'degrades', 'glycemic', 'suppressing', 'DPP', 'stimulate', 'additional', '1', 'The', 'emptying', 'has', 'peptidase', 'active', 'GLP', 'food', 'gastric', 'reducing', 'helps', 'polypeptide', 'Alogliptin', 'control', 'with', 'in', 'dependent', 'beta', 'amount', 'satiety', 'effects', 'pancreatic', 'like', 'which', '4', 'insulin', 'cells', 'and', 'inducing', 'plasma', 'GIP', 'intake', 'inhibition', 'secretion', 'of', 'glucagon']",2,71,other,0,1,False,False,False,0.05105653813348249,0.027180067950169876
A10BH04,Alogliptin,"['A10BH04', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BH,Saxagliptin,1043560,saxagliptin,,,,"['dipeptidyl', 'incretins', 'insulinotropic', 'normally', 'peptide', 'glucose', 'inhibits', 'increases', 'the', 'degrades', 'glycemic', 'suppressing', 'DPP', 'stimulate', 'additional', '1', 'The', 'emptying', 'has', 'peptidase', 'active', 'GLP', 'food', 'gastric', 'reducing', 'helps', 'polypeptide', 'Alogliptin', 'control', 'with', 'in', 'dependent', 'beta', 'amount', 'satiety', 'effects', 'pancreatic', 'like', 'which', '4', 'insulin', 'cells', 'and', 'inducing', 'plasma', 'GIP', 'intake', 'inhibition', 'secretion', 'of', 'glucagon']",2,71,other,0,1,False,False,False,0.05105653813348249,0.027180067950169876
A10BH04,Alogliptin,"['A10BH04', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.","ADipeptidyl peptidase 4 (inhibitor, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BH,Vildagliptin,596554,vildagliptin,"vildagliptin Oral Product, vildagliptin Pill","Oral Product, Pill",,"['dipeptidyl', 'incretins', 'insulinotropic', 'normally', 'peptide', 'glucose', 'inhibits', 'increases', 'the', 'degrades', 'glycemic', 'suppressing', 'DPP', 'stimulate', 'additional', '1', 'The', 'emptying', 'has', 'peptidase', 'active', 'GLP', 'food', 'gastric', 'reducing', 'helps', 'polypeptide', 'Alogliptin', 'control', 'with', 'in', 'dependent', 'beta', 'amount', 'satiety', 'effects', 'pancreatic', 'like', 'which', '4', 'insulin', 'cells', 'and', 'inducing', 'plasma', 'GIP', 'intake', 'inhibition', 'secretion', 'of', 'glucagon']",2,71,other,2,1,False,False,False,0.05105653813348249,0.027180067950169876
A10BH05,Linagliptin,"['A10BH05', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP)3,5. GLP-1 and GIP stimulate the release of insulin from beta cells in the pancreas while inhibiting release of glucagon from pancreatic beta cells5. These effects together reduce the breakdown of glycogen in the liver and increase insulin release in response to glucose53.","ADipeptidyl peptidase 4 (inhibitor, Humans)","Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise5. It should not be used to treat type I diabetes or in diabetic ketoacidosis.5 An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.6",A10BH,Sitagliptin and simvastatin,1189803,"simvastatin, sitagliptin",,,,"['insulinotropic', 'reversible', 'glucose', 'These', '3', 'while', 'response', 'slows', 'the', 'DPP', 'inhibiting', 'release', 'together', 'stimulate', 'pancreas', '1', 'reduce', 'increase', 'this', 'glucose53', 'GLP', 'inhibitor', 'competitive', 'Linagliptin', 'polypeptide', 'liver', 'in', 'beta', 'enzyme', 'a', 'dependant', 'from', 'effects', 'pancreatic', '4', 'insulin', 'cells', 'cells5', 'and', 'Inhibition', 'GIP', 'is', '5', 'glycogen', 'breakdown', 'to', 'of', 'glucagon']",2,63,other,0,2,False,False,False,0.06225867437966093,0.027180067950169876
A10BH05,Linagliptin,"['A10BH05', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP)3,5. GLP-1 and GIP stimulate the release of insulin from beta cells in the pancreas while inhibiting release of glucagon from pancreatic beta cells5. These effects together reduce the breakdown of glycogen in the liver and increase insulin release in response to glucose53.","ADipeptidyl peptidase 4 (inhibitor, Humans)","Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise5. It should not be used to treat type I diabetes or in diabetic ketoacidosis.5 An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.6",A10BH,Alogliptin,1368000,alogliptin,,,,"['insulinotropic', 'reversible', 'glucose', 'These', '3', 'while', 'response', 'slows', 'the', 'DPP', 'inhibiting', 'release', 'together', 'stimulate', 'pancreas', '1', 'reduce', 'increase', 'this', 'glucose53', 'GLP', 'inhibitor', 'competitive', 'Linagliptin', 'polypeptide', 'liver', 'in', 'beta', 'enzyme', 'a', 'dependant', 'from', 'effects', 'pancreatic', '4', 'insulin', 'cells', 'cells5', 'and', 'Inhibition', 'GIP', 'is', '5', 'glycogen', 'breakdown', 'to', 'of', 'glucagon']",2,63,other,0,1,False,False,False,0.06225867437966093,0.027180067950169876
A10BH05,Linagliptin,"['A10BH05', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP)3,5. GLP-1 and GIP stimulate the release of insulin from beta cells in the pancreas while inhibiting release of glucagon from pancreatic beta cells5. These effects together reduce the breakdown of glycogen in the liver and increase insulin release in response to glucose53.","ADipeptidyl peptidase 4 (inhibitor, Humans)","Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise5. It should not be used to treat type I diabetes or in diabetic ketoacidosis.5 An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.6",A10BH,Saxagliptin,1043560,saxagliptin,,,,"['insulinotropic', 'reversible', 'glucose', 'These', '3', 'while', 'response', 'slows', 'the', 'DPP', 'inhibiting', 'release', 'together', 'stimulate', 'pancreas', '1', 'reduce', 'increase', 'this', 'glucose53', 'GLP', 'inhibitor', 'competitive', 'Linagliptin', 'polypeptide', 'liver', 'in', 'beta', 'enzyme', 'a', 'dependant', 'from', 'effects', 'pancreatic', '4', 'insulin', 'cells', 'cells5', 'and', 'Inhibition', 'GIP', 'is', '5', 'glycogen', 'breakdown', 'to', 'of', 'glucagon']",2,63,other,0,1,False,False,False,0.06225867437966093,0.027180067950169876
A10BH05,Linagliptin,"['A10BH05', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,"Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP)3,5. GLP-1 and GIP stimulate the release of insulin from beta cells in the pancreas while inhibiting release of glucagon from pancreatic beta cells5. These effects together reduce the breakdown of glycogen in the liver and increase insulin release in response to glucose53.","ADipeptidyl peptidase 4 (inhibitor, Humans)","Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise5. It should not be used to treat type I diabetes or in diabetic ketoacidosis.5 An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.6",A10BH,Vildagliptin,596554,vildagliptin,"vildagliptin Oral Product, vildagliptin Pill","Oral Product, Pill",,"['insulinotropic', 'reversible', 'glucose', 'These', '3', 'while', 'response', 'slows', 'the', 'DPP', 'inhibiting', 'release', 'together', 'stimulate', 'pancreas', '1', 'reduce', 'increase', 'this', 'glucose53', 'GLP', 'inhibitor', 'competitive', 'Linagliptin', 'polypeptide', 'liver', 'in', 'beta', 'enzyme', 'a', 'dependant', 'from', 'effects', 'pancreatic', '4', 'insulin', 'cells', 'cells5', 'and', 'Inhibition', 'GIP', 'is', '5', 'glycogen', 'breakdown', 'to', 'of', 'glucagon']",2,63,other,2,1,False,False,False,0.06225867437966093,0.027180067950169876
A10BH06,Gemigliptin,"['A10BH06', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (inhibitor, Humans)",Not Available,A10BH,Sitagliptin and simvastatin,1189803,"simvastatin, sitagliptin",,,,"['Not', 'Available']",2,2,other,0,2,True,False,True,,0.027180067950169876
A10BH06,Gemigliptin,"['A10BH06', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (inhibitor, Humans)",Not Available,A10BH,Alogliptin,1368000,alogliptin,,,,"['Not', 'Available']",2,2,other,0,1,True,False,True,,0.027180067950169876
A10BH06,Gemigliptin,"['A10BH06', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (inhibitor, Humans)",Not Available,A10BH,Saxagliptin,1043560,saxagliptin,,,,"['Not', 'Available']",2,2,other,0,1,True,False,True,,0.027180067950169876
A10BH06,Gemigliptin,"['A10BH06', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (inhibitor, Humans)",Not Available,A10BH,Vildagliptin,596554,vildagliptin,"vildagliptin Oral Product, vildagliptin Pill","Oral Product, Pill",,"['Not', 'Available']",2,2,other,2,1,True,False,True,,0.027180067950169876
A10BH07,Evogliptin,"['A10BH07', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (inhibitor, Humans)",Not Available,A10BH,Sitagliptin and simvastatin,1189803,"simvastatin, sitagliptin",,,,"['Not', 'Available']",2,2,other,0,2,True,False,True,,0.027180067950169876
A10BH07,Evogliptin,"['A10BH07', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (inhibitor, Humans)",Not Available,A10BH,Alogliptin,1368000,alogliptin,,,,"['Not', 'Available']",2,2,other,0,1,True,False,True,,0.027180067950169876
A10BH07,Evogliptin,"['A10BH07', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (inhibitor, Humans)",Not Available,A10BH,Saxagliptin,1043560,saxagliptin,,,,"['Not', 'Available']",2,2,other,0,1,True,False,True,,0.027180067950169876
A10BH07,Evogliptin,"['A10BH07', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (inhibitor, Humans)",Not Available,A10BH,Vildagliptin,596554,vildagliptin,"vildagliptin Oral Product, vildagliptin Pill","Oral Product, Pill",,"['Not', 'Available']",2,2,other,2,1,True,False,True,,0.027180067950169876
A10BH08,Teneligliptin,"['A10BH08', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (modulator, Humans)",Not Available,A10BH,Sitagliptin and simvastatin,1189803,"simvastatin, sitagliptin",,,,"['Not', 'Available']",2,2,other,0,2,True,False,True,,0.0
A10BH08,Teneligliptin,"['A10BH08', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (modulator, Humans)",Not Available,A10BH,Alogliptin,1368000,alogliptin,,,,"['Not', 'Available']",2,2,other,0,1,True,False,True,,0.0
A10BH08,Teneligliptin,"['A10BH08', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (modulator, Humans)",Not Available,A10BH,Saxagliptin,1043560,saxagliptin,,,,"['Not', 'Available']",2,2,other,0,1,True,False,True,,0.0
A10BH08,Teneligliptin,"['A10BH08', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ADipeptidyl peptidase 4 (modulator, Humans)",Not Available,A10BH,Vildagliptin,596554,vildagliptin,"vildagliptin Oral Product, vildagliptin Pill","Oral Product, Pill",,"['Not', 'Available']",2,2,other,2,1,True,False,True,,0.0
A10BH51,Sitagliptin and simvastatin,"['A10BH51', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,,,,A10BH,Sitagliptin and simvastatin,1189803,"simvastatin, sitagliptin",,,,[],0,0,unknown,0,2,False,False,False,,0.3827859569648924
A10BH51,Sitagliptin and simvastatin,"['A10BH51', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,,,,A10BH,Alogliptin,1368000,alogliptin,,,,[],0,0,unknown,0,1,False,False,False,,0.3827859569648924
A10BH51,Sitagliptin and simvastatin,"['A10BH51', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,,,,A10BH,Saxagliptin,1043560,saxagliptin,,,,[],0,0,unknown,0,1,False,False,False,,0.3827859569648924
A10BH51,Sitagliptin and simvastatin,"['A10BH51', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,,,,A10BH,Vildagliptin,596554,vildagliptin,"vildagliptin Oral Product, vildagliptin Pill","Oral Product, Pill",,[],0,0,unknown,2,1,False,False,False,,0.3827859569648924
A10BH52,Gemigliptin and rosuvastatin,"['A10BH52', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,,,,A10BH,Sitagliptin and simvastatin,1189803,"simvastatin, sitagliptin",,,,[],0,0,unknown,0,2,False,False,False,,0.3827859569648924
A10BH52,Gemigliptin and rosuvastatin,"['A10BH52', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,,,,A10BH,Alogliptin,1368000,alogliptin,,,,[],0,0,unknown,0,1,False,False,False,,0.3827859569648924
A10BH52,Gemigliptin and rosuvastatin,"['A10BH52', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,,,,A10BH,Saxagliptin,1043560,saxagliptin,,,,[],0,0,unknown,0,1,False,False,False,,0.3827859569648924
A10BH52,Gemigliptin and rosuvastatin,"['A10BH52', 'A10BH', 'A10B', 'A10', 'A']",True,1,1,,,,A10BH,Vildagliptin,596554,vildagliptin,"vildagliptin Oral Product, vildagliptin Pill","Oral Product, Pill",,[],0,0,unknown,2,1,False,False,False,,0.3827859569648924
A10BJ01,Exenatide,"['A10BJ01', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Exenatide is a human glucacon-like peptide-1(GLP-1) receptor agonistLabel. By activating this receptor, insulin secretion is increased and glucagon secretion is decreased in a glucose dependant mannerLabel. Exenatide also slows gastric emptying and decreases food intakeLabel. These effects work synergistically to improve glycemic control by reducing the likelihood of hyper and hypoglycemiaLabel.","AGlucagon-like peptide 1 receptor (agonist, Humans)","Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old,10 while the immediate-acting formulation is approved only for adult patients.8",A10BJ,Semaglutide,1991302,semaglutide,"semaglutide Injectable Product, semaglutide Oral Product, semaglutide Pill","Injectable Product, Oral Product, Pill","Ozempic Injectable Product, Rybelsus Oral Product, Rybelsus Pill, Wegovy Injectable Product","['peptide', 'glucose', 'These', 'improve', 'slows', 'by', 'the', 'human', 'decreased', 'glycemic', 'hypoglycemiaLabel', '1', 'work', 'this', 'Exenatide', 'increased', 'emptying', 'receptor', 'By', 'GLP', 'food', 'gastric', 'reducing', 'synergistically', 'also', 'control', 'likelihood', 'in', 'dependant', 'a', 'agonistLabel', 'effects', 'like', 'mannerLabel', 'insulin', 'activating', 'and', 'intakeLabel', 'glucacon', 'hyper', 'is', 'to', 'secretion', 'decreases', 'of', 'glucagon']",2,51,other,3,1,False,False,False,0.04342507723470396,0.03397508493771234
A10BJ01,Exenatide,"['A10BJ01', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Exenatide is a human glucacon-like peptide-1(GLP-1) receptor agonistLabel. By activating this receptor, insulin secretion is increased and glucagon secretion is decreased in a glucose dependant mannerLabel. Exenatide also slows gastric emptying and decreases food intakeLabel. These effects work synergistically to improve glycemic control by reducing the likelihood of hyper and hypoglycemiaLabel.","AGlucagon-like peptide 1 receptor (agonist, Humans)","Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old,10 while the immediate-acting formulation is approved only for adult patients.8",A10BJ,Dulaglutide,1551291,dulaglutide,dulaglutide Injectable Product,Injectable Product,Trulicity Injectable Product,"['peptide', 'glucose', 'These', 'improve', 'slows', 'by', 'the', 'human', 'decreased', 'glycemic', 'hypoglycemiaLabel', '1', 'work', 'this', 'Exenatide', 'increased', 'emptying', 'receptor', 'By', 'GLP', 'food', 'gastric', 'reducing', 'synergistically', 'also', 'control', 'likelihood', 'in', 'dependant', 'a', 'agonistLabel', 'effects', 'like', 'mannerLabel', 'insulin', 'activating', 'and', 'intakeLabel', 'glucacon', 'hyper', 'is', 'to', 'secretion', 'decreases', 'of', 'glucagon']",2,51,other,1,1,False,False,False,0.04342507723470396,0.03397508493771234
A10BJ01,Exenatide,"['A10BJ01', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Exenatide is a human glucacon-like peptide-1(GLP-1) receptor agonistLabel. By activating this receptor, insulin secretion is increased and glucagon secretion is decreased in a glucose dependant mannerLabel. Exenatide also slows gastric emptying and decreases food intakeLabel. These effects work synergistically to improve glycemic control by reducing the likelihood of hyper and hypoglycemiaLabel.","AGlucagon-like peptide 1 receptor (agonist, Humans)","Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old,10 while the immediate-acting formulation is approved only for adult patients.8",A10BJ,Albiglutide,1534763,albiglutide,albiglutide Injectable Product,Injectable Product,Tanzeum Injectable Product,"['peptide', 'glucose', 'These', 'improve', 'slows', 'by', 'the', 'human', 'decreased', 'glycemic', 'hypoglycemiaLabel', '1', 'work', 'this', 'Exenatide', 'increased', 'emptying', 'receptor', 'By', 'GLP', 'food', 'gastric', 'reducing', 'synergistically', 'also', 'control', 'likelihood', 'in', 'dependant', 'a', 'agonistLabel', 'effects', 'like', 'mannerLabel', 'insulin', 'activating', 'and', 'intakeLabel', 'glucacon', 'hyper', 'is', 'to', 'secretion', 'decreases', 'of', 'glucagon']",2,51,other,1,1,False,False,False,0.04342507723470396,0.03397508493771234
A10BJ01,Exenatide,"['A10BJ01', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Exenatide is a human glucacon-like peptide-1(GLP-1) receptor agonistLabel. By activating this receptor, insulin secretion is increased and glucagon secretion is decreased in a glucose dependant mannerLabel. Exenatide also slows gastric emptying and decreases food intakeLabel. These effects work synergistically to improve glycemic control by reducing the likelihood of hyper and hypoglycemiaLabel.","AGlucagon-like peptide 1 receptor (agonist, Humans)","Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old,10 while the immediate-acting formulation is approved only for adult patients.8",A10BJ,Exenatide,60548,exenatide,exenatide Injectable Product,Injectable Product,"Byetta Injectable Product, Bydureon Injectable Product","['peptide', 'glucose', 'These', 'improve', 'slows', 'by', 'the', 'human', 'decreased', 'glycemic', 'hypoglycemiaLabel', '1', 'work', 'this', 'Exenatide', 'increased', 'emptying', 'receptor', 'By', 'GLP', 'food', 'gastric', 'reducing', 'synergistically', 'also', 'control', 'likelihood', 'in', 'dependant', 'a', 'agonistLabel', 'effects', 'like', 'mannerLabel', 'insulin', 'activating', 'and', 'intakeLabel', 'glucacon', 'hyper', 'is', 'to', 'secretion', 'decreases', 'of', 'glucagon']",2,51,other,1,1,False,False,False,0.04342507723470396,0.03397508493771234
A10BJ02,Liraglutide,"['A10BJ02', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Liraglutide is an acylated synthetic glucagon-like peptide-1 analogLabel,1,2. Liraglutide is an agonist of the glucagon-like peptide-1 receptor which is coupled to adenylate cyclaseLabel. The increase in cyclic AMP stimulates the glucose dependant release of insulin, inhibits the glucose dependant release of glucagon, and slows gastric emptying to increase control of blood sugarLabel,3.","AGlucagon-like peptide 1 receptor (agonist, Humans)","Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m2), or who are overweight (BMI≥27 kg/m2) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years old who weigh ≥60 kg and have an initial BMI corresponding to obesity based on international cut-offs.7",A10BJ,Semaglutide,1991302,semaglutide,"semaglutide Injectable Product, semaglutide Oral Product, semaglutide Pill","Injectable Product, Oral Product, Pill","Ozempic Injectable Product, Rybelsus Oral Product, Rybelsus Pill, Wegovy Injectable Product","['peptide', 'glucose', 'synthetic', 'coupled', 'inhibits', '3', 'analogLabel', 'the', 'cyclaseLabel', 'slows', 'cyclic', 'release', '1', 'The', 'increase', 'AMP', 'emptying', 'receptor', 'adenylate', 'gastric', '2', 'control', 'in', 'Liraglutide', 'dependant', 'an', 'like', 'agonist', 'which', 'insulin', 'acylated', 'and', 'blood', 'is', 'to', 'stimulates', 'sugarLabel', 'of', 'glucagon']",2,52,chronic,3,1,False,False,False,0.054019528708770144,0.03397508493771234
A10BJ02,Liraglutide,"['A10BJ02', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Liraglutide is an acylated synthetic glucagon-like peptide-1 analogLabel,1,2. Liraglutide is an agonist of the glucagon-like peptide-1 receptor which is coupled to adenylate cyclaseLabel. The increase in cyclic AMP stimulates the glucose dependant release of insulin, inhibits the glucose dependant release of glucagon, and slows gastric emptying to increase control of blood sugarLabel,3.","AGlucagon-like peptide 1 receptor (agonist, Humans)","Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m2), or who are overweight (BMI≥27 kg/m2) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years old who weigh ≥60 kg and have an initial BMI corresponding to obesity based on international cut-offs.7",A10BJ,Dulaglutide,1551291,dulaglutide,dulaglutide Injectable Product,Injectable Product,Trulicity Injectable Product,"['peptide', 'glucose', 'synthetic', 'coupled', 'inhibits', '3', 'analogLabel', 'the', 'cyclaseLabel', 'slows', 'cyclic', 'release', '1', 'The', 'increase', 'AMP', 'emptying', 'receptor', 'adenylate', 'gastric', '2', 'control', 'in', 'Liraglutide', 'dependant', 'an', 'like', 'agonist', 'which', 'insulin', 'acylated', 'and', 'blood', 'is', 'to', 'stimulates', 'sugarLabel', 'of', 'glucagon']",2,52,chronic,1,1,False,False,False,0.054019528708770144,0.03397508493771234
A10BJ02,Liraglutide,"['A10BJ02', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Liraglutide is an acylated synthetic glucagon-like peptide-1 analogLabel,1,2. Liraglutide is an agonist of the glucagon-like peptide-1 receptor which is coupled to adenylate cyclaseLabel. The increase in cyclic AMP stimulates the glucose dependant release of insulin, inhibits the glucose dependant release of glucagon, and slows gastric emptying to increase control of blood sugarLabel,3.","AGlucagon-like peptide 1 receptor (agonist, Humans)","Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m2), or who are overweight (BMI≥27 kg/m2) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years old who weigh ≥60 kg and have an initial BMI corresponding to obesity based on international cut-offs.7",A10BJ,Albiglutide,1534763,albiglutide,albiglutide Injectable Product,Injectable Product,Tanzeum Injectable Product,"['peptide', 'glucose', 'synthetic', 'coupled', 'inhibits', '3', 'analogLabel', 'the', 'cyclaseLabel', 'slows', 'cyclic', 'release', '1', 'The', 'increase', 'AMP', 'emptying', 'receptor', 'adenylate', 'gastric', '2', 'control', 'in', 'Liraglutide', 'dependant', 'an', 'like', 'agonist', 'which', 'insulin', 'acylated', 'and', 'blood', 'is', 'to', 'stimulates', 'sugarLabel', 'of', 'glucagon']",2,52,chronic,1,1,False,False,False,0.054019528708770144,0.03397508493771234
A10BJ02,Liraglutide,"['A10BJ02', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Liraglutide is an acylated synthetic glucagon-like peptide-1 analogLabel,1,2. Liraglutide is an agonist of the glucagon-like peptide-1 receptor which is coupled to adenylate cyclaseLabel. The increase in cyclic AMP stimulates the glucose dependant release of insulin, inhibits the glucose dependant release of glucagon, and slows gastric emptying to increase control of blood sugarLabel,3.","AGlucagon-like peptide 1 receptor (agonist, Humans)","Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m2), or who are overweight (BMI≥27 kg/m2) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years old who weigh ≥60 kg and have an initial BMI corresponding to obesity based on international cut-offs.7",A10BJ,Exenatide,60548,exenatide,exenatide Injectable Product,Injectable Product,"Byetta Injectable Product, Bydureon Injectable Product","['peptide', 'glucose', 'synthetic', 'coupled', 'inhibits', '3', 'analogLabel', 'the', 'cyclaseLabel', 'slows', 'cyclic', 'release', '1', 'The', 'increase', 'AMP', 'emptying', 'receptor', 'adenylate', 'gastric', '2', 'control', 'in', 'Liraglutide', 'dependant', 'an', 'like', 'agonist', 'which', 'insulin', 'acylated', 'and', 'blood', 'is', 'to', 'stimulates', 'sugarLabel', 'of', 'glucagon']",2,52,chronic,1,1,False,False,False,0.054019528708770144,0.03397508493771234
A10BJ03,Lixisenatide,"['A10BJ03', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"The activation of the GLP-1 receptor by lixisenatide results in the activation of adenylyl cyclase.2 This increases the concentration of cyclic adenosine monophosphate in the cell leading to the activation of protein kinase A (PKA) as well as Epac1 and Epac2.  PKA, Epac1, and Epac2 are involved the in release of Ca2+ from the endoplasmic reticulum which is known as the ""amplification"" pathway which increases insulin release when the triggering pathway is activated. By activating this amplification pathway lixisenatide increases glucose stimulated insulin secretion.","AGlucagon-like peptide 1 receptor (agonist, Humans)",Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus.5 It is also available in combination with insulin glargine for the same indication.6,A10BJ,Semaglutide,1991302,semaglutide,"semaglutide Injectable Product, semaglutide Oral Product, semaglutide Pill","Injectable Product, Oral Product, Pill","Ozempic Injectable Product, Rybelsus Oral Product, Rybelsus Pill, Wegovy Injectable Product","['involved', 'adenosine', 'glucose', 'triggering', 'reticulum', 'Ca2', 'activation', 'This', 'increases', 'by', 'the', 'when', 'cyclic', 'release', 'cell', 'adenylyl', 'The', '1', 'lixisenatide', 'are', 'endoplasmic', 'amplification', 'activated', 'Epac1', 'this', 'receptor', 'A', 'By', 'GLP', 'known', 'cyclase', '2', 'in', 'stimulated', 'leading', 'from', 'kinase', 'PKA', 'which', 'insulin', 'activating', 'and', 'concentration', 'is', 'pathway', 'protein', 'Epac2', 'as', 'to', 'monophosphate', 'results', 'well', 'secretion', 'of']",2,84,other,3,1,False,False,False,0.06483974685161478,0.03397508493771234
A10BJ03,Lixisenatide,"['A10BJ03', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"The activation of the GLP-1 receptor by lixisenatide results in the activation of adenylyl cyclase.2 This increases the concentration of cyclic adenosine monophosphate in the cell leading to the activation of protein kinase A (PKA) as well as Epac1 and Epac2.  PKA, Epac1, and Epac2 are involved the in release of Ca2+ from the endoplasmic reticulum which is known as the ""amplification"" pathway which increases insulin release when the triggering pathway is activated. By activating this amplification pathway lixisenatide increases glucose stimulated insulin secretion.","AGlucagon-like peptide 1 receptor (agonist, Humans)",Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus.5 It is also available in combination with insulin glargine for the same indication.6,A10BJ,Dulaglutide,1551291,dulaglutide,dulaglutide Injectable Product,Injectable Product,Trulicity Injectable Product,"['involved', 'adenosine', 'glucose', 'triggering', 'reticulum', 'Ca2', 'activation', 'This', 'increases', 'by', 'the', 'when', 'cyclic', 'release', 'cell', 'adenylyl', 'The', '1', 'lixisenatide', 'are', 'endoplasmic', 'amplification', 'activated', 'Epac1', 'this', 'receptor', 'A', 'By', 'GLP', 'known', 'cyclase', '2', 'in', 'stimulated', 'leading', 'from', 'kinase', 'PKA', 'which', 'insulin', 'activating', 'and', 'concentration', 'is', 'pathway', 'protein', 'Epac2', 'as', 'to', 'monophosphate', 'results', 'well', 'secretion', 'of']",2,84,other,1,1,False,False,False,0.06483974685161478,0.03397508493771234
A10BJ03,Lixisenatide,"['A10BJ03', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"The activation of the GLP-1 receptor by lixisenatide results in the activation of adenylyl cyclase.2 This increases the concentration of cyclic adenosine monophosphate in the cell leading to the activation of protein kinase A (PKA) as well as Epac1 and Epac2.  PKA, Epac1, and Epac2 are involved the in release of Ca2+ from the endoplasmic reticulum which is known as the ""amplification"" pathway which increases insulin release when the triggering pathway is activated. By activating this amplification pathway lixisenatide increases glucose stimulated insulin secretion.","AGlucagon-like peptide 1 receptor (agonist, Humans)",Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus.5 It is also available in combination with insulin glargine for the same indication.6,A10BJ,Albiglutide,1534763,albiglutide,albiglutide Injectable Product,Injectable Product,Tanzeum Injectable Product,"['involved', 'adenosine', 'glucose', 'triggering', 'reticulum', 'Ca2', 'activation', 'This', 'increases', 'by', 'the', 'when', 'cyclic', 'release', 'cell', 'adenylyl', 'The', '1', 'lixisenatide', 'are', 'endoplasmic', 'amplification', 'activated', 'Epac1', 'this', 'receptor', 'A', 'By', 'GLP', 'known', 'cyclase', '2', 'in', 'stimulated', 'leading', 'from', 'kinase', 'PKA', 'which', 'insulin', 'activating', 'and', 'concentration', 'is', 'pathway', 'protein', 'Epac2', 'as', 'to', 'monophosphate', 'results', 'well', 'secretion', 'of']",2,84,other,1,1,False,False,False,0.06483974685161478,0.03397508493771234
A10BJ03,Lixisenatide,"['A10BJ03', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"The activation of the GLP-1 receptor by lixisenatide results in the activation of adenylyl cyclase.2 This increases the concentration of cyclic adenosine monophosphate in the cell leading to the activation of protein kinase A (PKA) as well as Epac1 and Epac2.  PKA, Epac1, and Epac2 are involved the in release of Ca2+ from the endoplasmic reticulum which is known as the ""amplification"" pathway which increases insulin release when the triggering pathway is activated. By activating this amplification pathway lixisenatide increases glucose stimulated insulin secretion.","AGlucagon-like peptide 1 receptor (agonist, Humans)",Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus.5 It is also available in combination with insulin glargine for the same indication.6,A10BJ,Exenatide,60548,exenatide,exenatide Injectable Product,Injectable Product,"Byetta Injectable Product, Bydureon Injectable Product","['involved', 'adenosine', 'glucose', 'triggering', 'reticulum', 'Ca2', 'activation', 'This', 'increases', 'by', 'the', 'when', 'cyclic', 'release', 'cell', 'adenylyl', 'The', '1', 'lixisenatide', 'are', 'endoplasmic', 'amplification', 'activated', 'Epac1', 'this', 'receptor', 'A', 'By', 'GLP', 'known', 'cyclase', '2', 'in', 'stimulated', 'leading', 'from', 'kinase', 'PKA', 'which', 'insulin', 'activating', 'and', 'concentration', 'is', 'pathway', 'protein', 'Epac2', 'as', 'to', 'monophosphate', 'results', 'well', 'secretion', 'of']",2,84,other,1,1,False,False,False,0.06483974685161478,0.03397508493771234
A10BJ04,Albiglutide,"['A10BJ04', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Albiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.,"AGlucagon-like peptide 1 receptor (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BJ,Semaglutide,1991302,semaglutide,"semaglutide Injectable Product, semaglutide Oral Product, semaglutide Pill","Injectable Product, Oral Product, Pill","Ozempic Injectable Product, Rybelsus Oral Product, Rybelsus Pill, Wegovy Injectable Product","['peptide', 'glucose', 'slows', 'the', 'Albiglutide', '1', 'emptying', 'receptor', 'GLP', 'gastric', 'also', 'dependent', 'an', 'like', 'augments', 'agonist', 'insulin', 'and', 'is', 'secretion', 'of', 'glucagon']",2,21,other,3,1,False,False,False,0.03101163335994271,0.03397508493771234
A10BJ04,Albiglutide,"['A10BJ04', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Albiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.,"AGlucagon-like peptide 1 receptor (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BJ,Dulaglutide,1551291,dulaglutide,dulaglutide Injectable Product,Injectable Product,Trulicity Injectable Product,"['peptide', 'glucose', 'slows', 'the', 'Albiglutide', '1', 'emptying', 'receptor', 'GLP', 'gastric', 'also', 'dependent', 'an', 'like', 'augments', 'agonist', 'insulin', 'and', 'is', 'secretion', 'of', 'glucagon']",2,21,other,1,1,False,False,False,0.03101163335994271,0.03397508493771234
A10BJ04,Albiglutide,"['A10BJ04', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Albiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.,"AGlucagon-like peptide 1 receptor (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BJ,Albiglutide,1534763,albiglutide,albiglutide Injectable Product,Injectable Product,Tanzeum Injectable Product,"['peptide', 'glucose', 'slows', 'the', 'Albiglutide', '1', 'emptying', 'receptor', 'GLP', 'gastric', 'also', 'dependent', 'an', 'like', 'augments', 'agonist', 'insulin', 'and', 'is', 'secretion', 'of', 'glucagon']",2,21,other,1,1,False,False,False,0.03101163335994271,0.03397508493771234
A10BJ04,Albiglutide,"['A10BJ04', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Albiglutide is an agonist of the GLP-1 (glucagon-like peptide 1) receptor and augments glucose-dependent insulin secretion. Albiglutide also slows gastric emptying.,"AGlucagon-like peptide 1 receptor (agonist, Humans)",Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BJ,Exenatide,60548,exenatide,exenatide Injectable Product,Injectable Product,"Byetta Injectable Product, Bydureon Injectable Product","['peptide', 'glucose', 'slows', 'the', 'Albiglutide', '1', 'emptying', 'receptor', 'GLP', 'gastric', 'also', 'dependent', 'an', 'like', 'augments', 'agonist', 'insulin', 'and', 'is', 'secretion', 'of', 'glucagon']",2,21,other,1,1,False,False,False,0.03101163335994271,0.03397508493771234
A10BJ05,Dulaglutide,"['A10BJ05', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric emptying.6,7","AGlucagon-like peptide 1 receptor (agonist, Humans)",Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus.7 It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.7,A10BJ,Semaglutide,1991302,semaglutide,"semaglutide Injectable Product, semaglutide Oral Product, semaglutide Pill","Injectable Product, Oral Product, Pill","Ozempic Injectable Product, Rybelsus Oral Product, Rybelsus Pill, Wegovy Injectable Product","['glucose', 'slows', 'the', 'concentrations', 'cyclic', 'increasing', 'release', '1', 'cAMP', 'AMP', 'emptying', 'receptor', 'GLP', 'found', 'gastric', 'Additionally', 'reduction', 'in', 'beta', 'dulaglutide', 'leading', '6', 'pancreatic', 'insulin', 'cells', 'and', 'Dulaglutide', 'subsequent', 'intracellular', 'blood', 'activates', 'to', 'secretion', '7', 'decreases', 'of', 'glucagon']",2,38,other,3,1,False,False,False,0.04717806922761727,0.03397508493771234
A10BJ05,Dulaglutide,"['A10BJ05', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric emptying.6,7","AGlucagon-like peptide 1 receptor (agonist, Humans)",Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus.7 It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.7,A10BJ,Dulaglutide,1551291,dulaglutide,dulaglutide Injectable Product,Injectable Product,Trulicity Injectable Product,"['glucose', 'slows', 'the', 'concentrations', 'cyclic', 'increasing', 'release', '1', 'cAMP', 'AMP', 'emptying', 'receptor', 'GLP', 'found', 'gastric', 'Additionally', 'reduction', 'in', 'beta', 'dulaglutide', 'leading', '6', 'pancreatic', 'insulin', 'cells', 'and', 'Dulaglutide', 'subsequent', 'intracellular', 'blood', 'activates', 'to', 'secretion', '7', 'decreases', 'of', 'glucagon']",2,38,other,1,1,False,False,False,0.04717806922761727,0.03397508493771234
A10BJ05,Dulaglutide,"['A10BJ05', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric emptying.6,7","AGlucagon-like peptide 1 receptor (agonist, Humans)",Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus.7 It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.7,A10BJ,Albiglutide,1534763,albiglutide,albiglutide Injectable Product,Injectable Product,Tanzeum Injectable Product,"['glucose', 'slows', 'the', 'concentrations', 'cyclic', 'increasing', 'release', '1', 'cAMP', 'AMP', 'emptying', 'receptor', 'GLP', 'found', 'gastric', 'Additionally', 'reduction', 'in', 'beta', 'dulaglutide', 'leading', '6', 'pancreatic', 'insulin', 'cells', 'and', 'Dulaglutide', 'subsequent', 'intracellular', 'blood', 'activates', 'to', 'secretion', '7', 'decreases', 'of', 'glucagon']",2,38,other,1,1,False,False,False,0.04717806922761727,0.03397508493771234
A10BJ05,Dulaglutide,"['A10BJ05', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,"Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric emptying.6,7","AGlucagon-like peptide 1 receptor (agonist, Humans)",Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus.7 It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.7,A10BJ,Exenatide,60548,exenatide,exenatide Injectable Product,Injectable Product,"Byetta Injectable Product, Bydureon Injectable Product","['glucose', 'slows', 'the', 'concentrations', 'cyclic', 'increasing', 'release', '1', 'cAMP', 'AMP', 'emptying', 'receptor', 'GLP', 'found', 'gastric', 'Additionally', 'reduction', 'in', 'beta', 'dulaglutide', 'leading', '6', 'pancreatic', 'insulin', 'cells', 'and', 'Dulaglutide', 'subsequent', 'intracellular', 'blood', 'activates', 'to', 'secretion', '7', 'decreases', 'of', 'glucagon']",2,38,other,1,1,False,False,False,0.04717806922761727,0.03397508493771234
A10BJ06,Semaglutide,"['A10BJ06', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Mechanism of glycemic control,"AGlucagon-like peptide 1 receptor (agonist, Humans)","Semaglutide is always intended to be used with a reduced calorie diet and increased physical activity. It is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus.14,15 However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis.  Semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosis.14",A10BJ,Semaglutide,1991302,semaglutide,"semaglutide Injectable Product, semaglutide Oral Product, semaglutide Pill","Injectable Product, Oral Product, Pill","Ozempic Injectable Product, Rybelsus Oral Product, Rybelsus Pill, Wegovy Injectable Product","['glycemic', 'of', 'Mechanism', 'control']",2,4,other,3,1,False,False,False,0.012120063786782915,0.03397508493771234
A10BJ06,Semaglutide,"['A10BJ06', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Mechanism of glycemic control,"AGlucagon-like peptide 1 receptor (agonist, Humans)","Semaglutide is always intended to be used with a reduced calorie diet and increased physical activity. It is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus.14,15 However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis.  Semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosis.14",A10BJ,Dulaglutide,1551291,dulaglutide,dulaglutide Injectable Product,Injectable Product,Trulicity Injectable Product,"['glycemic', 'of', 'Mechanism', 'control']",2,4,other,1,1,False,False,False,0.012120063786782915,0.03397508493771234
A10BJ06,Semaglutide,"['A10BJ06', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Mechanism of glycemic control,"AGlucagon-like peptide 1 receptor (agonist, Humans)","Semaglutide is always intended to be used with a reduced calorie diet and increased physical activity. It is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus.14,15 However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis.  Semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosis.14",A10BJ,Albiglutide,1534763,albiglutide,albiglutide Injectable Product,Injectable Product,Tanzeum Injectable Product,"['glycemic', 'of', 'Mechanism', 'control']",2,4,other,1,1,False,False,False,0.012120063786782915,0.03397508493771234
A10BJ06,Semaglutide,"['A10BJ06', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Mechanism of glycemic control,"AGlucagon-like peptide 1 receptor (agonist, Humans)","Semaglutide is always intended to be used with a reduced calorie diet and increased physical activity. It is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus.14,15 However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis.  Semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosis.14",A10BJ,Exenatide,60548,exenatide,exenatide Injectable Product,Injectable Product,"Byetta Injectable Product, Bydureon Injectable Product","['glycemic', 'of', 'Mechanism', 'control']",2,4,other,1,1,False,False,False,0.012120063786782915,0.03397508493771234
A10BJ07,Beinaglutide,"['A10BJ07', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Not Available,"Not Available (Completed, Treatment); Not Available (Unknown Status, Treatment); 4 (Recruiting, Treatment)",Not Available,A10BJ,Semaglutide,1991302,semaglutide,"semaglutide Injectable Product, semaglutide Oral Product, semaglutide Pill","Injectable Product, Oral Product, Pill","Ozempic Injectable Product, Rybelsus Oral Product, Rybelsus Pill, Wegovy Injectable Product","['Not', 'Available']",4,2,other,3,1,True,True,True,,0.0
A10BJ07,Beinaglutide,"['A10BJ07', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Not Available,"Not Available (Completed, Treatment); Not Available (Unknown Status, Treatment); 4 (Recruiting, Treatment)",Not Available,A10BJ,Dulaglutide,1551291,dulaglutide,dulaglutide Injectable Product,Injectable Product,Trulicity Injectable Product,"['Not', 'Available']",4,2,other,1,1,True,True,True,,0.0
A10BJ07,Beinaglutide,"['A10BJ07', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Not Available,"Not Available (Completed, Treatment); Not Available (Unknown Status, Treatment); 4 (Recruiting, Treatment)",Not Available,A10BJ,Albiglutide,1534763,albiglutide,albiglutide Injectable Product,Injectable Product,Tanzeum Injectable Product,"['Not', 'Available']",4,2,other,1,1,True,True,True,,0.0
A10BJ07,Beinaglutide,"['A10BJ07', 'A10BJ', 'A10B', 'A10', 'A']",True,1,1,Not Available,"Not Available (Completed, Treatment); Not Available (Unknown Status, Treatment); 4 (Recruiting, Treatment)",Not Available,A10BJ,Exenatide,60548,exenatide,exenatide Injectable Product,Injectable Product,"Byetta Injectable Product, Bydureon Injectable Product","['Not', 'Available']",4,2,other,1,1,True,True,True,,0.0
A10BK01,Dapagliflozin,"['A10BK01', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,Dapagliflozin inhibits the sodium-glucose cotransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron.1 SGLT2 facilitates 90% of glucose reabsorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine.1 This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.1,"ASodium/glucose cotransporter 2 (antagonistinhibitor, Humans)","Dapagliflozin is indicated as an adjunct treatment, alongside diet and exercise, to improve glycemic control in patients ≥10 years of age with type 2 diabetes mellitus.13,1,2 For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure.9 Dapagliflozin is also indicated to either reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.9 Combination products with dapagliflozin also exist, either as a dapagliflozin-saxagliptin or dapagliflozin-metformin hydrochloride formulation.7,8 Both are used as an adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes.7,8",A10BK,Bexagliflozin,2627044,bexagliflozin,"bexagliflozin Oral Product, bexagliflozin Pill","Oral Product, Pill","Bexacat Oral Product, Bexacat Pill, Brenzavvy Oral Product, Brenzavvy Pill","['excretion', 'urine', 'its', 'glucose', 'patients', 'inhibits', 'This', 'located', 'be', 'the', 'proximal', 'facilitates', 'glycemic', 'excreted', 'type', 'diabetes', '1', 'SGLT2', 'primarily', 'better', 'sodium', 'reabsorption', '2', 'nephron', '90', 'control', 'with', 'in', 'so', 'allows', 'loss', 'which', 'Dapagliflozin', 'weight', 'and', 'mellitus', 'kidneys', 'is', 'cotransporter', 'for', 'potentially', 'inhibition', 'to', 'tubule', 'of']",2,57,chronic,2,1,False,False,False,0.04873948639573832,0.0
A10BK01,Dapagliflozin,"['A10BK01', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,Dapagliflozin inhibits the sodium-glucose cotransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron.1 SGLT2 facilitates 90% of glucose reabsorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine.1 This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.1,"ASodium/glucose cotransporter 2 (antagonistinhibitor, Humans)","Dapagliflozin is indicated as an adjunct treatment, alongside diet and exercise, to improve glycemic control in patients ≥10 years of age with type 2 diabetes mellitus.13,1,2 For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure.9 Dapagliflozin is also indicated to either reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.9 Combination products with dapagliflozin also exist, either as a dapagliflozin-saxagliptin or dapagliflozin-metformin hydrochloride formulation.7,8 Both are used as an adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes.7,8",A10BK,Sotagliflozin,2638675,sotagliflozin,"sotagliflozin Oral Product, sotagliflozin Pill","Oral Product, Pill","Inpefa Oral Product, Inpefa Pill","['excretion', 'urine', 'its', 'glucose', 'patients', 'inhibits', 'This', 'located', 'be', 'the', 'proximal', 'facilitates', 'glycemic', 'excreted', 'type', 'diabetes', '1', 'SGLT2', 'primarily', 'better', 'sodium', 'reabsorption', '2', 'nephron', '90', 'control', 'with', 'in', 'so', 'allows', 'loss', 'which', 'Dapagliflozin', 'weight', 'and', 'mellitus', 'kidneys', 'is', 'cotransporter', 'for', 'potentially', 'inhibition', 'to', 'tubule', 'of']",2,57,chronic,2,1,False,False,False,0.04873948639573832,0.0
A10BK02,Canagliflozin,"['A10BK02', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,"The sodium-glucose co-transporter2 (SGLT2), is found in the proximal tubules of the kidney, and reabsorbs filtered glucose from the renal tubular lumen. Canagliflozin inhibits the SGLT2 co-transporter. This inhibition leads to lower reabsorption of filtered glucose into the body and decreases the renal threshold for glucose (RTG), leading to increased glucose excretion in the urine Label.","ASodium/glucose cotransporter 2 (inhibitor, Humans)",This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus Label.,A10BK,Bexagliflozin,2627044,bexagliflozin,"bexagliflozin Oral Product, bexagliflozin Pill","Oral Product, Pill","Bexacat Oral Product, Bexacat Pill, Brenzavvy Oral Product, Brenzavvy Pill","['Label', 'excretion', 'urine', 'glucose', 'inhibits', 'This', 'renal', 'the', 'proximal', 'The', 'leads', 'SGLT2', 'increased', 'found', 'sodium', 'Canagliflozin', 'reabsorption', 'tubular', 'in', 'co', 'transporter2', 'kidney', 'body', 'from', 'leading', 'into', 'lumen', 'and', 'filtered', 'RTG', 'reabsorbs', 'for', 'is', 'transporter', 'tubules', 'threshold', 'inhibition', 'to', 'decreases', 'lower', 'of']",2,56,other,2,1,False,False,False,0.051328903289361585,0.00903954802259887
A10BK02,Canagliflozin,"['A10BK02', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,"The sodium-glucose co-transporter2 (SGLT2), is found in the proximal tubules of the kidney, and reabsorbs filtered glucose from the renal tubular lumen. Canagliflozin inhibits the SGLT2 co-transporter. This inhibition leads to lower reabsorption of filtered glucose into the body and decreases the renal threshold for glucose (RTG), leading to increased glucose excretion in the urine Label.","ASodium/glucose cotransporter 2 (inhibitor, Humans)",This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus Label.,A10BK,Sotagliflozin,2638675,sotagliflozin,"sotagliflozin Oral Product, sotagliflozin Pill","Oral Product, Pill","Inpefa Oral Product, Inpefa Pill","['Label', 'excretion', 'urine', 'glucose', 'inhibits', 'This', 'renal', 'the', 'proximal', 'The', 'leads', 'SGLT2', 'increased', 'found', 'sodium', 'Canagliflozin', 'reabsorption', 'tubular', 'in', 'co', 'transporter2', 'kidney', 'body', 'from', 'leading', 'into', 'lumen', 'and', 'filtered', 'RTG', 'reabsorbs', 'for', 'is', 'transporter', 'tubules', 'threshold', 'inhibition', 'to', 'decreases', 'lower', 'of']",2,56,other,2,1,False,False,False,0.051328903289361585,0.00903954802259887
A10BK03,Empagliflozin,"['A10BK03', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,"The vast majority of glucose filtered through the glomerulus is reabsorbed within the proximal tubule, primarily via SGLT2 (sodium-glucose linked co-transporter-2) which is responsible for ~90% of the total glucose reabsorption within the kidneys. Na+/K+-ATPase on the basolateral membrane of proximal tubular cells utilize ATP to actively pump Na+ ions into the interstitium surrounding the tubule, establishing a Na+ gradient within the tubular cell. SGLT2 on the apical membrane of these cells then utilize this gradient to facilitate secondary active co-transport of both Na+ and glucose out of the filtrate, thereby reabsorbing glucose back into the blood – inhibiting this co-transport, then, allows for a marked increase in glucosuria and decrease in blood glucose levels.10 Empagliflozin is a potent inhibitor of renal SGLT2 transporters located in the proximal tubules of the kidneys and works to lower blood glucose levels via an increase in glucosuria.18","ASodium/glucose cotransporter 2 (inhibitor, Humans)","Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients aged 10 years and older with type 2 diabetes. It is used either alone or in combination with metformin or linagliptin.16,15,18 It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or as a combination product with metformin.18,21",A10BK,Bexagliflozin,2627044,bexagliflozin,"bexagliflozin Oral Product, bexagliflozin Pill","Oral Product, Pill","Bexacat Oral Product, Bexacat Pill, Brenzavvy Oral Product, Brenzavvy Pill","['total', 'vast', 'glomerulus', '10', 'reabsorption', '2', 'an', 'cells', 'decrease', 'blood', 'basolateral', 'interstitium', 'ATP', 'surrounding', 'apical', 'glucose', 'located', 'marked', 'proximal', 'majority', 'inhibiting', 'increase', 'glucosuria', 'potent', 'out', 'Empagliflozin', 'filtrate', 'allows', 'K', 'which', 'secondary', 'works', 'and', 'for', 'via', 'gradient', 'to', 'tubule', 'then', 'through', 'levels', 'both', 'thereby', 'utilize', 'linked', 'membrane', 'SGLT2', 'primarily', 'these', 'in', '18', 'facilitate', 'reabsorbed', 'filtered', 'transport', 'is', 'on', 'ATPase', 'establishing', 'of', 'reabsorbing', 'renal', 'the', 'back', 'cell', 'The', 'this', 'active', 'inhibitor', 'sodium', 'tubular', 'Na', '90', 'responsible', 'co', 'a', 'transporters', 'into', 'ions', 'pump', 'kidneys', 'transporter', 'tubules', 'within', 'lower', 'actively']",2,144,other,2,1,False,False,False,0.05415432166652289,0.00903954802259887
A10BK03,Empagliflozin,"['A10BK03', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,"The vast majority of glucose filtered through the glomerulus is reabsorbed within the proximal tubule, primarily via SGLT2 (sodium-glucose linked co-transporter-2) which is responsible for ~90% of the total glucose reabsorption within the kidneys. Na+/K+-ATPase on the basolateral membrane of proximal tubular cells utilize ATP to actively pump Na+ ions into the interstitium surrounding the tubule, establishing a Na+ gradient within the tubular cell. SGLT2 on the apical membrane of these cells then utilize this gradient to facilitate secondary active co-transport of both Na+ and glucose out of the filtrate, thereby reabsorbing glucose back into the blood – inhibiting this co-transport, then, allows for a marked increase in glucosuria and decrease in blood glucose levels.10 Empagliflozin is a potent inhibitor of renal SGLT2 transporters located in the proximal tubules of the kidneys and works to lower blood glucose levels via an increase in glucosuria.18","ASodium/glucose cotransporter 2 (inhibitor, Humans)","Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients aged 10 years and older with type 2 diabetes. It is used either alone or in combination with metformin or linagliptin.16,15,18 It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or as a combination product with metformin.18,21",A10BK,Sotagliflozin,2638675,sotagliflozin,"sotagliflozin Oral Product, sotagliflozin Pill","Oral Product, Pill","Inpefa Oral Product, Inpefa Pill","['total', 'vast', 'glomerulus', '10', 'reabsorption', '2', 'an', 'cells', 'decrease', 'blood', 'basolateral', 'interstitium', 'ATP', 'surrounding', 'apical', 'glucose', 'located', 'marked', 'proximal', 'majority', 'inhibiting', 'increase', 'glucosuria', 'potent', 'out', 'Empagliflozin', 'filtrate', 'allows', 'K', 'which', 'secondary', 'works', 'and', 'for', 'via', 'gradient', 'to', 'tubule', 'then', 'through', 'levels', 'both', 'thereby', 'utilize', 'linked', 'membrane', 'SGLT2', 'primarily', 'these', 'in', '18', 'facilitate', 'reabsorbed', 'filtered', 'transport', 'is', 'on', 'ATPase', 'establishing', 'of', 'reabsorbing', 'renal', 'the', 'back', 'cell', 'The', 'this', 'active', 'inhibitor', 'sodium', 'tubular', 'Na', '90', 'responsible', 'co', 'a', 'transporters', 'into', 'ions', 'pump', 'kidneys', 'transporter', 'tubules', 'within', 'lower', 'actively']",2,144,other,2,1,False,False,False,0.05415432166652289,0.00903954802259887
A10BK04,Ertugliflozin,"['A10BK04', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,"Kidneys play an integral role in glucose homeostasis. After being filtered into urine within the nephron, most of the plasma glucose is reabsorbed through two types of sodium-dependent glucose cotransporters (SGLTs), SGLT1 and SGLT2, expressed in proximal renal tubules.4 More specifically, SGLT2 is responsible for 80–90% of renal glucose reabsorption while SGLT1 is responsible for the remaining 10-20%.4 Under physiological conditions, less than one percent of glucose is excreted in urine.1,4 In the case of hyperglycemia, SGLTs become saturated and the renal threshold for urinary glucose excretion is increased. Kidneys respond to an elevated threshold for glycosuria by elevating glucose reabsorption and increasing maximum glucose reabsorptive capacity.4","ASodium/glucose cotransporter 2 (inhibitor, Humans)","Ertugliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM).10 It is also available in combination with either metformin or sitagliptin.7,8",A10BK,Bexagliflozin,2627044,bexagliflozin,"bexagliflozin Oral Product, bexagliflozin Pill","Oral Product, Pill","Bexacat Oral Product, Bexacat Pill, Brenzavvy Oral Product, Brenzavvy Pill","['through', 'conditions', 'excretion', 'urine', 'SGLT1', 'glucose', 'being', 'less', 'than', 'while', 'renal', 'role', 'the', 'proximal', 'by', 'most', 'homeostasis', 'excreted', 'physiological', 'saturated', 'remaining', 'increasing', 'types', 'Under', 'elevated', '1', 'cotransporters', 'More', 'SGLT2', 'integral', 'increased', 'become', 'two', 'elevating', '80', 'hyperglycemia', 'sodium', '10', 'reabsorption', 'capacity', 'After', 'urinary', 'nephron', '90', 'maximum', 'in', 'dependent', 'responsible', 'reabsorptive', 'an', 'case', 'Kidneys', 'specifically', 'into', '4', 'In', 'and', 'play', 'plasma', 'reabsorbed', '20', 'filtered', 'SGLTs', 'expressed', 'percent', 'respond', 'for', 'is', 'glycosuria', 'tubules', 'threshold', 'to', 'one', 'within', 'of']",2,107,other,2,1,False,False,False,0.04439758640399567,0.00903954802259887
A10BK04,Ertugliflozin,"['A10BK04', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,"Kidneys play an integral role in glucose homeostasis. After being filtered into urine within the nephron, most of the plasma glucose is reabsorbed through two types of sodium-dependent glucose cotransporters (SGLTs), SGLT1 and SGLT2, expressed in proximal renal tubules.4 More specifically, SGLT2 is responsible for 80–90% of renal glucose reabsorption while SGLT1 is responsible for the remaining 10-20%.4 Under physiological conditions, less than one percent of glucose is excreted in urine.1,4 In the case of hyperglycemia, SGLTs become saturated and the renal threshold for urinary glucose excretion is increased. Kidneys respond to an elevated threshold for glycosuria by elevating glucose reabsorption and increasing maximum glucose reabsorptive capacity.4","ASodium/glucose cotransporter 2 (inhibitor, Humans)","Ertugliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM).10 It is also available in combination with either metformin or sitagliptin.7,8",A10BK,Sotagliflozin,2638675,sotagliflozin,"sotagliflozin Oral Product, sotagliflozin Pill","Oral Product, Pill","Inpefa Oral Product, Inpefa Pill","['through', 'conditions', 'excretion', 'urine', 'SGLT1', 'glucose', 'being', 'less', 'than', 'while', 'renal', 'role', 'the', 'proximal', 'by', 'most', 'homeostasis', 'excreted', 'physiological', 'saturated', 'remaining', 'increasing', 'types', 'Under', 'elevated', '1', 'cotransporters', 'More', 'SGLT2', 'integral', 'increased', 'become', 'two', 'elevating', '80', 'hyperglycemia', 'sodium', '10', 'reabsorption', 'capacity', 'After', 'urinary', 'nephron', '90', 'maximum', 'in', 'dependent', 'responsible', 'reabsorptive', 'an', 'case', 'Kidneys', 'specifically', 'into', '4', 'In', 'and', 'play', 'plasma', 'reabsorbed', '20', 'filtered', 'SGLTs', 'expressed', 'percent', 'respond', 'for', 'is', 'glycosuria', 'tubules', 'threshold', 'to', 'one', 'within', 'of']",2,107,other,2,1,False,False,False,0.04439758640399567,0.00903954802259887
A10BK05,Ipragliflozin,"['A10BK05', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ASodium/glucose cotransporter 2 (modulator, Humans)",Not Available,A10BK,Bexagliflozin,2627044,bexagliflozin,"bexagliflozin Oral Product, bexagliflozin Pill","Oral Product, Pill","Bexacat Oral Product, Bexacat Pill, Brenzavvy Oral Product, Brenzavvy Pill","['Not', 'Available']",2,2,other,2,1,True,False,True,,0.0
A10BK05,Ipragliflozin,"['A10BK05', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,Not Available,"ASodium/glucose cotransporter 2 (modulator, Humans)",Not Available,A10BK,Sotagliflozin,2638675,sotagliflozin,"sotagliflozin Oral Product, sotagliflozin Pill","Oral Product, Pill","Inpefa Oral Product, Inpefa Pill","['Not', 'Available']",2,2,other,2,1,True,False,True,,0.0
A10BK06,Sotagliflozin,"['A10BK06', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,"Sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2) are integral in the transport of glucose in the body. SGLT1 is the major transporter for glucose absorption in the gastrointestinal tract,1 while SGLT2 is the predominant transporter responsible for reabsorption of glucose in the glomerulus.3","ASodium/glucose cotransporter 2 (inhibitor, Humans); ASodium/glucose cotransporter 1 (inhibitor, Humans)","In the US, sotagliflozin is indicated to reduce the risk of cardiovascular death and heart failure in adults with heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.7",A10BK,Bexagliflozin,2627044,bexagliflozin,"bexagliflozin Oral Product, bexagliflozin Pill","Oral Product, Pill","Bexacat Oral Product, Bexacat Pill, Brenzavvy Oral Product, Brenzavvy Pill","['SGLT1', 'glucose', 'Sodium', 'while', '3', 'the', 'major', 'gastrointestinal', 'types', '1', 'are', 'SGLT2', 'integral', 'glomerulus', 'reabsorption', '2', 'in', 'responsible', 'co', 'body', 'and', 'predominant', 'transport', 'for', 'is', 'transporter', 'tract', 'absorption', 'of']",3,45,chronic,2,1,False,False,False,0.04692373215337518,0.00903954802259887
A10BK06,Sotagliflozin,"['A10BK06', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,"Sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2) are integral in the transport of glucose in the body. SGLT1 is the major transporter for glucose absorption in the gastrointestinal tract,1 while SGLT2 is the predominant transporter responsible for reabsorption of glucose in the glomerulus.3","ASodium/glucose cotransporter 2 (inhibitor, Humans); ASodium/glucose cotransporter 1 (inhibitor, Humans)","In the US, sotagliflozin is indicated to reduce the risk of cardiovascular death and heart failure in adults with heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.7",A10BK,Sotagliflozin,2638675,sotagliflozin,"sotagliflozin Oral Product, sotagliflozin Pill","Oral Product, Pill","Inpefa Oral Product, Inpefa Pill","['SGLT1', 'glucose', 'Sodium', 'while', '3', 'the', 'major', 'gastrointestinal', 'types', '1', 'are', 'SGLT2', 'integral', 'glomerulus', 'reabsorption', '2', 'in', 'responsible', 'co', 'body', 'and', 'predominant', 'transport', 'for', 'is', 'transporter', 'tract', 'absorption', 'of']",3,45,chronic,2,1,False,False,False,0.04692373215337518,0.00903954802259887
A10BK07,Luseogliflozin,"['A10BK07', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BK,Bexagliflozin,2627044,bexagliflozin,"bexagliflozin Oral Product, bexagliflozin Pill","Oral Product, Pill","Bexacat Oral Product, Bexacat Pill, Brenzavvy Oral Product, Brenzavvy Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BK07,Luseogliflozin,"['A10BK07', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BK,Sotagliflozin,2638675,sotagliflozin,"sotagliflozin Oral Product, sotagliflozin Pill","Oral Product, Pill","Inpefa Oral Product, Inpefa Pill","['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BK08,Bexagliflozin,"['A10BK08', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,"Bexagliflozin is a highly selective sodium–glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 is located in the proximal renal tubule, a part of the kidney where most reabsorption takes place, and they transport glucose and sodium from the tubular lumen to the epithelium. By inhibiting SGLT2, bexagliflozin reduces glucose reabsorption in the kidney and promotes its excretion in urine. Therefore, in patients with type 2 diabetes mellitus (T2DM), bexagliflozin reduces blood glucose levels independently of insulin sensitivity.4,6","ASodium/glucose cotransporter 2 (inhibitor, Humans)",Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.6,A10BK,Bexagliflozin,2627044,bexagliflozin,"bexagliflozin Oral Product, bexagliflozin Pill","Oral Product, Pill","Bexacat Oral Product, Bexacat Pill, Brenzavvy Oral Product, Brenzavvy Pill","['levels', 'excretion', 'promotes', 'its', 'glucose', 'place', 'urine', 'patients', 'they', 'renal', 'located', 'the', 'proximal', 'highly', 'where', 'most', 'inhibiting', 'type', 'epithelium', 'part', 'diabetes', 'takes', 'SGLT2', 'selective', 'By', 'inhibitor', 'sodium', 'Therefore', 'reabsorption', 'tubular', 'bexagliflozin', '2', 'with', 'in', 'co', 'a', 'kidney', 'from', '6', 'Bexagliflozin', 'insulin', 'lumen', 'reduces', '4', 'and', 'blood', 'mellitus', 'transport', 'is', 'transporter', 'sensitivity', 'independently', 'T2DM', 'to', 'tubule', 'of']",2,75,other,2,1,False,False,False,0.05078473639870638,0.00903954802259887
A10BK08,Bexagliflozin,"['A10BK08', 'A10BK', 'A10B', 'A10', 'A']",True,1,1,"Bexagliflozin is a highly selective sodium–glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 is located in the proximal renal tubule, a part of the kidney where most reabsorption takes place, and they transport glucose and sodium from the tubular lumen to the epithelium. By inhibiting SGLT2, bexagliflozin reduces glucose reabsorption in the kidney and promotes its excretion in urine. Therefore, in patients with type 2 diabetes mellitus (T2DM), bexagliflozin reduces blood glucose levels independently of insulin sensitivity.4,6","ASodium/glucose cotransporter 2 (inhibitor, Humans)",Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.6,A10BK,Sotagliflozin,2638675,sotagliflozin,"sotagliflozin Oral Product, sotagliflozin Pill","Oral Product, Pill","Inpefa Oral Product, Inpefa Pill","['levels', 'excretion', 'promotes', 'its', 'glucose', 'place', 'urine', 'patients', 'they', 'renal', 'located', 'the', 'proximal', 'highly', 'where', 'most', 'inhibiting', 'type', 'epithelium', 'part', 'diabetes', 'takes', 'SGLT2', 'selective', 'By', 'inhibitor', 'sodium', 'Therefore', 'reabsorption', 'tubular', 'bexagliflozin', '2', 'with', 'in', 'co', 'a', 'kidney', 'from', '6', 'Bexagliflozin', 'insulin', 'lumen', 'reduces', '4', 'and', 'blood', 'mellitus', 'transport', 'is', 'transporter', 'sensitivity', 'independently', 'T2DM', 'to', 'tubule', 'of']",2,75,other,2,1,False,False,False,0.05078473639870638,0.00903954802259887
A10BX01,Guar gum,"['A10BX01', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BX,Tirzepatide,2601723,tirzepatide,tirzepatide Injectable Product,Injectable Product,"Mounjaro Injectable Product, Zepbound Injectable Product","['Not', 'Available']",1,2,other,1,1,True,True,True,,
A10BX01,Guar gum,"['A10BX01', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BX,Benfluorex,18880,benfluorex,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
A10BX01,Guar gum,"['A10BX01', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BX,Pramlintide,139953,pramlintide,pramlintide Injectable Product,Injectable Product,Symlin Injectable Product,"['Not', 'Available']",1,2,other,1,1,True,True,True,,
A10BX01,Guar gum,"['A10BX01', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BX,Nateglinide,274332,nateglinide,"nateglinide Oral Product, nateglinide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BX01,Guar gum,"['A10BX01', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BX,Guar gum,26344,guar gum,"guar gum Oral Product, guar gum Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BX02,Repaglinide,"['A10BX02', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Repaglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, repaglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, repaglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of repaglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Repaglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AHistamine H1 receptor (antagonist, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BX,Tirzepatide,2601723,tirzepatide,tirzepatide Injectable Product,Injectable Product,"Mounjaro Injectable Product, Zepbound Injectable Product","['therapy', 'postprandial', 'insulinotropic', 'at', 'release', 'appear', 'not', 'contrast', 'muscle', '15', 'secretatogogues', 'presence', '10', 'duration', 'approximately', 'cells', 'tissue', 'blood', 'more', 'cardiac', 'ATP', 'glucose', 'absence', 'observed', 'by', 'be', 'little', 'highest', 'As', 'increase', 'are', 'sensitive', 'selective', 'reducing', 'channel', 'affect', 'and', 'intermediate', 'activity', 'for', 'requires', 'to', 'decreases', 'levels', 'L', 'appears', 'functioning', 'sulfonylurea', 'effect', 'than', 'or', '3', 'Repaglinide', 'repaglinide', 'no', 'concentrations', 'greater', 'potentiates', 'does', 'extracellular', 'meals', 'month', 'it', 'in', 'dependent', 'thyroid', 'pancreatic', 'potassium', 'insulin', 'fasting', 'already', 'is', 'on', 'before', 'of', 'effective', 'the', 'between', 'high', 'The', 'has', 'mmol', 'a', 'stimulated', 'skeletal', 'effects', 'β', 'In', 'Rather', 'such', 'overnight', 'longer', 'one']",5,142,other,1,1,False,False,False,0.06499640131863807,0.07029478458049887
A10BX02,Repaglinide,"['A10BX02', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Repaglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, repaglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, repaglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of repaglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Repaglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AHistamine H1 receptor (antagonist, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BX,Benfluorex,18880,benfluorex,,,,"['therapy', 'postprandial', 'insulinotropic', 'at', 'release', 'appear', 'not', 'contrast', 'muscle', '15', 'secretatogogues', 'presence', '10', 'duration', 'approximately', 'cells', 'tissue', 'blood', 'more', 'cardiac', 'ATP', 'glucose', 'absence', 'observed', 'by', 'be', 'little', 'highest', 'As', 'increase', 'are', 'sensitive', 'selective', 'reducing', 'channel', 'affect', 'and', 'intermediate', 'activity', 'for', 'requires', 'to', 'decreases', 'levels', 'L', 'appears', 'functioning', 'sulfonylurea', 'effect', 'than', 'or', '3', 'Repaglinide', 'repaglinide', 'no', 'concentrations', 'greater', 'potentiates', 'does', 'extracellular', 'meals', 'month', 'it', 'in', 'dependent', 'thyroid', 'pancreatic', 'potassium', 'insulin', 'fasting', 'already', 'is', 'on', 'before', 'of', 'effective', 'the', 'between', 'high', 'The', 'has', 'mmol', 'a', 'stimulated', 'skeletal', 'effects', 'β', 'In', 'Rather', 'such', 'overnight', 'longer', 'one']",5,142,other,0,1,False,False,False,0.06499640131863807,0.07029478458049887
A10BX02,Repaglinide,"['A10BX02', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Repaglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, repaglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, repaglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of repaglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Repaglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AHistamine H1 receptor (antagonist, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BX,Pramlintide,139953,pramlintide,pramlintide Injectable Product,Injectable Product,Symlin Injectable Product,"['therapy', 'postprandial', 'insulinotropic', 'at', 'release', 'appear', 'not', 'contrast', 'muscle', '15', 'secretatogogues', 'presence', '10', 'duration', 'approximately', 'cells', 'tissue', 'blood', 'more', 'cardiac', 'ATP', 'glucose', 'absence', 'observed', 'by', 'be', 'little', 'highest', 'As', 'increase', 'are', 'sensitive', 'selective', 'reducing', 'channel', 'affect', 'and', 'intermediate', 'activity', 'for', 'requires', 'to', 'decreases', 'levels', 'L', 'appears', 'functioning', 'sulfonylurea', 'effect', 'than', 'or', '3', 'Repaglinide', 'repaglinide', 'no', 'concentrations', 'greater', 'potentiates', 'does', 'extracellular', 'meals', 'month', 'it', 'in', 'dependent', 'thyroid', 'pancreatic', 'potassium', 'insulin', 'fasting', 'already', 'is', 'on', 'before', 'of', 'effective', 'the', 'between', 'high', 'The', 'has', 'mmol', 'a', 'stimulated', 'skeletal', 'effects', 'β', 'In', 'Rather', 'such', 'overnight', 'longer', 'one']",5,142,other,1,1,False,False,False,0.06499640131863807,0.07029478458049887
A10BX02,Repaglinide,"['A10BX02', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Repaglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, repaglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, repaglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of repaglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Repaglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AHistamine H1 receptor (antagonist, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BX,Nateglinide,274332,nateglinide,"nateglinide Oral Product, nateglinide Pill","Oral Product, Pill",,"['therapy', 'postprandial', 'insulinotropic', 'at', 'release', 'appear', 'not', 'contrast', 'muscle', '15', 'secretatogogues', 'presence', '10', 'duration', 'approximately', 'cells', 'tissue', 'blood', 'more', 'cardiac', 'ATP', 'glucose', 'absence', 'observed', 'by', 'be', 'little', 'highest', 'As', 'increase', 'are', 'sensitive', 'selective', 'reducing', 'channel', 'affect', 'and', 'intermediate', 'activity', 'for', 'requires', 'to', 'decreases', 'levels', 'L', 'appears', 'functioning', 'sulfonylurea', 'effect', 'than', 'or', '3', 'Repaglinide', 'repaglinide', 'no', 'concentrations', 'greater', 'potentiates', 'does', 'extracellular', 'meals', 'month', 'it', 'in', 'dependent', 'thyroid', 'pancreatic', 'potassium', 'insulin', 'fasting', 'already', 'is', 'on', 'before', 'of', 'effective', 'the', 'between', 'high', 'The', 'has', 'mmol', 'a', 'stimulated', 'skeletal', 'effects', 'β', 'In', 'Rather', 'such', 'overnight', 'longer', 'one']",5,142,other,2,1,False,False,False,0.06499640131863807,0.07029478458049887
A10BX02,Repaglinide,"['A10BX02', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Repaglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, repaglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, repaglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of repaglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Repaglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.","AATP-binding cassette sub-family C member 9 (blocker, Humans); AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AHistamine H1 receptor (antagonist, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,A10BX,Guar gum,26344,guar gum,"guar gum Oral Product, guar gum Pill","Oral Product, Pill",,"['therapy', 'postprandial', 'insulinotropic', 'at', 'release', 'appear', 'not', 'contrast', 'muscle', '15', 'secretatogogues', 'presence', '10', 'duration', 'approximately', 'cells', 'tissue', 'blood', 'more', 'cardiac', 'ATP', 'glucose', 'absence', 'observed', 'by', 'be', 'little', 'highest', 'As', 'increase', 'are', 'sensitive', 'selective', 'reducing', 'channel', 'affect', 'and', 'intermediate', 'activity', 'for', 'requires', 'to', 'decreases', 'levels', 'L', 'appears', 'functioning', 'sulfonylurea', 'effect', 'than', 'or', '3', 'Repaglinide', 'repaglinide', 'no', 'concentrations', 'greater', 'potentiates', 'does', 'extracellular', 'meals', 'month', 'it', 'in', 'dependent', 'thyroid', 'pancreatic', 'potassium', 'insulin', 'fasting', 'already', 'is', 'on', 'before', 'of', 'effective', 'the', 'between', 'high', 'The', 'has', 'mmol', 'a', 'stimulated', 'skeletal', 'effects', 'β', 'In', 'Rather', 'such', 'overnight', 'longer', 'one']",5,142,other,2,1,False,False,False,0.06499640131863807,0.07029478458049887
A10BX03,Nateglinide,"['A10BX03', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Nateglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, nateglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, nateglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of nateglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Nateglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.,A10BX,Tirzepatide,2601723,tirzepatide,tirzepatide Injectable Product,Injectable Product,"Mounjaro Injectable Product, Zepbound Injectable Product","['therapy', 'postprandial', 'insulinotropic', 'nateglinide', 'at', 'release', 'appear', 'not', 'contrast', 'muscle', '15', 'secretatogogues', 'presence', '10', 'duration', 'approximately', 'cells', 'tissue', 'blood', 'more', 'cardiac', 'ATP', 'glucose', 'absence', 'observed', 'by', 'be', 'little', 'highest', 'As', 'increase', 'are', 'sensitive', 'selective', 'reducing', 'channel', 'affect', 'and', 'intermediate', 'Nateglinide', 'activity', 'for', 'requires', 'to', 'decreases', 'levels', 'L', 'appears', 'functioning', 'sulfonylurea', 'effect', 'than', 'or', '3', 'no', 'concentrations', 'greater', 'potentiates', 'does', 'extracellular', 'meals', 'month', 'it', 'in', 'dependent', 'thyroid', 'pancreatic', 'potassium', 'insulin', 'fasting', 'already', 'is', 'on', 'before', 'of', 'effective', 'the', 'between', 'high', 'The', 'has', 'mmol', 'a', 'stimulated', 'skeletal', 'effects', 'β', 'In', 'Rather', 'such', 'overnight', 'longer', 'one']",3,142,other,1,1,False,False,False,0.06499640131863807,0.07596371882086168
A10BX03,Nateglinide,"['A10BX03', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Nateglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, nateglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, nateglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of nateglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Nateglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.,A10BX,Benfluorex,18880,benfluorex,,,,"['therapy', 'postprandial', 'insulinotropic', 'nateglinide', 'at', 'release', 'appear', 'not', 'contrast', 'muscle', '15', 'secretatogogues', 'presence', '10', 'duration', 'approximately', 'cells', 'tissue', 'blood', 'more', 'cardiac', 'ATP', 'glucose', 'absence', 'observed', 'by', 'be', 'little', 'highest', 'As', 'increase', 'are', 'sensitive', 'selective', 'reducing', 'channel', 'affect', 'and', 'intermediate', 'Nateglinide', 'activity', 'for', 'requires', 'to', 'decreases', 'levels', 'L', 'appears', 'functioning', 'sulfonylurea', 'effect', 'than', 'or', '3', 'no', 'concentrations', 'greater', 'potentiates', 'does', 'extracellular', 'meals', 'month', 'it', 'in', 'dependent', 'thyroid', 'pancreatic', 'potassium', 'insulin', 'fasting', 'already', 'is', 'on', 'before', 'of', 'effective', 'the', 'between', 'high', 'The', 'has', 'mmol', 'a', 'stimulated', 'skeletal', 'effects', 'β', 'In', 'Rather', 'such', 'overnight', 'longer', 'one']",3,142,other,0,1,False,False,False,0.06499640131863807,0.07596371882086168
A10BX03,Nateglinide,"['A10BX03', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Nateglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, nateglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, nateglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of nateglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Nateglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.,A10BX,Pramlintide,139953,pramlintide,pramlintide Injectable Product,Injectable Product,Symlin Injectable Product,"['therapy', 'postprandial', 'insulinotropic', 'nateglinide', 'at', 'release', 'appear', 'not', 'contrast', 'muscle', '15', 'secretatogogues', 'presence', '10', 'duration', 'approximately', 'cells', 'tissue', 'blood', 'more', 'cardiac', 'ATP', 'glucose', 'absence', 'observed', 'by', 'be', 'little', 'highest', 'As', 'increase', 'are', 'sensitive', 'selective', 'reducing', 'channel', 'affect', 'and', 'intermediate', 'Nateglinide', 'activity', 'for', 'requires', 'to', 'decreases', 'levels', 'L', 'appears', 'functioning', 'sulfonylurea', 'effect', 'than', 'or', '3', 'no', 'concentrations', 'greater', 'potentiates', 'does', 'extracellular', 'meals', 'month', 'it', 'in', 'dependent', 'thyroid', 'pancreatic', 'potassium', 'insulin', 'fasting', 'already', 'is', 'on', 'before', 'of', 'effective', 'the', 'between', 'high', 'The', 'has', 'mmol', 'a', 'stimulated', 'skeletal', 'effects', 'β', 'In', 'Rather', 'such', 'overnight', 'longer', 'one']",3,142,other,1,1,False,False,False,0.06499640131863807,0.07596371882086168
A10BX03,Nateglinide,"['A10BX03', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Nateglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, nateglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, nateglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of nateglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Nateglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.,A10BX,Nateglinide,274332,nateglinide,"nateglinide Oral Product, nateglinide Pill","Oral Product, Pill",,"['therapy', 'postprandial', 'insulinotropic', 'nateglinide', 'at', 'release', 'appear', 'not', 'contrast', 'muscle', '15', 'secretatogogues', 'presence', '10', 'duration', 'approximately', 'cells', 'tissue', 'blood', 'more', 'cardiac', 'ATP', 'glucose', 'absence', 'observed', 'by', 'be', 'little', 'highest', 'As', 'increase', 'are', 'sensitive', 'selective', 'reducing', 'channel', 'affect', 'and', 'intermediate', 'Nateglinide', 'activity', 'for', 'requires', 'to', 'decreases', 'levels', 'L', 'appears', 'functioning', 'sulfonylurea', 'effect', 'than', 'or', '3', 'no', 'concentrations', 'greater', 'potentiates', 'does', 'extracellular', 'meals', 'month', 'it', 'in', 'dependent', 'thyroid', 'pancreatic', 'potassium', 'insulin', 'fasting', 'already', 'is', 'on', 'before', 'of', 'effective', 'the', 'between', 'high', 'The', 'has', 'mmol', 'a', 'stimulated', 'skeletal', 'effects', 'β', 'In', 'Rather', 'such', 'overnight', 'longer', 'one']",3,142,other,2,1,False,False,False,0.06499640131863807,0.07596371882086168
A10BX03,Nateglinide,"['A10BX03', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Nateglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, nateglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, nateglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of nateglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Nateglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.,A10BX,Guar gum,26344,guar gum,"guar gum Oral Product, guar gum Pill","Oral Product, Pill",,"['therapy', 'postprandial', 'insulinotropic', 'nateglinide', 'at', 'release', 'appear', 'not', 'contrast', 'muscle', '15', 'secretatogogues', 'presence', '10', 'duration', 'approximately', 'cells', 'tissue', 'blood', 'more', 'cardiac', 'ATP', 'glucose', 'absence', 'observed', 'by', 'be', 'little', 'highest', 'As', 'increase', 'are', 'sensitive', 'selective', 'reducing', 'channel', 'affect', 'and', 'intermediate', 'Nateglinide', 'activity', 'for', 'requires', 'to', 'decreases', 'levels', 'L', 'appears', 'functioning', 'sulfonylurea', 'effect', 'than', 'or', '3', 'no', 'concentrations', 'greater', 'potentiates', 'does', 'extracellular', 'meals', 'month', 'it', 'in', 'dependent', 'thyroid', 'pancreatic', 'potassium', 'insulin', 'fasting', 'already', 'is', 'on', 'before', 'of', 'effective', 'the', 'between', 'high', 'The', 'has', 'mmol', 'a', 'stimulated', 'skeletal', 'effects', 'β', 'In', 'Rather', 'such', 'overnight', 'longer', 'one']",3,142,other,2,1,False,False,False,0.06499640131863807,0.07596371882086168
A10BX05,Pramlintide,"['A10BX05', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in glucagon levels, and by increasing sensations of satiety, thereby reducing caloric intake and potentiating weight loss. There appears to be at least three distinct receptor complexes that bind with high affinity to amylin. All three complexes contain the calcitonin receptor at the core, plus one of three Receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.","AGlucagon-like peptide 1 receptor (agonist, Humans); ACalcitonin receptor (agonist, Humans); AReceptor activity-modifying protein 1 (agonist, Humans); AReceptor activity-modifying protein 2 (agonist, Humans); AReceptor activity-modifying protein 3 (agonist, Humans)",For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.,A10BX,Tirzepatide,2601723,tirzepatide,tirzepatide Injectable Product,Injectable Product,"Mounjaro Injectable Product, Zepbound Injectable Product","['functional', 'at', 'modifying', 'analog', 'control', 'satiety', 'loss', 'an', 'weight', 'There', 'calcitonin', 'All', 'glucagon', 'that', 'rise', 'plus', 'by', 'be', 'prevention', 'glucodynamic', 'complexes', 'sensations', 'receptor', 'reducing', 'proteins', 'systems', 'with', 'occurring', 'and', 'RAMP1', 'affinity', 'amylin', 'contain', 'activity', 'to', 'through', 'levels', 'appears', 'improve', 'or', 'hormone', 'increasing', 'mimicking', 'thereby', 'acts', 'Receptor', 'emptying', 'gastric', 'in', 'naturally', 'pancreatic', 'post', 'rate', 'modulation', 'is', 'distinct', 'bind', 'caloric', 'of', 'core', 'its', 'amlyinomimetic', 'the', 'glycemic', 'gastrointestinal', 'three', 'high', 'prandial', 'has', 'potentiating', 'Amylin', 'Pramlintide', 'a', 'number', 'RAMP2', 'RAMP3', 'intake', 'pramlintide', 'least', 'one']",6,103,other,1,1,False,False,False,0.052158758825719756,0.032879818594104306
A10BX05,Pramlintide,"['A10BX05', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in glucagon levels, and by increasing sensations of satiety, thereby reducing caloric intake and potentiating weight loss. There appears to be at least three distinct receptor complexes that bind with high affinity to amylin. All three complexes contain the calcitonin receptor at the core, plus one of three Receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.","AGlucagon-like peptide 1 receptor (agonist, Humans); ACalcitonin receptor (agonist, Humans); AReceptor activity-modifying protein 1 (agonist, Humans); AReceptor activity-modifying protein 2 (agonist, Humans); AReceptor activity-modifying protein 3 (agonist, Humans)",For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.,A10BX,Benfluorex,18880,benfluorex,,,,"['functional', 'at', 'modifying', 'analog', 'control', 'satiety', 'loss', 'an', 'weight', 'There', 'calcitonin', 'All', 'glucagon', 'that', 'rise', 'plus', 'by', 'be', 'prevention', 'glucodynamic', 'complexes', 'sensations', 'receptor', 'reducing', 'proteins', 'systems', 'with', 'occurring', 'and', 'RAMP1', 'affinity', 'amylin', 'contain', 'activity', 'to', 'through', 'levels', 'appears', 'improve', 'or', 'hormone', 'increasing', 'mimicking', 'thereby', 'acts', 'Receptor', 'emptying', 'gastric', 'in', 'naturally', 'pancreatic', 'post', 'rate', 'modulation', 'is', 'distinct', 'bind', 'caloric', 'of', 'core', 'its', 'amlyinomimetic', 'the', 'glycemic', 'gastrointestinal', 'three', 'high', 'prandial', 'has', 'potentiating', 'Amylin', 'Pramlintide', 'a', 'number', 'RAMP2', 'RAMP3', 'intake', 'pramlintide', 'least', 'one']",6,103,other,0,1,False,False,False,0.052158758825719756,0.032879818594104306
A10BX05,Pramlintide,"['A10BX05', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in glucagon levels, and by increasing sensations of satiety, thereby reducing caloric intake and potentiating weight loss. There appears to be at least three distinct receptor complexes that bind with high affinity to amylin. All three complexes contain the calcitonin receptor at the core, plus one of three Receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.","AGlucagon-like peptide 1 receptor (agonist, Humans); ACalcitonin receptor (agonist, Humans); AReceptor activity-modifying protein 1 (agonist, Humans); AReceptor activity-modifying protein 2 (agonist, Humans); AReceptor activity-modifying protein 3 (agonist, Humans)",For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.,A10BX,Pramlintide,139953,pramlintide,pramlintide Injectable Product,Injectable Product,Symlin Injectable Product,"['functional', 'at', 'modifying', 'analog', 'control', 'satiety', 'loss', 'an', 'weight', 'There', 'calcitonin', 'All', 'glucagon', 'that', 'rise', 'plus', 'by', 'be', 'prevention', 'glucodynamic', 'complexes', 'sensations', 'receptor', 'reducing', 'proteins', 'systems', 'with', 'occurring', 'and', 'RAMP1', 'affinity', 'amylin', 'contain', 'activity', 'to', 'through', 'levels', 'appears', 'improve', 'or', 'hormone', 'increasing', 'mimicking', 'thereby', 'acts', 'Receptor', 'emptying', 'gastric', 'in', 'naturally', 'pancreatic', 'post', 'rate', 'modulation', 'is', 'distinct', 'bind', 'caloric', 'of', 'core', 'its', 'amlyinomimetic', 'the', 'glycemic', 'gastrointestinal', 'three', 'high', 'prandial', 'has', 'potentiating', 'Amylin', 'Pramlintide', 'a', 'number', 'RAMP2', 'RAMP3', 'intake', 'pramlintide', 'least', 'one']",6,103,other,1,1,False,False,False,0.052158758825719756,0.032879818594104306
A10BX05,Pramlintide,"['A10BX05', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in glucagon levels, and by increasing sensations of satiety, thereby reducing caloric intake and potentiating weight loss. There appears to be at least three distinct receptor complexes that bind with high affinity to amylin. All three complexes contain the calcitonin receptor at the core, plus one of three Receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.","AGlucagon-like peptide 1 receptor (agonist, Humans); ACalcitonin receptor (agonist, Humans); AReceptor activity-modifying protein 1 (agonist, Humans); AReceptor activity-modifying protein 2 (agonist, Humans); AReceptor activity-modifying protein 3 (agonist, Humans)",For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.,A10BX,Nateglinide,274332,nateglinide,"nateglinide Oral Product, nateglinide Pill","Oral Product, Pill",,"['functional', 'at', 'modifying', 'analog', 'control', 'satiety', 'loss', 'an', 'weight', 'There', 'calcitonin', 'All', 'glucagon', 'that', 'rise', 'plus', 'by', 'be', 'prevention', 'glucodynamic', 'complexes', 'sensations', 'receptor', 'reducing', 'proteins', 'systems', 'with', 'occurring', 'and', 'RAMP1', 'affinity', 'amylin', 'contain', 'activity', 'to', 'through', 'levels', 'appears', 'improve', 'or', 'hormone', 'increasing', 'mimicking', 'thereby', 'acts', 'Receptor', 'emptying', 'gastric', 'in', 'naturally', 'pancreatic', 'post', 'rate', 'modulation', 'is', 'distinct', 'bind', 'caloric', 'of', 'core', 'its', 'amlyinomimetic', 'the', 'glycemic', 'gastrointestinal', 'three', 'high', 'prandial', 'has', 'potentiating', 'Amylin', 'Pramlintide', 'a', 'number', 'RAMP2', 'RAMP3', 'intake', 'pramlintide', 'least', 'one']",6,103,other,2,1,False,False,False,0.052158758825719756,0.032879818594104306
A10BX05,Pramlintide,"['A10BX05', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Pramlintide is an amlyinomimetic, a functional analog of the naturally occurring pancreatic hormone amylin. Amylin has activity in a number of gastrointestinal and glucodynamic systems, and by mimicking its activity, pramlintide acts to improve glycemic control through modulation of the rate of gastric emptying, prevention of post-prandial rise in glucagon levels, and by increasing sensations of satiety, thereby reducing caloric intake and potentiating weight loss. There appears to be at least three distinct receptor complexes that bind with high affinity to amylin. All three complexes contain the calcitonin receptor at the core, plus one of three Receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.","AGlucagon-like peptide 1 receptor (agonist, Humans); ACalcitonin receptor (agonist, Humans); AReceptor activity-modifying protein 1 (agonist, Humans); AReceptor activity-modifying protein 2 (agonist, Humans); AReceptor activity-modifying protein 3 (agonist, Humans)",For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.,A10BX,Guar gum,26344,guar gum,"guar gum Oral Product, guar gum Pill","Oral Product, Pill",,"['functional', 'at', 'modifying', 'analog', 'control', 'satiety', 'loss', 'an', 'weight', 'There', 'calcitonin', 'All', 'glucagon', 'that', 'rise', 'plus', 'by', 'be', 'prevention', 'glucodynamic', 'complexes', 'sensations', 'receptor', 'reducing', 'proteins', 'systems', 'with', 'occurring', 'and', 'RAMP1', 'affinity', 'amylin', 'contain', 'activity', 'to', 'through', 'levels', 'appears', 'improve', 'or', 'hormone', 'increasing', 'mimicking', 'thereby', 'acts', 'Receptor', 'emptying', 'gastric', 'in', 'naturally', 'pancreatic', 'post', 'rate', 'modulation', 'is', 'distinct', 'bind', 'caloric', 'of', 'core', 'its', 'amlyinomimetic', 'the', 'glycemic', 'gastrointestinal', 'three', 'high', 'prandial', 'has', 'potentiating', 'Amylin', 'Pramlintide', 'a', 'number', 'RAMP2', 'RAMP3', 'intake', 'pramlintide', 'least', 'one']",6,103,other,2,1,False,False,False,0.052158758825719756,0.032879818594104306
A10BX06,Benfluorex,"['A10BX06', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BX,Tirzepatide,2601723,tirzepatide,tirzepatide Injectable Product,Injectable Product,"Mounjaro Injectable Product, Zepbound Injectable Product","['Not', 'Available']",1,2,other,1,1,True,True,True,,
A10BX06,Benfluorex,"['A10BX06', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BX,Benfluorex,18880,benfluorex,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
A10BX06,Benfluorex,"['A10BX06', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BX,Pramlintide,139953,pramlintide,pramlintide Injectable Product,Injectable Product,Symlin Injectable Product,"['Not', 'Available']",1,2,other,1,1,True,True,True,,
A10BX06,Benfluorex,"['A10BX06', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BX,Nateglinide,274332,nateglinide,"nateglinide Oral Product, nateglinide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BX06,Benfluorex,"['A10BX06', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,No targets found,Not Available,A10BX,Guar gum,26344,guar gum,"guar gum Oral Product, guar gum Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
A10BX08,Mitiglinide,"['A10BX08', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",For the treatment of type 2 diabetes.,A10BX,Tirzepatide,2601723,tirzepatide,tirzepatide Injectable Product,Injectable Product,"Mounjaro Injectable Product, Zepbound Injectable Product","['through', 'exocytosis', 'by', 'the', 'complex', 'voltage', 'depolarization', 'stimulate', 'binding', 'blocking', 'sensitive', 'Kir6', 'granules', 'channels', 'influx', '2', 'triggers', 'Mitiglinide', 'in', 'beta', 'pancreatic', 'KATP', 'causes', 'potassium', 'K', 'subsequently', 'Closure', 'insulin', 'thought', 'cells', 'which', 'and', 'High', 'intracellular', 'is', 'ATP', 'to', 'stimulates', 'calcium', 'secretion', 'gated', 'of', 'SUR1']",4,47,other,1,1,False,False,False,0.060166208599709455,0.12018140589569161
A10BX08,Mitiglinide,"['A10BX08', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",For the treatment of type 2 diabetes.,A10BX,Benfluorex,18880,benfluorex,,,,"['through', 'exocytosis', 'by', 'the', 'complex', 'voltage', 'depolarization', 'stimulate', 'binding', 'blocking', 'sensitive', 'Kir6', 'granules', 'channels', 'influx', '2', 'triggers', 'Mitiglinide', 'in', 'beta', 'pancreatic', 'KATP', 'causes', 'potassium', 'K', 'subsequently', 'Closure', 'insulin', 'thought', 'cells', 'which', 'and', 'High', 'intracellular', 'is', 'ATP', 'to', 'stimulates', 'calcium', 'secretion', 'gated', 'of', 'SUR1']",4,47,other,0,1,False,False,False,0.060166208599709455,0.12018140589569161
A10BX08,Mitiglinide,"['A10BX08', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",For the treatment of type 2 diabetes.,A10BX,Pramlintide,139953,pramlintide,pramlintide Injectable Product,Injectable Product,Symlin Injectable Product,"['through', 'exocytosis', 'by', 'the', 'complex', 'voltage', 'depolarization', 'stimulate', 'binding', 'blocking', 'sensitive', 'Kir6', 'granules', 'channels', 'influx', '2', 'triggers', 'Mitiglinide', 'in', 'beta', 'pancreatic', 'KATP', 'causes', 'potassium', 'K', 'subsequently', 'Closure', 'insulin', 'thought', 'cells', 'which', 'and', 'High', 'intracellular', 'is', 'ATP', 'to', 'stimulates', 'calcium', 'secretion', 'gated', 'of', 'SUR1']",4,47,other,1,1,False,False,False,0.060166208599709455,0.12018140589569161
A10BX08,Mitiglinide,"['A10BX08', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",For the treatment of type 2 diabetes.,A10BX,Nateglinide,274332,nateglinide,"nateglinide Oral Product, nateglinide Pill","Oral Product, Pill",,"['through', 'exocytosis', 'by', 'the', 'complex', 'voltage', 'depolarization', 'stimulate', 'binding', 'blocking', 'sensitive', 'Kir6', 'granules', 'channels', 'influx', '2', 'triggers', 'Mitiglinide', 'in', 'beta', 'pancreatic', 'KATP', 'causes', 'potassium', 'K', 'subsequently', 'Closure', 'insulin', 'thought', 'cells', 'which', 'and', 'High', 'intracellular', 'is', 'ATP', 'to', 'stimulates', 'calcium', 'secretion', 'gated', 'of', 'SUR1']",4,47,other,2,1,False,False,False,0.060166208599709455,0.12018140589569161
A10BX08,Mitiglinide,"['A10BX08', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.","AATP-binding cassette sub-family C member 8 (inhibitor, Humans); AATP-sensitive inward rectifier potassium channel 10 (blocker, Humans); UPeroxisome proliferator-activated receptor gamma (agonist, Humans)",For the treatment of type 2 diabetes.,A10BX,Guar gum,26344,guar gum,"guar gum Oral Product, guar gum Pill","Oral Product, Pill",,"['through', 'exocytosis', 'by', 'the', 'complex', 'voltage', 'depolarization', 'stimulate', 'binding', 'blocking', 'sensitive', 'Kir6', 'granules', 'channels', 'influx', '2', 'triggers', 'Mitiglinide', 'in', 'beta', 'pancreatic', 'KATP', 'causes', 'potassium', 'K', 'subsequently', 'Closure', 'insulin', 'thought', 'cells', 'which', 'and', 'High', 'intracellular', 'is', 'ATP', 'to', 'stimulates', 'calcium', 'secretion', 'gated', 'of', 'SUR1']",4,47,other,2,1,False,False,False,0.060166208599709455,0.12018140589569161
A10BX15,Imeglimin,"['A10BX15', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,"A5'-AMP-activated protein kinase catalytic subunit alpha-1 (modulator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (modulator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (modulator, Humans)",Not Available,A10BX,Tirzepatide,2601723,tirzepatide,tirzepatide Injectable Product,Injectable Product,"Mounjaro Injectable Product, Zepbound Injectable Product","['Not', 'Available']",4,2,other,1,1,True,False,True,,0.0
A10BX15,Imeglimin,"['A10BX15', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,"A5'-AMP-activated protein kinase catalytic subunit alpha-1 (modulator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (modulator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (modulator, Humans)",Not Available,A10BX,Benfluorex,18880,benfluorex,,,,"['Not', 'Available']",4,2,other,0,1,True,False,True,,0.0
A10BX15,Imeglimin,"['A10BX15', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,"A5'-AMP-activated protein kinase catalytic subunit alpha-1 (modulator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (modulator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (modulator, Humans)",Not Available,A10BX,Pramlintide,139953,pramlintide,pramlintide Injectable Product,Injectable Product,Symlin Injectable Product,"['Not', 'Available']",4,2,other,1,1,True,False,True,,0.0
A10BX15,Imeglimin,"['A10BX15', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,"A5'-AMP-activated protein kinase catalytic subunit alpha-1 (modulator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (modulator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (modulator, Humans)",Not Available,A10BX,Nateglinide,274332,nateglinide,"nateglinide Oral Product, nateglinide Pill","Oral Product, Pill",,"['Not', 'Available']",4,2,other,2,1,True,False,True,,0.0
A10BX15,Imeglimin,"['A10BX15', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,"A5'-AMP-activated protein kinase catalytic subunit alpha-1 (modulator, Humans); A5'-AMP-activated protein kinase subunit beta-1 (modulator, Humans); A5'-AMP-activated protein kinase subunit gamma-1 (modulator, Humans)",Not Available,A10BX,Guar gum,26344,guar gum,"guar gum Oral Product, guar gum Pill","Oral Product, Pill",,"['Not', 'Available']",4,2,other,2,1,True,False,True,,0.0
A10BX16,Tirzepatide,"['A10BX16', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are expressed throughout the body, including pancreatic beta-cells and the gastrointestinal tract. They have been implicated in the pathophysiology of type II diabetes mellitus as GLP-1R signalling is involved in glucose control by enhancing glucose-stimulated insulin secretion, delaying gastric transit, decreasing plasma glucagon levels, and reducing body weight by activating anorexigenic pathways in the brain.1 Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are peptide hormones involved in glucose homeostasis: they promote glucose-stimulated insulin secretion from the pancreatic beta-cells.2 However, GIP is the main incretin hormone that exerts insulinotropic effects in response to food intake.1,2","AGlucagon-like peptide 1 receptor (agonist, Humans); AGastric inhibitory polypeptide receptor (agonist, Humans)","Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus or for the chronic weight management for adult patients that are obese or overweight with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). 4,6,8 In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.6",A10BX,Tirzepatide,2601723,tirzepatide,tirzepatide Injectable Product,Injectable Product,"Mounjaro Injectable Product, Zepbound Injectable Product","['levels', 'that', 'insulinotropic', 'peptide', 'involved', 'signalling', 'glucose', 'delaying', 'brain', 'hormones', 'they', 'Glucagon', 'response', 'by', 'the', 'II', 'main', 'gastrointestinal', 'type', 'homeostasis', 'hormone', 'diabetes', '1', 'are', 'have', 'GLP', 'food', 'gastric', 'transit', 'reducing', 'exerts', 'polypeptide', 'enhancing', 'However', '2', 'decreasing', 'throughout', 'control', 'anorexigenic', 'in', 'dependent', 'beta', 'stimulated', 'body', 'from', 'effects', 'pancreatic', 'incretin', 'Both', 'like', 'pathophysiology', 'cells', 'insulin', 'weight', 'activating', 'and', '1R', 'plasma', 'promote', 'pathways', 'expressed', 'mellitus', 'GIP', 'is', 'intake', 'implicated', 'been', 'tract', 'as', 'to', 'secretion', 'receptors', 'They', 'of', 'glucagon', 'including']",3,99,chronic,1,1,False,False,False,0.05603868645131931,0.032879818594104306
A10BX16,Tirzepatide,"['A10BX16', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are expressed throughout the body, including pancreatic beta-cells and the gastrointestinal tract. They have been implicated in the pathophysiology of type II diabetes mellitus as GLP-1R signalling is involved in glucose control by enhancing glucose-stimulated insulin secretion, delaying gastric transit, decreasing plasma glucagon levels, and reducing body weight by activating anorexigenic pathways in the brain.1 Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are peptide hormones involved in glucose homeostasis: they promote glucose-stimulated insulin secretion from the pancreatic beta-cells.2 However, GIP is the main incretin hormone that exerts insulinotropic effects in response to food intake.1,2","AGlucagon-like peptide 1 receptor (agonist, Humans); AGastric inhibitory polypeptide receptor (agonist, Humans)","Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus or for the chronic weight management for adult patients that are obese or overweight with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). 4,6,8 In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.6",A10BX,Benfluorex,18880,benfluorex,,,,"['levels', 'that', 'insulinotropic', 'peptide', 'involved', 'signalling', 'glucose', 'delaying', 'brain', 'hormones', 'they', 'Glucagon', 'response', 'by', 'the', 'II', 'main', 'gastrointestinal', 'type', 'homeostasis', 'hormone', 'diabetes', '1', 'are', 'have', 'GLP', 'food', 'gastric', 'transit', 'reducing', 'exerts', 'polypeptide', 'enhancing', 'However', '2', 'decreasing', 'throughout', 'control', 'anorexigenic', 'in', 'dependent', 'beta', 'stimulated', 'body', 'from', 'effects', 'pancreatic', 'incretin', 'Both', 'like', 'pathophysiology', 'cells', 'insulin', 'weight', 'activating', 'and', '1R', 'plasma', 'promote', 'pathways', 'expressed', 'mellitus', 'GIP', 'is', 'intake', 'implicated', 'been', 'tract', 'as', 'to', 'secretion', 'receptors', 'They', 'of', 'glucagon', 'including']",3,99,chronic,0,1,False,False,False,0.05603868645131931,0.032879818594104306
A10BX16,Tirzepatide,"['A10BX16', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are expressed throughout the body, including pancreatic beta-cells and the gastrointestinal tract. They have been implicated in the pathophysiology of type II diabetes mellitus as GLP-1R signalling is involved in glucose control by enhancing glucose-stimulated insulin secretion, delaying gastric transit, decreasing plasma glucagon levels, and reducing body weight by activating anorexigenic pathways in the brain.1 Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are peptide hormones involved in glucose homeostasis: they promote glucose-stimulated insulin secretion from the pancreatic beta-cells.2 However, GIP is the main incretin hormone that exerts insulinotropic effects in response to food intake.1,2","AGlucagon-like peptide 1 receptor (agonist, Humans); AGastric inhibitory polypeptide receptor (agonist, Humans)","Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus or for the chronic weight management for adult patients that are obese or overweight with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). 4,6,8 In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.6",A10BX,Pramlintide,139953,pramlintide,pramlintide Injectable Product,Injectable Product,Symlin Injectable Product,"['levels', 'that', 'insulinotropic', 'peptide', 'involved', 'signalling', 'glucose', 'delaying', 'brain', 'hormones', 'they', 'Glucagon', 'response', 'by', 'the', 'II', 'main', 'gastrointestinal', 'type', 'homeostasis', 'hormone', 'diabetes', '1', 'are', 'have', 'GLP', 'food', 'gastric', 'transit', 'reducing', 'exerts', 'polypeptide', 'enhancing', 'However', '2', 'decreasing', 'throughout', 'control', 'anorexigenic', 'in', 'dependent', 'beta', 'stimulated', 'body', 'from', 'effects', 'pancreatic', 'incretin', 'Both', 'like', 'pathophysiology', 'cells', 'insulin', 'weight', 'activating', 'and', '1R', 'plasma', 'promote', 'pathways', 'expressed', 'mellitus', 'GIP', 'is', 'intake', 'implicated', 'been', 'tract', 'as', 'to', 'secretion', 'receptors', 'They', 'of', 'glucagon', 'including']",3,99,chronic,1,1,False,False,False,0.05603868645131931,0.032879818594104306
A10BX16,Tirzepatide,"['A10BX16', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are expressed throughout the body, including pancreatic beta-cells and the gastrointestinal tract. They have been implicated in the pathophysiology of type II diabetes mellitus as GLP-1R signalling is involved in glucose control by enhancing glucose-stimulated insulin secretion, delaying gastric transit, decreasing plasma glucagon levels, and reducing body weight by activating anorexigenic pathways in the brain.1 Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are peptide hormones involved in glucose homeostasis: they promote glucose-stimulated insulin secretion from the pancreatic beta-cells.2 However, GIP is the main incretin hormone that exerts insulinotropic effects in response to food intake.1,2","AGlucagon-like peptide 1 receptor (agonist, Humans); AGastric inhibitory polypeptide receptor (agonist, Humans)","Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus or for the chronic weight management for adult patients that are obese or overweight with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). 4,6,8 In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.6",A10BX,Nateglinide,274332,nateglinide,"nateglinide Oral Product, nateglinide Pill","Oral Product, Pill",,"['levels', 'that', 'insulinotropic', 'peptide', 'involved', 'signalling', 'glucose', 'delaying', 'brain', 'hormones', 'they', 'Glucagon', 'response', 'by', 'the', 'II', 'main', 'gastrointestinal', 'type', 'homeostasis', 'hormone', 'diabetes', '1', 'are', 'have', 'GLP', 'food', 'gastric', 'transit', 'reducing', 'exerts', 'polypeptide', 'enhancing', 'However', '2', 'decreasing', 'throughout', 'control', 'anorexigenic', 'in', 'dependent', 'beta', 'stimulated', 'body', 'from', 'effects', 'pancreatic', 'incretin', 'Both', 'like', 'pathophysiology', 'cells', 'insulin', 'weight', 'activating', 'and', '1R', 'plasma', 'promote', 'pathways', 'expressed', 'mellitus', 'GIP', 'is', 'intake', 'implicated', 'been', 'tract', 'as', 'to', 'secretion', 'receptors', 'They', 'of', 'glucagon', 'including']",3,99,chronic,2,1,False,False,False,0.05603868645131931,0.032879818594104306
A10BX16,Tirzepatide,"['A10BX16', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,"Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are expressed throughout the body, including pancreatic beta-cells and the gastrointestinal tract. They have been implicated in the pathophysiology of type II diabetes mellitus as GLP-1R signalling is involved in glucose control by enhancing glucose-stimulated insulin secretion, delaying gastric transit, decreasing plasma glucagon levels, and reducing body weight by activating anorexigenic pathways in the brain.1 Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are peptide hormones involved in glucose homeostasis: they promote glucose-stimulated insulin secretion from the pancreatic beta-cells.2 However, GIP is the main incretin hormone that exerts insulinotropic effects in response to food intake.1,2","AGlucagon-like peptide 1 receptor (agonist, Humans); AGastric inhibitory polypeptide receptor (agonist, Humans)","Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus or for the chronic weight management for adult patients that are obese or overweight with at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). 4,6,8 In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.6",A10BX,Guar gum,26344,guar gum,"guar gum Oral Product, guar gum Pill","Oral Product, Pill",,"['levels', 'that', 'insulinotropic', 'peptide', 'involved', 'signalling', 'glucose', 'delaying', 'brain', 'hormones', 'they', 'Glucagon', 'response', 'by', 'the', 'II', 'main', 'gastrointestinal', 'type', 'homeostasis', 'hormone', 'diabetes', '1', 'are', 'have', 'GLP', 'food', 'gastric', 'transit', 'reducing', 'exerts', 'polypeptide', 'enhancing', 'However', '2', 'decreasing', 'throughout', 'control', 'anorexigenic', 'in', 'dependent', 'beta', 'stimulated', 'body', 'from', 'effects', 'pancreatic', 'incretin', 'Both', 'like', 'pathophysiology', 'cells', 'insulin', 'weight', 'activating', 'and', '1R', 'plasma', 'promote', 'pathways', 'expressed', 'mellitus', 'GIP', 'is', 'intake', 'implicated', 'been', 'tract', 'as', 'to', 'secretion', 'receptors', 'They', 'of', 'glucagon', 'including']",3,99,chronic,2,1,False,False,False,0.05603868645131931,0.032879818594104306
A10BX17,Carfloglitazar,"['A10BX17', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10BX,Tirzepatide,2601723,tirzepatide,tirzepatide Injectable Product,Injectable Product,"Mounjaro Injectable Product, Zepbound Injectable Product","['mechanism', 'No', 'found']",1,3,other,1,1,True,True,True,,
A10BX17,Carfloglitazar,"['A10BX17', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10BX,Benfluorex,18880,benfluorex,,,,"['mechanism', 'No', 'found']",1,3,other,0,1,True,True,True,,
A10BX17,Carfloglitazar,"['A10BX17', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10BX,Pramlintide,139953,pramlintide,pramlintide Injectable Product,Injectable Product,Symlin Injectable Product,"['mechanism', 'No', 'found']",1,3,other,1,1,True,True,True,,
A10BX17,Carfloglitazar,"['A10BX17', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10BX,Nateglinide,274332,nateglinide,"nateglinide Oral Product, nateglinide Pill","Oral Product, Pill",,"['mechanism', 'No', 'found']",1,3,other,2,1,True,True,True,,
A10BX17,Carfloglitazar,"['A10BX17', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,No mechanism found,No targets found,No indication found,A10BX,Guar gum,26344,guar gum,"guar gum Oral Product, guar gum Pill","Oral Product, Pill",,"['mechanism', 'No', 'found']",1,3,other,2,1,True,True,True,,
A10BX18,Dorzagliatin,"['A10BX18', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,"AHexokinase-4 (activator, Humans)",Not Available,A10BX,Tirzepatide,2601723,tirzepatide,tirzepatide Injectable Product,Injectable Product,"Mounjaro Injectable Product, Zepbound Injectable Product","['Not', 'Available']",2,2,other,1,1,True,False,True,,0.0
A10BX18,Dorzagliatin,"['A10BX18', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,"AHexokinase-4 (activator, Humans)",Not Available,A10BX,Benfluorex,18880,benfluorex,,,,"['Not', 'Available']",2,2,other,0,1,True,False,True,,0.0
A10BX18,Dorzagliatin,"['A10BX18', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,"AHexokinase-4 (activator, Humans)",Not Available,A10BX,Pramlintide,139953,pramlintide,pramlintide Injectable Product,Injectable Product,Symlin Injectable Product,"['Not', 'Available']",2,2,other,1,1,True,False,True,,0.0
A10BX18,Dorzagliatin,"['A10BX18', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,"AHexokinase-4 (activator, Humans)",Not Available,A10BX,Nateglinide,274332,nateglinide,"nateglinide Oral Product, nateglinide Pill","Oral Product, Pill",,"['Not', 'Available']",2,2,other,2,1,True,False,True,,0.0
A10BX18,Dorzagliatin,"['A10BX18', 'A10BX', 'A10B', 'A10', 'A']",True,1,1,Not Available,"AHexokinase-4 (activator, Humans)",Not Available,A10BX,Guar gum,26344,guar gum,"guar gum Oral Product, guar gum Pill","Oral Product, Pill",,"['Not', 'Available']",2,2,other,2,1,True,False,True,,0.0
A10XA01,Tolrestat,"['A10XA01', 'A10XA', 'A10X', 'A10', 'A']",True,1,1,Not Available,"ASigma non-opioid intracellular receptor 1 (binder, Humans); AAldo-keto reductase family 1 member B1 (inhibitor, Humans); UAldo-keto reductase family 1 member A1 (Not Available, Humans); UAldo-keto reductase family 1 member B10 (Not Available, Humans)",For the pharmacological control of certain diabetic complications.,A10XA,Tolrestat,38386,tolrestat,,,,"['Not', 'Available']",5,2,other,0,1,True,True,False,,0.0
A10XX01,Teplizumab,"['A10XX01', 'A10XX', 'A10X', 'A10', 'A']",True,1,1,"Type 1 diabetes (T1D) is an autoimmune condition in which T cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and reliance on exogenous insulin. T1D is a progressive disease with three recognizable stages and in which only Stage 3 is associated with clinically apparent symptoms.1 The earliest indication of T1D risk is the presence of at least two autoantibodies against relevant antigens, confirming an important role for B cells in what has traditionally been considered a T cell-dominated condition.1,2 Combined with other observations from animal and human studies, it is clear that T and B cells play a role in T1D; treatment has focussed on targeting each of them independently, as well as their interactions.2","AT-cell surface glycoprotein CD3 epsilon chain (antibody, Humans)",Teplizumab is indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.11,A10XX,Teplizumab,2621880,teplizumab,teplizumab Injectable Product,Injectable Product,Tzield Injectable Product,"['antigens', 'observations', 'focussed', 'at', 'production', 'autoimmune', '1', 'important', 'leads', 'two', 'presence', 'destruction', '2', 'control', 'confirming', 'condition', 'exogenous', 'loss', 'an', 'interactions', 'cells', 'play', 'mediated', 'Combined', 'traditionally', 'associated', 'treatment', 'that', 'each', 'their', 'what', 'earliest', 'targeting', 'autoantibodies', 'with', 'symptoms', 'T1D', 'other', 'risk', 'which', 'and', 'for', 'clinically', 'independently', 'as', 'to', 'stages', '3', 'role', 'only', 'Type', 'dominated', 'relevant', 'it', 'in', 'studies', 'from', 'pancreatic', 'insulin', 'Stage', 'apparent', 'is', 'on', 'been', 'well', 'of', 'disease', 'animal', 'the', 'human', 'glycemic', 'T', 'cell', 'three', 'them', 'diabetes', 'indication', 'recognizable', 'The', 'impaired', 'against', 'has', 'progressive', 'reliance', 'a', 'clear', 'β', 'considered', 'B', 'least']",2,122,other,1,1,False,False,False,0.05146072817429933,0.0
A12AA10,Calcium glucoheptonate,"['A12AA10', 'A12AA', 'A12A', 'A12', 'A']",True,1,1,"Calcium gluceptate replenishes the deminished levels of calcium in the body, returning them to normal levels.",No targets found,"For treatment of mild hypocalcemia due to neonatal tetany, tetany due to parathyroid deficiency or vitamin D deficiency, and alkalosis, as prophylaxis of hypocalcemia during exchange transfusions, in the treatment of intestinal malabsorption, and to replenish electrolytes.",A12AA,Calcium glucoheptonate,47618,calcium gluceptate,,,,"['normal', 'levels', 'them', 'in', 'replenishes', 'body', 'calcium', 'returning', 'the', 'Calcium', 'to', 'deminished', 'of', 'gluceptate']",1,16,other,0,1,False,True,False,0.024536334680702824,
B03AA10,Ferrous ascorbate,"['B03AA10', 'B03AA', 'B03A', 'B03', 'B']",True,1,1,"Iron is necessary for the production of hemoglobin. Iron-deficiency can lead to decreased production of hemoglobin and a microcytic, hypochromic anemia.","UTransferrin receptor protein 1 (Not Available, Humans); UEgl nine homolog 1 (Not Available, Humans); UHistone deacetylase 8 (Not Available, Humans); UAlpha-hemoglobin-stabilizing protein (Not Available, Humans); UHemoglobin subunit alpha (Not Available, Humans); UFrataxin, mitochondrial (Not Available, Humans); UFerritin heavy chain (Not Available, Humans); UFlap endonuclease 1 (Not Available, Humans); UEndonuclease 8-like 1 (Not Available, Humans); UEndonuclease 8-like 2 (Not Available, Humans); UDNA polymerase beta (Not Available, Humans); UCeruloplasmin (Not Available, Humans); USerotransferrin (Not Available, Humans)",Used in preventing and treating iron-deficiency anemia.,B03AA,Ferrous ascorbate,4356,ferrous ascorbate,,,,"['can', 'microcytic', 'hemoglobin', 'anemia', 'for', 'is', 'necessary', 'Iron', 'a', 'hypochromic', 'deficiency', 'to', 'the', 'decreased', 'lead', 'of', 'production', 'and']",15,21,other,0,1,False,True,False,0.024618208463938408,0.0
B05XA10,Magnesium phosphate,"['B05XA10', 'B05XA', 'B05X', 'B05', 'B']",True,1,1,Not Available,No targets found,Not Available,B05XA,Magnesium phosphate,29164,magnesium phosphate,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
B06AA10,Desoxyribonuclease,"['B06AA10', 'B06AA', 'B06A', 'B06', 'B']",True,1,1,Not Available,"3 (Withdrawn, Treatment)",Not Available,B06AA,Desoxyribonuclease,3210,deoxyribonucleases,,,,"['Not', 'Available']",2,2,other,0,1,True,False,True,,0.0
C01CA10,Methoxamine,"['C01CA10', 'C01CA', 'C01C', 'C01', 'C']",True,1,1,"Methoxamine acts through peripheral vasoconstriction by acting as a pure alpha-1 adrenergic receptor agonist, consequently increasing systemic blood pressure (both systolic and diastolic).","AAlpha-1A adrenergic receptor (agonist, Humans); UAlpha-1D adrenergic receptor (binder, Humans); UAlpha-1B adrenergic receptor (agonist, Humans)",Indicated for the treatment and management of hypotension.,C01CA,Methoxamine,203187,methoxamine,,,,"['through', 'acting', 'diastolic', 'both', 'by', 'increasing', 'acts', '1', 'peripheral', 'receptor', 'pressure', 'Methoxamine', 'a', 'adrenergic', 'alpha', 'agonist', 'and', 'pure', 'consequently', 'blood', 'systolic', 'systemic', 'as', 'vasoconstriction']",4,23,other,0,1,False,False,False,0.015590286398040809,0.0
C03BA10,Xipamide,"['C03BA10', 'C03BA', 'C03B', 'C03', 'C']",True,1,1,Not Available,No targets found,Not Available,C03BA,Xipamide,11371,xipamide,"xipamide Oral Product, xipamide Pill","Oral Product, Pill",,"['Not', 'Available']",1,2,other,2,1,True,True,True,,
C05AA10,Fluocinolone acetonide,"['C05AA10', 'C05AA', 'C05A', 'C05', 'C']",True,1,1,"Fluocinolone acetonide is a corticosteroid and thus, it can be inferred that it acts by inhibiting the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, collagen deposition, and scar formation.19","AGlucocorticoid receptor (agonist, Humans); AAnnexin A1 (inducer, Humans); AAnnexin A2 (inducer, Humans); AAnnexin A3 (inducer, Humans); AAnnexin A4 (inducer, Humans); AAnnexin A5 (inducer, Humans); UPhospholipase A2 (inhibitor, Humans)",Fluocinolone acetonide has been used extensively in different medical areas.,C05AA,Fluocinolone acetonide,4461,fluocinolone,"clioquinol / fluocinolone Topical Product, fluocinolone / neomycin Topical Product, fluocinolone / hydroquinone / tretinoin Topical Product, fluocinolone Drug Implant Product, fluocinolone Otic Product, fluocinolone Topical Product, fluocinolone Shampoo Product, dimethyl sulfoxide / fluocinolone Otic Product, ciprofloxacin / fluocinolone Otic Product","Topical Product, Otic Product, Drug Implant Product, Shampoo Product","Derma-Smoothe FS Topical Product, Dermotic Otic Product, Tri-Luma Topical Product, Retisert Drug Implant Product, Synalar Topical Product, Capex Shampoo Product, Synotic Otic Product, Neo-Synalar Topical Product, Iluvien Drug Implant Product, Otovel Otic Product, Flac Otic Product, Yutiq Drug Implant Product","['that', 'deposition', 'scar', 'inferred', 'dilation', 'be', 'by', 'the', '19', 'capillary', 'inhibiting', 'Fluocinolone', 'acts', 'migration', 'it', 'can', 'edema', 'leukocyte', 'collagen', 'a', 'formation', 'fibrin', 'and', 'corticosteroid', 'is', 'fibroblast', 'proliferation', 'acetonide', 'thus']",8,33,other,4,1,False,False,False,0.016140265366514278,0.0
C08CA10,Nilvadipine,"['C08CA10', 'C08CA', 'C08C', 'C08', 'C']",True,1,1,"Nilvadipine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.","AVoltage-dependent L-type calcium channel subunit alpha-1C (inhibitor, Humans); AVoltage-dependent calcium channel subunit alpha-2/delta-1 (inhibitor, Humans); AVoltage-dependent L-type calcium channel subunit beta-2 (inhibitor, Humans); AVoltage-dependent L-type calcium channel subunit alpha-1D (inhibitor, Humans); UVoltage-dependent L-type calcium channel subunit alpha-1S (inhibitor, Humans); UVoltage-dependent calcium channel subunit alpha-2/delta-3 (inhibitor, Humans); UVoltage-dependent T-type calcium channel subunit alpha-1H (inhibitor, Humans); UVoltage-dependent T-type calcium channel subunit alpha-1I (inhibitor, Humans); UVoltage gated L-type calcium channel (blocker, Humans); UVoltage-dependent T-type calcium channel (inhibitor, Humans)","For the management of vasospastic angina, chronic stable angina and hypertension.",C08CA,Nilvadipine,53692,nilvadipine,,,,"['through', 'inhibits', 'dilation', 'total', 'by', 'the', 'plugging', 'decreased', 'processes', 'extracellular', 'The', 'membrane', 'increased', 'peripheral', 'muscle', 'pressure', 'influx', 'coronary', 'resistance', 'in', 'Nilvadipine', 'arteries', 'channel', 'physically', 'oxygen', 'cells', 'decrease', 'and', 'pores', 'contractile', 'intracellular', 'tissue', 'blood', 'systemic', 'delivery', 'vascular', 'causing', 'calcium', 'smooth', 'to', 'afterload', 'myocardial', 'of']",11,57,chronic,0,1,False,False,False,0.050455696736444705,0.0
C09AA10,Trandolapril,"['C09AA10', 'C09AA', 'C09A', 'C09', 'C']",True,1,1,"There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Trandolaprilat, the active metabolite of trandolapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Trandolaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.","AAngiotensin-converting enzyme (inhibitor, Humans)","For the treatment of mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure (CHF), to improve survival following myocardial infarction (MI) in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of CHF within a few days following acute MI, and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy.",C09AA,Trandolapril,38454,trandolapril,"trandolapril / verapamil Oral Product, trandolapril / verapamil Pill, trandolapril Oral Product, trandolapril Pill","Oral Product, Pill",,"['involved', 'oviduct', 'inhibits', 'while', 'regulation', 'ATII', 'described', 'C', 'maturation', 'release', 'predominantly', 'likely', 'stimulation', 'competes', 'two', 'roles', 'also', 'inhibit', 'mechanisms', 'body', 'causes', 'domain', 'an', 'loss', 'thought', 'play', 'plasma', 'mediated', 'There', 'blood', 'enzymatic', 'comprised', 'they', 'by', 'gene', 'baroreceptors', 'sequence', 'inhibiting', 'pressor', 'section', 'increase', 'isoform', 'are', 'Trandolaprilat', 'much', 'isoforms', 'ATI', 'with', 'differentiation', 'which', 'and', 'Pharmacology', 'affinity', 'similarity', 'somatic', 'proteolysis', 'activity', 'for', 'via', 'as', 'to', 'decreases', 'levels', 'or', 'both', 'role', 'sperm', 'N', 'greater', 'binding', 'testicular', 'inhibitory', 'reflex', 'polypeptide', 'stem', 'in', 'trandolapril', 'Somatic', 'from', 'feedback', 'due', 'is', 'mass', 'on', 'inhibition', 'distinct', 'bind', 'metabolite', 'of', 'above', 'molecular', '1277', 'the', 'duplication', 'Decreasing', 'physiological', 'epithelium', 'cell', 'high', 'The', 'against', 'domains', 'have', 'has', 'single', 'active', 'pressure', 'plays', 'ACE', 'chain', 'Although', 'a', 'hematopoietic', 'glycoprotein', 'effects', 'inhibitors', 'arise', 'proliferation', 'but', 'renin', 'functionally', 'lower', 'exists', 'tandem']",2,201,acute,2,1,False,False,False,0.05349569535850987,0.0
D04AA10,Promethazine,"['D04AA10', 'D04AA', 'D04A', 'D04', 'D']",True,1,1,"Promethazine is a an antagonist of histamine H1, post-synaptic mesolimbic dopamine, alpha adrenergic, muscarinic, and NMDA receptors.2,8,9 The antihistamine action is used to treat allergic reactions.7 Antagonism of muscarinic and NMDA receptors contribute to its use as a sleep aid, as well as for anxiety and tension.9 Antagonism of histamine H1, muscarinic, and dopamine receptors in the medullary vomiting center make promethazine useful in the treatment of nausea and vomiting.10","AHistamine H1 receptor (antagonist, Humans); UD(2) dopamine receptor (antagonist, Humans); UMuscarinic acetylcholine receptor M1 (antagonist, Humans); UMuscarinic acetylcholine receptor M2 (antagonist, Humans); UMuscarinic acetylcholine receptor M3 (antagonist, Humans); UMuscarinic acetylcholine receptor M4 (antagonist, Humans); UMuscarinic acetylcholine receptor M5 (antagonist, Humans); UAlpha adrenergic receptor (antagonist, Humans); UHistamine H2 receptor (antagonist, Humans); UP2 Purinoceptors (inhibitor, ); UVoltage-gated sodium channel alpha subunit (inhibitor, Humans); UVoltage-gated Potassium Channels (inducer, ); UCalmodulin (inhibitor, Humans)","Promethazine tablets and suppositories are indicated to treat rhinitis, allergic conjunctivitis, allergic reactions to blood or plasma, dermographism, anaphylactic reactions, sedation, nausea, vomiting, pain, motion sickness, and allergic skin reactions.2,12 Promethazine cough syrup with phenylephrine and codeine is indicated to relieve cough and upper respiratory symptoms, and nasal congestion associated with allergy or the common cold.13",D04AA,Promethazine,142445,promethazine,"acetaminophen / promethazine Oral Liquid Product, acetaminophen / promethazine Oral Product, codeine / phenylephrine / promethazine Oral Liquid Product, codeine / phenylephrine / promethazine Oral Product, codeine / promethazine Oral Liquid Product, codeine / promethazine Oral Product, dextromethorphan / promethazine Oral Liquid Product, dextromethorphan / promethazine Oral Product, phenylephrine / promethazine Oral Liquid Product, phenylephrine / promethazine Oral Product, meperidine / promethazine Oral Product, meperidine / promethazine Pill, promethazine Injectable Product, promethazine Oral Liquid Product, promethazine Oral Product, promethazine Pill, promethazine Rectal Product","Injectable Product, Rectal Product, Oral Product, Pill, Oral Liquid Product","Phenadoz Rectal Product, Phenergan Injectable Product, Phenergan Rectal Product, Promethegan Rectal Product","['treatment', 'treat', 'its', 'make', 'used', 'nausea', '8', 'the', 'use', 'anxiety', 'The', 'center', 'mesolimbic', 'NMDA', 'reactions', 'medullary', '10', 'action', '2', 'in', 'muscarinic', 'a', 'allergic', 'adrenergic', 'Promethazine', 'alpha', 'promethazine', 'an', 'aid', 'post', 'and', 'contribute', 'sleep', 'tension', 'H1', 'vomiting', 'for', 'is', '9', 'antagonist', 'Antagonism', 'as', 'dopamine', 'antihistamine', 'to', 'useful', '7', 'receptors', 'well', 'synaptic', 'of', 'histamine']",14,70,other,5,1,False,False,False,0.04397028384482408,0.001128668171557562
G03AA10,Gestodene and ethinylestradiol,"['G03AA10', 'G03AA', 'G03A', 'G03', 'G']",True,1,1,,,,G03AA,Gestodene and ethinylestradiol,608868,"gestodene, ethinyl estradiol","ethinyl estradiol / gestodene Oral Product, ethinyl estradiol / gestodene Pill","Oral Product, Pill",,[],0,0,unknown,2,2,False,False,False,,0.38487584650112866
J01CA10,Mezlocillin,"['J01CA10', 'J01CA', 'J01C', 'J01', 'J']",True,1,1,"By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, mezlocillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that mezlocillin interferes with an autolysin inhibitor.","APenicillin-binding protein 1A (inhibitor, Clostridium perfringens (strain 13 / Type A)); APeptidoglycan synthase FtsI (binder, Escherichia coli (strain K12)); APenicillin-binding protein 3 (inhibitor, Streptococcus pneumoniae); UPenicillin-binding protein 2 (inhibitor, Escherichia coli (strain K12))","Used to treat serious gram–negative infections of the lungs, urinary tract, and skin.",J01CA,Mezlocillin,6927,mezlocillin,mezlocillin Injectable Product,Injectable Product,,"['then', 'that', 'inhibits', 'autolytic', 'located', 'by', 'the', 'wall', 'Cell', 'cell', 'binding', 'inside', 'possible', 'By', 'synthesis', 'inhibitor', 'bacterial', 'it', 'third', 'proteins', 'interferes', 'autolysins', 'with', 'penicillin', 'lysis', 'mezlocillin', 'an', 'stage', 'and', 'mediated', 'enzymes', 'such', 'of', 'is', 'specific', 'autolysin', 'as', 'to', 'last', 'PBPs']",5,49,other,1,1,False,False,False,0.032607189662953395,0.0
J01FA10,Azithromycin,"['J01FA10', 'J01FA', 'J01F', 'J01', 'J']",True,1,1,"In order to replicate, bacteria require a specific process of protein synthesis, enabled by ribosomal proteins 6. Azithromycin binds to the 23S rRNA of the bacterial 50S ribosomal subunit. It stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit Label, 5. This results in the control of various bacterial infections 7, Label.   The strong affinity of macrolides, including azithromycin, for bacterial ribosomes, is consistent with their broad‐spectrum antibacterial activities 7.","A23S ribosomal RNA (inhibitor, Enteric bacteria and other eubacteria); UProtein-arginine deiminase type-4 (inhibitor, Humans)",Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin Label.,J01FA,Azithromycin,1298839,azithromycin,,,,"['Label', 'Azithromycin', '23S', 'ribosomal', 'broad', 'This', 'by', 'the', 'results', 'replicate', 'inhibiting', 'The', 'binds', 'various', 'their', 'synthesis', 'azithromycin', 'bacterial', 'process', 'It', 'step', 'consistent', 'activities', 'proteins', '50S', 'control', 'macrolides', 'with', 'in', 'strong', 'a', '6', 'require', 'infections', 'antibacterial', 'translocation', 'subunit', 'In', 'and', 'affinity', 'assembly', 'transpeptidation', 'ribosomes', 'for', 'is', 'specific', 'enabled', 'protein', 'stops', 'spectrum', '5', 'to', 'bacteria', 'order', '7', 'of', 'including', 'rRNA']",3,83,other,0,1,False,False,False,0.0482158200425846,0.0
L01AA10,Melphalan flufenamide,"['L01AA10', 'L01AA', 'L01A', 'L01', 'L']",True,1,1,"Melphalan flufenamide is a more lipophilic prodrug of melphalan, which allows it to be more readily uptaken by cells.1,2 It is likely taken up into malignant cells by passive diffusion, where it is hydrolyzed by aminopeptidase N.1 The expression of aminopeptidases, along with other hydrolytic enzymes, is upregulated in many malignant cells, making the hydrolysis reaction to melphalan more favourable in a malignant cell.1 Increased concentrations of free melphalan in malignant cells leads to rapid irreversible DNA damage and apoptosis, reducing the potential for the development of resistance.1","ADNA (cross-linking/alkylation, Humans)","Melphalan flufenamide is indicated in combination with dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received ≥4 therapies and are refractory to at least one proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody.9 The FDA has withdrawn the drug from the market for this indication following phase 3 trial data showing decreased overall survival.11",L01AA,Melphalan flufenamide,2531369,melphalan flufenamide,melphalan flufenamide Injectable Product,Injectable Product,,"['upregulated', 'diffusion', 'Increased', 'aminopeptidase', 'reaction', 'Melphalan', 'be', 'by', 'the', 'prodrug', 'where', 'N', 'hydrolysis', 'concentrations', 'cell', 'hydrolytic', 'likely', 'up', '1', 'The', 'aminopeptidases', 'leads', 'melphalan', 'flufenamide', 'along', 'reducing', 'It', 'many', 'resistance', 'it', '2', 'malignant', 'with', 'in', 'favourable', 'damage', 'allows', 'a', 'readily', 'other', 'DNA', 'development', 'into', 'making', 'cells', 'which', 'expression', 'free', 'and', 'potential', 'lipophilic', 'enzymes', 'for', 'is', 'taken', 'more', 'uptaken', 'hydrolyzed', 'to', 'rapid', 'irreversible', 'apoptosis', 'passive', 'of']",2,88,other,1,1,False,False,False,0.04576706258717695,0.0
L03AA10,Lenograstim,"['L03AA10', 'L03AA', 'L03A', 'L03', 'L']",True,1,1,"Lenograstim is the glycosylated recombinant form of human granulocyte colony stimulating factor. Lenograstim accelerates neutrophil recovery significantly after chemotherapy, with beneficial effects on clinical end-points such as incidence of laboratory-confirmed infection and length of hospital stay. Chemotherapy dose intensity has also been increased in patients receiving lenograstim, notably those with breast or small cell lung cancer, although improvements in tumour response and survival have not been demonstrated. Lenograstim also assists neutrophil recovery in patients undergoing bone marrow transplantation, and stimulates the production of peripheral blood stem cells (PBSCs) for autologous transfusion after aggressive chemotherapy.","AGranulocyte colony-stimulating factor receptor (agonist, Humans)","The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. 
Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy.
Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim  is also indicated to accelerate the engraftment of these cells after their reinfusion.",L03AA,Lenograstim,70167,lenograstim,lenograstim Injectable Product,Injectable Product,,"['improvements', 'confirmed', 'response', 'granulocyte', 'production', 'hospital', 'peripheral', 'not', 'recombinant', 'Chemotherapy', 'also', 'aggressive', 'receiving', 'although', 'chemotherapy', 'beneficial', 'stimulating', 'cells', 'blood', 'incidence', 'stay', 'transfusion', 'assists', 'patients', 'recovery', 'transplantation', 'notably', 'laboratory', 'Lenograstim', 'undergoing', 'with', 'significantly', 'accelerates', 'PBSCs', 'and', 'for', 'as', 'stimulates', 'tumour', 'infection', 'factor', 'or', 'lenograstim', 'increased', 'points', 'small', 'lung', 'clinical', 'colony', 'stem', 'in', 'end', 'form', 'bone', 'marrow', 'cancer', 'breast', 'autologous', 'is', 'on', 'neutrophil', 'been', 'those', 'of', 'after', 'intensity', 'the', 'human', 'cell', 'have', 'has', 'dose', 'demonstrated', 'survival', 'effects', 'such', 'length', 'glycosylated']",2,94,other,1,1,False,False,False,0.038713616237594034,0.0
N02AA10,Papaveretum,"['N02AA10', 'N02AA', 'N02A', 'N02', 'N']",True,1,1,No mechanism found,No targets found,No indication found,N02AA,Papaveretum,253192,papaveretum,,,,"['mechanism', 'No', 'found']",1,3,other,0,1,True,True,True,,
N02BA10,Benorilate,"['N02BA10', 'N02BA', 'N02B', 'N02', 'N']",True,1,1,Not Available,No targets found,Not Available,N02BA,Benorilate,1372,benorilate,"benorilate Oral Liquid Product, benorilate Oral Product, benorilate Pill","Oral Product, Pill, Oral Liquid Product",,"['Not', 'Available']",1,2,other,3,1,True,True,True,,
N05BA10,Ketazolam,"['N05BA10', 'N05BA', 'N05B', 'N05', 'N']",True,1,1,"Benzodiazepines share a similar chemical structure and their effects in humans are mainly produced by the allosteric modification of a specific kind of neurotransmitter receptor, the GABAA receptor, which increases the conductance of this inhibitory channel; this results in the various therapeutic effects as well as adverse effects of benzodiazepines. Binding of benzodiazepines to this receptor complex promotes binding of GABA, which in turn increases the conduction of chloride ions across the neuronal cell membrane. This increased conductance raises the membrane potential of the neuron resulting in inhibition of neuronal firing. In addition, different GABAA receptor subtypes have varying distributions within different regions of the brain and therefore control distinct neuronal circuits. Hence, activation of different GABAA receptor subtypes by benzodiazepines may result in distinct pharmacological actions.","AGABA(A) Receptor (positive allosteric modulator, Humans); AGABA(A) Receptor Benzodiazepine Binding Site (ligand, Humans)","Ketazolam could be used for the treatment of anxiety. In approved countries, it is indicated for the treatment of anxiety, tension, irritability and similar stress related symptoms.",N05BA,Ketazolam,28181,ketazolam,,,,"['Benzodiazepines', 'GABA', 'control', 'addition', 'GABAA', 'share', 'circuits', 'therapeutic', 'neuronal', 'subtypes', 'activation', 'produced', 'modification', 'increases', 'by', 'neuron', 'Binding', 'structure', 'are', 'mainly', 'their', 'chemical', 'receptor', 'distributions', 'channel', 'which', 'and', 'potential', 'regions', 'firing', 'as', 'to', 'promotes', 'neurotransmitter', 'complex', 'binding', 'similar', 'various', 'membrane', 'increased', 'pharmacological', 'inhibitory', 'benzodiazepines', 'actions', 'in', 'may', 'allosteric', 'kind', 'inhibition', 'distinct', 'well', 'raises', 'of', 'adverse', 'brain', 'different', 'This', 'the', 'across', 'cell', 'this', 'Hence', 'chloride', 'conduction', 'have', 'result', 'a', 'therefore', 'effects', 'humans', 'ions', 'In', 'resulting', 'turn', 'conductance', 'specific', 'results', 'within', 'varying']",3,127,other,0,1,False,False,False,0.05121899518303585,0.0
N05CA10,Cyclobarbital,"['N05CA10', 'N05CA', 'N05C', 'N05', 'N']",True,1,1,Not Available,No targets found,Not Available,N05CA,Cyclobarbital,2978,cyclobarbital,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
N06AA10,Nortriptyline,"['N06AA10', 'N06AA', 'N06A', 'N06', 'N']",True,1,1,"Though prescribing information does not identify a specific mechanism of action for nortriptyline18, is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at the level of the beta-adrenergic receptors. It displays a more selective reuptake inhibition for noradrenaline, which may explain increased symptom improvement after nortriptyline therapy.16 Tricyclic antidepressants do not inhibit monoamine oxidase nor do they affect dopamine reuptake.18 As with other tricyclics, nortriptyline displays affinity for other receptors including mACh receptors, histamine receptors, 5-HT receptors, in addition to other receptors.10,11,16","ASodium-dependent noradrenaline transporter (inhibitor, Humans); ASodium-dependent serotonin transporter (inhibitor, Humans); A5-hydroxytryptamine receptor 2A (antagonist, Humans); U5-hydroxytryptamine receptor 1A (antagonist, Humans); NHistamine H1 receptor (antagonist, Humans); NAlpha-1A adrenergic receptor (antagonist, Humans); NAlpha-1D adrenergic receptor (antagonist, Humans); U5-hydroxytryptamine receptor 2C (antagonistdownregulator, Humans); UAlpha-1B adrenergic receptor (antagonist, Humans); UAlpha-2 adrenergic receptors (antagonist, Humans); UBeta adrenergic receptor (antagonist, Humans); UD(2) dopamine receptor (antagonist, Humans); USigma receptor (binder, Humans); U5-hydroxytryptamine receptor 2C (antagonist, Rat); UMuscarinic acetylcholine receptor (antagonist, Humans)","Nortriptyline is indicated for the relief of the symptoms of major depressive disorder (MDD).18 Some off-label uses for this drug include treatment of chronic pain, myofascial pain, neuralgia, and irritable bowel syndrome.7,18",N06AA,Nortriptyline,203130,nortriptyline,,,,"['therapy', 'that', 'after', 'inhibits', 'or', 'they', 'mechanism', 'nortriptyline18', 'the', 'neurotransmitter', 'mACh', 'noradrenaline', 'at', 'explain', 'does', 'nor', 'acts', 'As', 'Though', 'not', 'believed', 'membrane', 'selective', 'increased', 'It', '10', 'action', 'symptom', 'tricyclics', 'with', 'inhibit', 'in', 'information', 'reuptake', 'beta', 'a', 'displays', 'may', 'adrenergic', 'improvement', 'monoamine', 'oxidase', 'affect', '18', 'other', 'addition', '11', 'which', 'antidepressants', 'HT', 'affinity', 'nortriptyline', 'do', '16', 'level', 'for', 'is', 'prescribing', 'identify', 'specific', 'either', 'more', '5', 'inhibition', 'dopamine', 'to', 'serotonin', 'receptors', 'neuronal', 'Tricyclic', 'of', 'including', 'histamine']",16,91,chronic,0,1,False,False,False,0.03714335268922814,0.002257336343115124
N06BA10,Fenetylline,"['N06BA10', 'N06BA', 'N06B', 'N06', 'N']",True,1,1,Not Available,No targets found,Not Available,N06BA,Fenetylline,24840,fenethylline,,,,"['Not', 'Available']",1,2,other,0,1,True,True,True,,
R06AA10,Trimethobenzamide,"['R06AA10', 'R06AA', 'R06A', 'R06', 'R']",True,1,1,"The mechanism of action of trimethobenzamide as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited.","AD(2) dopamine receptor (inhibitor, Humans)",For the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.,R06AA,Trimethobenzamide,38685,trimethobenzamide,"benzocaine / trimethobenzamide Rectal Product, trimethobenzamide Injectable Product, trimethobenzamide Oral Product, trimethobenzamide Pill, trimethobenzamide Rectal Product","Injectable Product, Rectal Product, Oral Product, Pill",Tigan Injectable Product,"['obscure', 'through', 'medulla', 'emetic', 'trigger', 'animals', 'mechanism', 'CTZ', 'the', 'similarly', 'inhibited', 'involve', 'The', 'are', 'trimethobenzamide', 'center', 'not', 'determined', 'chemoreceptor', 'action', 'in', 'area', 'may', 'direct', 'conveyed', 'an', 'apparently', 'zone', 'which', 'vomiting', 'oblongata', 'is', 'as', 'to', 'but', 'impulses', 'of']",2,47,other,4,1,False,False,False,0.043912500280206546,0.0
